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Ik kan niet lopen, hoe ver moet ik nog?
Geen mens hoort dat ik schreeuw wanneer ik schreeuw
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GENERAL INTRODUCTION
BOX 1
A 88-year old woman was admitted to a psycho-geriatric department of  a nursing 
home due to progressive dementia. Her medical history included osteoarthritis and 
multiple depressions. She complained about abdominal pain and showed aberrant 
motor behavior, irritability and cursing.
After initiation of  antibiotic treatment for an urinary tract infection, her 
abdominal pain diminished. Unfortunately, the effects on her behavior were only 
of  short duration. She became depressed and started yelling and cried frequently. 
Acetaminophen was increased to 1000mg four times daily. Additionally, mirtazapine 
was started for alleviating her depressive symptoms. Nonetheless, her restlessness got 
worse and she became aggressive towards both caregivers and other patients. Light 
therapy was started and an occupational therapist and dietician were consulted 
to improve her posture and intake. None of  these interventions were effective. Her 
physician initiated a symptomatic treatment with risperidone and oxazepam, although 
these interventions had to be stopped due to excessive somnolence. A psychiatrist was 
consulted, who prescribed carbamazepine, of  which the dose was increased to 600mg 
daily. Unfortunately, the behavioral disturbances continued and she died shortly after 
due to diminished intake and physical exhaustion. 
Neuropsychiatric symptoms in dementia
Although cognitive impairment is the most widely known feature of  dementia, 
behavioral and psychological symptoms are very common as well, and often dominate 
the clinical presentation. Symptoms include, among others, delusions, agitation, 
depression and anxiety, which are referred to as ‘neuropsychiatric symptoms’ (NPS). 
NPS affect almost every individual with dementia (80-85%) at some point in the course 
of  the disease and are particularly prevalent among nursing home patients.1-3 Persistent 
symptoms lead to a significant reduction in quality of  life4 and cognitive functioning,5 
high caregiver distress6 and may result in early institutionalization.7 Despite the clinical 
relevance, the treatment of  NPS is still suboptimal, as illustrated in the case report (Box 
1). This imposes an enormous challenge for physicians working with dementia patients. 
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Non-drug based, or better called psychosocial treatments, such as person centered care, 
sensory interventions, and coaching of  caregivers are preferred as a first line approach, 
although their efficacy remains only sparsely evidenced and most interventions are not 
easily applicable in clinical practice.8 Therefore, to date, antipsychotic drugs (APs) are 
widely used in the symptomatic treatment of  several dementia-related NPS.9 Nonetheless, 
the scientific rationale behind this choice of  drugs is limited, as the efficacy is only 
modest, while they are associated with relevant and serious side effects, such as falls, 
cardiac symptoms, cerebrovascular events and even death.10-12 Other frequently used 
psychotropic drugs, such as antidepressants, anti-epileptic drugs and benzodiazepines, 
all have their own relevant side effects in frail dementia patients,13 and are therefore 
not an appropriate alternative. This highlights the need for alternative pharmacological 
interventions with an improved ratio of  beneficial versus adverse effects.
BOX 2
Dementia
Dementia is one of  the major causes of  disability and dependency among older 
persons worldwide.14 It is a common syndrome, characterized by a progressive decline in 
various (and at least two) neuropsychological and cortical functions, including memory, 
orientation, language and judgment. These disturbances affect the individual’s social 
and functional ability. Different types of  dementia exist, of  which Alzheimer’s disease 
is the most prevalent (60-70%), followed by vascular dementia, while -rising with age- 
different types of  etiology can also co-exist. Worldwide, 35.6 million people suffer from 
a type of  dementia, of  whom 250.000 are Dutch patients. This results in significant 
social and economical implications, which contributed to a renewed focus and financial 
support for scientific research on the (symptomatic) treatment of  dementia patients by 
the Dutch government.15
Medical cannabinoids, towards a new pharmacological intervention 
for NPS?
Low dose oral tetrahydrocannabinol (THC) (Box 3) is suggested to be a promising option 
for the treatment of  dementia-related NPS.16, 17 THC is the main psychoactive constituent 
of  the Cannabis sativa L. plant. Indeed, its psychological as well as physiological effects have 
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received extensive attention in the scientific field, and cannabinoids are currently used 
in the symptomatic treatment of  patients with multiple sclerosis.18 Additionally, several 
studies have been conducted regarding the efficacy of  cannabinoids in a broad range of  
conditions, including pain, chemotherapy-induced nausea and vomiting and anorexia, 
but showed controversial results.19-22 Currently, the general opinion among physicians 
concerning the use of  medical cannabinoids is slowly changing. An increasing number of  
US states is legalizing the use of  cannabinoids for medical purposes, which fuels the lively 
international debate of  the advantages and disadvantages of  medical cannabis among 
researchers and physicians.23 Despite the above mentioned positive effects, cannabinoids, 
including THC, can also induce several relevant side effects, such as dizziness, fatigue 
and balance disturbances.24 Especially in older, vulnerable patients, such as those with 
dementia, consideration for the harms of  this intervention is highly important and should 
be addressed before widespread use. 
BOX 3
The pharmacokinetic features of THC
THC is highly lipophilic and therefore rapidly distributes to fatty tissue, among 
which the central nervous system. It induces its effects by binding to CB1 and CB2 
receptors, localized throughout the nervous system.25, 26 CB receptor activation 
results in a depression of  the pre-synaptic membrane potential, in turn reducing 
neurotransmission and resulting in a negative feedback loop. THC is metabolized in the 
liver to its metabolites 11-OH-THC and THC-COOH through several cytochroom 
P45 subenzymes. The onset, quantity and duration of  its effects are dependent on 
several factors, among which route of  administration, dose and several patient-related 
factors. 
Aims of this thesis
To date, efficient pharmacological options for the treatment of  behavioral disturbances 
in dementia patients are lacking, while these symptoms are highly prevalent, induce 
significant burden for both patients as caregivers and result in high healthcare costs. 
The overall aim of  this thesis is to describe the effects of  oral THC in the treatment 
of  behavioral symptoms in patients with dementia, in order to determine whether this 
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intervention is appropriate in this vulnerable patient group. Specifically, we aimed to 
evaluate its efficacy, pharmacokinetic and pharmacodynamic properties and safety 
regarding adverse reactions, effects on vital signs and mobility in older patients with 
dementia. The studies described in this thesis are a product of  a broader research 
project on the efficacy of  Namisol® (a tablet containing THC) in the symptomatic 
treatment of  dementia-related NPS and chronic pancreatitis, which is a collaboration 
between Radboud university medical center, department of  Geriatric Medicine and 
Surgery, Clinical Research Centre Nijmegen (Nijmegen, The Netherlands) and Echo 
pharmaceuticals (Weesp, The Netherlands). All studies are investigator-driven and funded 
by the European Regional Development Fund and province of  Gelderland. In none of  
the studies the authors nor any other member of  the research team involved had conflicts 
of  interests with the product under study (Namisol®). Initially, we planned to conduct two 
studies on the efficacy of  Namisol® in NPS in dementia patients (described in Chapter 3 
and 4). As we identified a significant gap in the knowledge of  important safety aspects of  
oral THC formulations in older persons, including those with dementia (Chapter 2), we 
also conducted additional studies on the safety, pharmacokinetic properties and effects on 
mobility in older persons en patients with dementia (Chapter 5-7), which are described 
in the thesis outline. 
Thesis outline
Chapter 2. Although cannabinoids are widely studied for their therapeutic potential 
in a broad variety of  conditions, the results from young subjects cannot simply be 
extrapolated to older patients, especially those with cognitive disorders. This chapter 
describes a systematic literature search on medical cannabinoids in patients aged 65 
years and older, independent of  indication of  use and cognitive status, providing an 
introduction and starting point for our clinical studies.
Chapter 3. This chapter describes the results from a randomized, placebo-controlled, 
crossover trial on the efficacy of  two doses of  oral THC in the treatment of  behavioral 
disturbances in patients with dementia, with a focus on agitated behavior.
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Chapter 4. Here, we report on the results of  a second study on the efficacy of  oral 
THC on dementia related behavioral disturbances, compared to placebo. This was a 
multicenter study, including community-dwelling, as well as institutionalized dementia 
patients. Furthermore, the effects on pain-related behavior and pain intensity are 
explored. 
Chapter 5. Older and vulnerable persons are often excluded from intervention 
studies, resulting in a lack of  evidence based treatments for these specific groups. Up to 
date, only one Phase I trial is conducted studying the safety of  Namisol® in healthy young 
volunteers. In this study, we explored the effects of  several doses of  oral THC on the 
occurrence of  adverse effects, balance and attention in a group of  healthy, older persons.
Chapter 6. This chapter describes the results from a pharmacokinetic substudy of  
ten dementia patients treated with low dose oral THC. We report the pharmacokinetic 
profile of  THC and its active metabolite and describe several pharmacodynamic effects, 
thereby contributing to optimal and safe dosing in older dementia patients. 
Chapter 7. Before introducing a new psychopharmacological treatment for older 
patients, especially those with cognitive disturbances, effects on mobility should be 
explored as part of  the safety evaluation. In this chapter, we describe the first study 
investigating the effects of  THC on both balance and gait in patients with dementia, 
using objective and qualitative mobility assessment methods. 
Chapter 8. Provides a brief  summary of  the studies presented in this thesis.
Chapter 9. This last chapter provides a discussion of  the findings presented in this 
thesis. 
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Sinking 
Caught up in a whirling motion 
Such a strange sensation 
The currents uncertain 
Like sails of a mill 
I spin 
Like wheels I move in a circle 
While you stand on the bank 
Immune or evasive 
Throw me a lifeline 
Save me...
Joan Armatrading  -  Save Me
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Abstract
This systematic review aims to integrate the evidence on indications, efficacy, 
safety and pharmacokinetics of  medical cannabinoids in older subjects. The 
literature search was conducted using PubMed, EMBASE, CINAHL and Cochrane 
Library. We selected controlled trials including solely older subjects (≥ 65 years) or 
reporting data on older subgroups. 105 (74%) papers on controlled intervention 
trials, reported the inclusion of  older subjects. Five studies reported data on older 
persons separately. These were randomized controlled trials, including in total 267 
participants (mean age 47-78 years). Interventions were oral tetrahydrocannabinol 
(THC) (n=3) and oral THC combined with cannabidiol (n=2). The studies showed 
no efficacy on dyskinesia, breathlessness and chemotherapy induced nausea and 
vomiting. Two studies showed that THC might be useful in treatment of  anorexia 
and behavioral symptoms in dementia. Adverse events were more common 
during cannabinoid treatment compared to the control treatment, and were most 
frequently sedation like symptoms. Although trials studying medical cannabinoids 
included older subjects, there is a lack of  evidence of  its use specifically in older 
patients. Adequately powered trials are needed to assess the efficacy and safety of  
cannabinoids in older subjects, as the potential symptomatic benefit is especially 
attractive in this age group.
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Introduction
For many centuries the cannabis plant (Cannabis sativa L.) has been used worldwide for 
medical as well as recreational purposes. Possible indications of  cannabis, such as cancer 
pain, cachexia and neuropathic pain, are found in a quickly growing population of  older 
patients. Unfortunately, there are only limited data on the extent of  the use of  medicinal 
cannabinoids in older persons. Although international web-based surveys show only a 
low percentage of  older users, in the Dutch setting, more than one third of  patients using 
medicinal cannabis on prescription are over 60 years.1, 2 On the one hand, this group 
may highly benefit from medical application of  cannabis, because of  a greater emphasis 
on symptomatic and palliative effects of  medication, which is directly related to their 
limited life expectancy. On the other hand, an increased vulnerability of  the brain, due 
to a reduction in cognitive functioning and brain atrophy3, 4 and age related changes in 
pharmacokinetic factors5 may result in more severe adverse effects. 
Cannabis preparations contain numerous cannabinoids, including delta-9-
tetrahydrocannabinol (THC), with psychoactive effects, and cannabidiol (CBD), with 
neuroprotective, anticonvulsive, antiemetic and anti-inflammatory effects, as the major 
constituents. These cannabinoids act upon an endogenous cannabinoid system of  which 
two receptors (CB1 and CB2) have been identified.
6, 7 These receptors are mainly located 
in the central nervous system (CB1 and CB2) and the immune system (CB2).
8, 9 
Several trials studying the efficacy of  medical cannabinoids have been conducted, 
covering a wide range of  diseases and conditions, including neuropathic pain, 
chemotherapy-induced nausea and vomiting and loss of  appetite.10-13 Unfortunately, data 
on efficacy and safety established in studies with adults cannot simply be extrapolated 
to the older patient group, due to changes in pharmacokinetic and pharmacodynamic 
factors associated with increasing age, leading to differences in efficacy and a high 
risk of  developing adverse drug reaction. This can result in drug-related morbidity, 
hospital admission and mortality.14, 15 Examples of  changes in pharmacokinetic factors 
associated with increasing age are a decreased lean body mass, reduction of  renal and 
hepatic clearance and loss of  ability to maintain homeostasis.16, 17 The high prevalence 
of  co-morbidity and related polypharmacy further complicates drug treatment in this 
population. It is therefore highly relevant to study the effects of  medical cannabinoids in 
older patients separately, before advocating wide spread use.
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To date, no review on the efficacy and safety of  cannabinoids in older patients has 
been conducted. Although, the Cochrane Collaboration published a systematic review 
on cannabinoids in dementia patients,18 including one small randomized controlled trial 
(RCT) studying the efficacy of  nabilone on anorexia and behavioral disturbances in 
subjects with severe dementia.19 In the current systematic review we aimed to provide 
broader evidence on the safety and efficacy of  medical cannabinoids in older subjects, 
independent of  the reasons for prescription or the patients’ cognitive status.  
Methods
Search strategy
We performed a search of  PubMed, EMBASE, CINAHL and Cochrane Library 
databases up to October 7th 2013 for articles published in English. For PubMed, a 
comprehensive search was developed, which was adapted to the other databases (see 
appendices). The search strategy and eligibility criteria were specified in advance and 
documented in a study protocol. Relevant search term synonyms were determined 
using Thesaurus and discussion with experts. We used the following terms to determine 
the subject group: ‘aged’, ‘frail’, ‘elderly’, ‘older’, ‘aging’, ‘ageing’ and ‘geriatric’. 
To determine the intervention we used the terms: ‘cannabinoids’, ‘cannabinoid’, 
‘cannabinol’, ‘cannabidiol’, ‘tetrahydrocannabinol’, ‘marinol’, ‘cesamet’, ‘THC’, 
‘CBD’, ‘sativex’, ‘nabilone’, ‘dronabinol’, ‘delta-9-tetrahydrocannabinol’,’delta-THC’, 
‘cannabis’, ‘marihuana’, ‘marijuana’ and ‘hasish’. The existing clinical query ‘Therapy/
Broad’ was used in PubMed to select therapeutic studies. Duplicate publications were 
selected and removed. The final results were ranked alphabetically and received an 
article specific number. 
Eligibility criteria
Two reviewers (GE and ML) conducted the search by independently examining the title 
and available abstract of  each article, in an unblinded manner. Studies were considered 
for inclusion when they: (1) included exclusively older subjects (defined as ≥65 years) or 
a distinct subgroup of  older subjects and provided separate results on this subgroup; (2) 
studied the efficacy, safety or pharmacokinetics of  medical cannabinoids administered by 
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any route, at any dose and for any duration; (3) were prospective, controlled intervention 
trials and; (4) provided data on efficacy, safety, or pharmacokinetics. Studies were excluded 
when they (1) included exclusively younger subjects (<65 years); (2) studied cannabinoids 
for recreational purposes; (3) studied endocannabinoids or cannabinoid antagonists. 
Articles that seemed to meet the eligibility criteria based on title or abstract were screened 
in full-text by the same reviewers (GE and ML). In case of  disagreement or uncertainty 
two other researchers (MM and MOR) were consulted to reach consensus. The snowball 
method was used to manually identify relevant references from the reference lists of  
included articles.
Data extraction and assessment of methodological quality
A modified Cochrane data extraction sheet was used to extract data from the included 
articles. Data collection included study design, participant characteristics (including age, 
gender and number of  participants), intervention indication, intervention, outcome 
measures, results, data on adverse events and pharmacokinetics. The corresponding 
authors of  the included studies were contacted to request details on subject characteristics, 
study conduct, primary efficacy and safety data, if  not sufficiently described in the original 
articles. When feasible, study analyses were repeated for subjects aged 65 years and 
older. Additional information was provided by three out of  four corresponding authors 
that were contacted. One author could not be contacted, as that study was conducted 
more than 30 years ago.20 Two corresponding authors provided additional information 
on study methods, efficacy and safety.21, 22 One author provided information on study 
methods, in order to complete the risk of  bias table.19 No primary data from this study 
could be provided, as these had been discarded years ago. 
Quality assessment of  all included articles was carried out using a modified Effective 
Practice and Organisation of  Care form (EPOC, 2009). This form includes seven criteria 
for the assessment of  risk of  bias in individual studies: adequate sequence generation, 
allocation concealment, introduction of  a washout period, incomplete outcome data, 
blinding, protection against contamination, intention to treat analysis and selective 
reporting. A consensus-based risk of  bias table was constructed. 
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Data synthesis and analysis
It was not feasible to conduct a meta-analysis, due to the high clinical and 
methodological diversity. Results of  the included studies were therefore analyzed by 
making qualitative, descriptive summaries.
Results
Selection procedure
The selection procedure is shown in Figure 1. The search strategy identified 1676 
citations. Adjustment for duplicates left 1296 citations. Of  these, 1124 articles were 
excluded based on screening of  title and abstract. 172 full text articles were retrieved 
and assessed on eligibility. 105 (74%) out of  142 reports of  controlled intervention trials 
studying cannabinoids, included one or more subjects aged  ≥65 years. Nonetheless, most 
of  these articles did not report data on the older subject group separately.  Five studies 
could be included for analysis as these reported separate data on older subjects.19-23 The 
snowball method yielded no further studies.
Study characteristics
There was a substantial variation in study characteristics among the five included 
studies, which is outlined in Table 1. All studies were RCTs with a crossover design, of  
which one was preceded by an open label dose escalation study.21 In general, the study 
sample sizes were small (range 2 to 214 subjects). In total, 267 participants were included 
of  which 262 participants were included in studies’ analyses. The mean age of  the 
populations varied from 47 to 78 years. Only two studies assessed the efficacy of  medical 
cannabinoids in an exclusively older (≥65 years) population.19, 22 The three other studies 
were included in this systematic review as these included older subjects in an open label 
sub study,21 reported safety data on an older subgroup23 or reported results on efficacy per 
age group.20 The interventions existed of  THC administered as tablet,19, 20, 22 and THC 
in combination with cannabidiol (CBD) administered as tablet21 or as sublingual spray.23 
The treatment dosage varied extensively among the included studies, ranging from 2.5 
mg22 to maximally 62.5 mg of  THC daily.20 All studies used different outcome measures, 
linked to the different indications for prescription. Studied indications were anorexia and 
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behavioral disturbances in dementia, dyskinesia in Parkinson’s disease, chemotherapy 
induced nausea and vomiting, and breathlessness in Chronic Obstructive Pulmonary 
Disease (COPD). The duration of  intervention varied from 1 to 42 days per period. 
FIGURE 1
Flow diagram of the selection of studies included in this systematic review.
Search results
(Pubmed,Embase, Cinahl 
and Cochrane Library)
N=1676
Excluded dublicate articles
N=380
Number of articles
screened based
on title/abstract
N=1296
Excluded articles
based on title/abstract
N=1124
Number of full text
articles assessed
for eligibility
N=172
Excluded articles based
on full text
N=167
Reasons:
• No data on elderly subgroup: 100
• Only adult subjects included: 28
• Inappropriate study design:16
• Age (range or SD) unknown: 8
• Study results not described: 5
• Only adult subjects in intervention 
group: 4
• Language: 3
• No separate data on cannabinoids: 2
• Recreational use: 1
Studies included for analysis
N=5
Snow ball method
N=0
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The study from Volicer et al. was the only RCT with more than 10 participants that 
exclusively included older subjects. Therefore, we report on this study most extensively. 
This study involved fifteen hospitalized patients with severe Alzheimer’s disease, who 
exhibited food refusal. After baseline measurements, subjects were randomly assigned to 
dronabinol (THC) 2.5 mg twice daily first or placebo twice daily first. Treatment duration 
was six weeks, followed directly by the crossover treatment of  another six weeks. There 
was no washout period. Nutritional status was measured by body weight and triceps skin 
fold thickness (assessed weekly) and plasma albumin and lymphocyte count (assessed at 
the beginning and end of  each treatment period). Furthermore, behavioral disturbances 
were measured weekly by Cohen-Mansfield Agitation Inventory (CMAI) and Lawton 
Observed Affect Scale–Past. In total, eleven subjects completed both treatment periods 
and were analyzed. One participant died two weeks before completing the study, but was 
also included in the analysis. The average age was 72.7 years (range 65 to 82 years).
Risk of bias assessment
The risk of  bias is reported in Table 2. This table was finalized after receiving additional 
information by the corresponding authors.19, 21, 22 Four out of  five included studies showed 
a moderate to high risk of  bias in several relevant domains. The study of  Volicer et al. 
was judged to have a high risk of  bias. Although the researchers used a random number 
table for sequence generation, the only person who had access to this table, was also 
involved in outcome assessment, leading to a bias in allocation concealment and blind 
assessment of  outcomes. Furthermore, no washout period was introduced between the 
treatment periods, causing a significant risk of  carry over effect.  
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TABLE 2 
Risk of bias in the five studies reporting on medical application of cannabinoids in older 
subjects
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Ungerleider et al., 1982 + + + + ? - - +
Volicer et al., 1997 +a -a - - -a - - +
Carroll et al., 2004 + + + + + + + +
Pickering et al., 2011 + ? + - - - - +
Walther et al., 2011 +a +a - +a +a - - +a
+, yes; -, no; ?, unclear/not reported. a Data not reported in the article, but provided by author on request.
Efficacy
It was not feasible to report summary outcome measures as most studies did not 
report means and standard deviations per treatment group or study samples were too 
small to provide a reliable effect size. 
THC did not improve chemotherapy related nausea and vomiting,20 compared to 
prochlorperazine. In this study, different age groups were compared, but the efficacy on 
nausea reduction did not differ significantly between groups (χ2=2.13, NS). Furthermore, 
treatment with THC combined with CBD did not result in a statistical significant 
improvement of  breathlessness in COPD23 or dyskinesia in Parkinson’s disease,21 
compared to placebo. We reanalyzed the primary data on UPDRS total score from 
Carroll et al., including only subjects aged 65 years and older (n=12). This did not result 
in a significant difference between the treatment arms (p=0.27 for total UPDRS before 
levodopa challenge and p=0.86 for total UPDRS after levodopa challenge).
One study on the efficacy of  THC in two patients with Alzheimer’s disease showed 
a decline in nighttime motor activity, measured by wrist actigraphy in one male subject 
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until the third week of  treatment.22 This subject received dronabinol for two weeks, 
followed by placebo. There was no washout period. Behavioral disturbances declined 
during the entire 4-week study period, as measured with the Neuropsychiatric Inventory. 
In the other subject, who received placebo first, nighttime motor activity reduced only 
during the first week of  dronabinol treatment and increased again in the second week. 
Behavioral disturbances declined during placebo treatment, but increased again on the 
first week of  dronabinol. The provided primary efficacy data did not allow for statistical 
analysis, due to the very small sample size. 
The publication from Volicer and colleagues reported an increase in body weight 
during the study period of  12 weeks, regardless of  the order of  treatment. Weight gain 
was greater for subjects who received dronabinol first. In the first 6-week treatment 
period subjects receiving dronabinol gained 7.0 ± 1.5 lb compared to 4.6 ± 1.3 lb in 
subjects receiving placebo. Caloric intake was not changed. Triceps skin fold thickness 
seemed to increase during the total study period, but was not affected by treatment or 
order of  treatment. Disturbed behavior, as measured with CMAI, decreased during 
both dronabinol periods and this decrease persisted during the placebo period following 
dronabinol. Positive affect remained similar during both treatments, while negative affect 
decreased over the 12 week study period, and more while subjects received dronabinol, 
compared to placebo. The authors of  this study concluded that dronabinol might be 
useful in the treatment of  anorexia and disturbed behavior in patients with dementia. 
P-values or confidence intervals were not reported, nor were means and standard 
deviations of  the results from secondary outcome measures.
Safety
The results on adverse effects are reported in Table 3. Two RCTs reported data on 
adverse events for the total group of  participants, including those younger than 65 years. 
On request, Carroll provided safety data per subject in the open label phase, which are 
added to Table 3. Overall, adverse events were inconsistently assessed and it was not clear 
whether these events represent a clinically relevant change. Therefore, we only report the 
most frequently reported adverse events.
Overall, cannabinoid treatment resulted in more adverse effects than placebo or 
prochlorperazine (266 vs. 133).19-21, 23 Symptoms of  sedation/drowsiness were most 
frequently reported in the cannabinoid group. One study only assessed the occurrence of  
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severe adverse events, due to the lack of  reliable reporting of  adverse events by subjects 
with severe cognitive disorders.22 In the study with five COPD patients and six healthy 
controls, two older COPD subjects developed cardiac arrhythmias (Wenckebach block 
phenomenon and ventricular tachycardia) after receiving 2.7:2.5 mg and 8.1:7.5 mg 
THC:CBD, respectively.23 Another older subject with COPD developed symptoms of  
mild intoxication after 5.4:5 mg THC:CBD, which was not further clarified. This subject 
was unable to continue the measurements. None of  the studies reported cannabinoid 
related severe adverse effects, although one subject developed a grand mal seizure after 
first administration of  2.5 mg dronabinol and was withdrawn.19 The authors stated that it 
was not clear whether this event was related to dronabinol or progression of  Alzheimer’s 
disease. Despite the lack of  anticonvulsant treatment, the seizure did not recur. This 
subject died two months after the event of  causes unrelated to study participation. 
Pharmacokinetics
One study, with subjects between 51 and 78 years of  age receiving oral THC:CBD 
(0.034-0.25 mg THC/kg), collected blood samples for pharmacokinetic data.21 The 
maximum concentration (Cmax) of  THC was reached within 2 hours after ingestion of  
cannabis extract in most patients. Cmax varied from 0.25 to 5.4 ng/mL THC. There was 
no clear dose response. In subjects taking the same dose of  THC:CBD, a wide variability 
in blood concentration was seen. No pharmacokinetic data was presented separately for 
subjects ≥65 years.
CHAPTER 2
Efficacy and safety of medical cannabinoids in older subjects: a systematic review
33
2
TA
BL
E 
3
Re
su
lts
 o
n 
sa
fe
ty
 o
n 
m
ed
ic
al
 a
pp
lic
at
io
n 
of
 c
an
na
bi
no
id
s 
in
 o
ld
er
 s
ub
je
ct
s.
St
ud
y
n
In
te
rv
en
tio
n
M
os
t f
re
qu
en
t r
ep
or
te
d 
AE
s 
in
 
nu
m
be
r o
f s
ub
je
ct
s
(c
an
na
bi
no
id
 v
s.
 c
on
tr
ol
)
Se
ve
re
 A
Es
D
ro
p 
ou
ts
 
(to
ta
l)
D
ro
p 
ou
ts
 d
ur
in
g 
ca
nn
ab
in
oi
d 
tr
ea
tm
en
t
U
ng
er
le
id
er
 e
t a
l.,
 
19
82
21
4
or
al
 T
H
C 
7.
5
 m
g 
to
1
2
.5
 m
g 
fiv
e 
tim
es
 d
ai
ly
Se
da
tio
n 
(7
8
 v
s.
 5
6
, p
<
0
.0
1
)b
Ph
ys
io
lo
gi
ca
l (
6
2
 v
s.
 2
4
, p
<
0
.0
1
)c
Ps
yc
ho
lo
gi
ca
l (
5
9
 v
s.
 1
0
, p
<
0
.0
1
)d
?
75
?g
Vo
lic
er
 e
t a
l.,
 1
9
97
 a
12
or
al
 T
H
C 
2
.5
 m
g 
tw
ic
e 
da
ily
An
xi
et
y/
ne
rv
ou
sn
es
s 
(1
1
 v
s.
 1
2
)e
Em
ot
io
na
l l
ia
bi
lit
y 
(1
1
 v
s.
 1
0
)e
Ti
re
dn
es
s 
(9
 v
s.
 5
)e
So
m
no
le
nc
e 
(8
 v
s.
 4
)e
Eu
ph
or
ia
 (7
 v
s.
 5
)e
 
1 
gr
an
d 
m
al
 
se
iz
ur
e
1 
1h
Ca
rr
ol
l e
t a
l. 
2
0
0
4
, 
O
La
6
or
al
 T
H
C:
CB
D
 m
ea
n 
ac
hi
ev
ed
 d
ai
ly
 d
os
e 
0
.1
7
 m
g/
kg
/d
ay
 T
H
C
4
/6
 s
ub
je
ct
s 
di
d 
no
t r
ea
ch
 th
ei
r w
ei
gh
t-a
dj
us
te
d 
ta
rg
et
 d
os
e 
TH
C,
 d
ue
 to
 a
dv
er
se
 e
ve
nt
s,
 fo
llo
w
ed
 
by
 d
os
e 
ad
ju
st
m
en
t o
r d
is
co
nt
in
ua
tio
n.
B
al
an
ce
 d
is
or
de
r (
5
)f
G
as
tr
o-
in
te
st
in
al
 d
is
or
de
r (
4
)f
B
lu
rr
ed
 v
is
io
n 
(4
)f
M
us
cl
e 
w
ea
kn
es
s 
(4
)f
0
2
2
Ca
rr
ol
l e
t a
l.,
 2
0
0
4
, 
R
CT
17
or
al
 T
H
C:
CB
D
 m
ea
n 
do
se
 0
.1
4
6
 m
g/
kg
 d
ai
ly
 
(0
.0
3
4
-0
.2
5
) 
11
/1
7
 s
ub
je
ct
s 
di
d 
no
t r
ea
ch
 th
ei
r w
ei
gh
t-
ad
ju
st
ed
 ta
rg
et
 d
os
e 
TH
C,
 d
ue
 to
 a
dv
er
se
 e
ve
nt
s,
 
fo
llo
w
ed
 b
y 
do
se
 a
dj
us
tm
en
t, 
co
m
pa
re
d 
to
 9
/1
7
 
on
 p
la
ce
bo
.
D
ro
w
sy
/l
et
ha
rg
ic
 (9
 v
s.
 6
)
D
et
ac
he
d 
(4
 v
s.
 0
)
D
ry
 m
ou
th
 (4
 v
s.
 1
)
0
2
0
Pi
ck
er
in
g 
et
 a
l.,
 2
01
1
 
9
su
bl
in
gu
al
 T
H
C:
CB
D
2.
7/
2.
5 
m
g 
on
ce
 to
 fo
ur
 ti
m
es
 d
ai
ly
Ca
rd
ia
c 
ar
rh
yt
hm
ia
 (2
 v
s.
 0
)
M
ild
 in
to
xi
ca
tio
n 
(1
 v
s.
 0
)
D
ro
w
si
ne
ss
 (1
 v
s.
 0
)
0
3
3
W
al
th
er
 e
t a
l.,
 2
01
1
a
2
or
al
 T
H
C 
2
.5
 m
g 
on
ce
 d
ai
ly
N
A
0
0
0
Ab
br
ev
ia
tio
ns
: N
A,
 n
ot
 a
ss
es
se
d;
 A
E,
 a
dv
er
se
 e
ve
nt
.
a  
re
su
lts
 re
pr
es
en
t a
n 
ex
cl
us
iv
el
y 
ol
de
r s
ub
je
ct
 g
ro
up
. b
 s
ym
pt
om
s 
gr
ou
pe
d 
as
 ‘s
ed
at
io
n’
 in
cl
ud
ed
 s
le
ep
in
es
s,
 re
la
xe
d,
 o
r s
lu
gg
is
h.
 c  
sy
m
pt
om
s 
gr
ou
pe
d 
as
 ‘p
hy
si
ol
og
ic
al
’ 
in
cl
ud
ed
 d
iz
zi
ne
ss
, h
ea
da
ch
e,
 d
ry
 m
ou
th
, t
ac
hy
ca
rd
ia
, c
hi
lls
 o
r i
nc
re
as
ed
 p
ai
n.
 d
 s
ym
pt
om
s 
gr
ou
pe
d 
as
 ‘p
sy
ch
ol
og
ic
al
’ i
nc
lu
de
d 
m
en
ta
l c
lo
ud
in
g,
 s
pa
ce
/t
im
e 
di
st
or
tio
n,
 s
ho
rt
-
te
rm
 m
em
or
y 
lo
ss
 o
r d
is
so
ci
at
iv
e 
re
ac
tio
n.
 e
 fr
eq
ue
nc
y 
re
pr
es
en
ts
 th
e 
nu
m
be
r o
f r
ep
or
ts
. f
 d
at
a 
no
t r
ep
or
te
d 
in
 th
e 
ar
tic
le
, b
ut
 p
ro
vi
de
d 
by
 th
e 
co
rr
es
po
nd
in
g 
au
th
or
 o
n 
re
qu
es
t. 
g  
at
 le
as
t t
w
o 
su
bj
ec
ts
 d
is
co
nt
in
ue
d 
th
e 
st
ud
y 
be
ca
us
e 
of
 d
ys
ph
or
ia
 re
la
te
d 
to
 T
H
C.
 T
he
 re
as
on
s 
fo
r o
ve
ra
ll 
di
sc
on
tin
ua
tio
n 
w
er
e 
si
m
ila
r a
m
on
g 
th
e 
tw
o 
in
te
rv
en
tio
n 
gr
ou
ps
. 
h  
on
e 
su
bj
ec
t d
ev
el
op
ed
 a
 g
ra
nd
 m
al
 s
ei
zu
re
 a
ft
er
 fi
rs
t a
dm
in
is
tr
at
io
n 
of
 2
.5
 m
g 
TH
C 
an
d 
dr
op
pe
d 
ou
t. 
234
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
Discussion
Principal findings and previous literature
This systematic review aimed to evaluate study participation, intervention indications, 
efficacy and safety of  medical cannabinoids in older subjects. The age ranges of  subjects 
described in the papers suggest that elderly are indeed included in research studying 
medical cannabinoids for several indications. However, separate data on the older 
subgroup are very rare. The five studies that did report on older subjects showed no 
efficacy on dyskinesia, breathlessness (versus placebo) and chemotherapy induced nausea 
and vomiting (versus prochlorperazine). Studies on oral THC  in symptomatic treatment 
of  behavioral problems in dementia did not prove efficacy, because of  the small sizes and 
overall low to moderate methodological quality. 
Overall, despite the relatively low doses used in the included studies, adverse events 
were more frequently reported during cannabinoid treatment than during treatment 
with the control product, especially concerning sedation-like symptoms, as drowsiness, 
tiredness and somnolence. This is in line with the results of  a systematic review on 31 
studies on medical cannabinoids in adult subjects, reporting nervous system disorders as 
the most frequently occurring adverse events (36.7% in RCTs, 39.7% in observational 
studies), including dizziness, somnolence and sedation.24 This finding could be of  major 
clinical importance in older patients, as these adverse events may lead to an increased 
risk of  falls, especially when administering higher doses cannabinoids, as THC is known 
to cause a dose dependent increase in adverse events.25 In the previous systematic review 
from Wang et al., the rate of  serious adverse events did not differ significantly between 
cannabinoid group and controls (RR 1.04, 95% CI 0.78 to 1.39). In our own review, we 
only found one serious adverse event; the development of  a grand mal seizure in an older 
subject with Alzheimer’s disease, directly after receiving 2.5 mg dronabinol.19 
From previous literature, it is not clear whether cannabinoids induce seizures. Animal 
studies even suggest that cannabinoid agonists may actually have an anti-epileptic 
effect,26-28 while CB1 receptor antagonists lower the seizure threshold.
29  Unfortunately, 
a possible anti-epileptic effect of  cannabinoids could not be demonstrated in human 
studies.30 In the light of  the current preliminary literature status, caution is needed 
when prescribing cannabinoids to patients with a history of  seizures or to patients with 
structural brain lesions.
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Our search also included one study that reported the occurrence of  cardiac 
arrhythmias in two older subjects with COPD after administration of  sublingual THC 
and CBD combined.23 Cannabinoids may influence the cardiovascular system, mainly by 
increasing heart rate.25, 31, 32 This effect is probably caused by direct CB1 receptor agonism 
in cardiac tissue, independent of  catecholaminergic ativity.33 To our knowledge, no 
systematically collected data are available on oral cannabinoids and cardiac arrhythmias, 
except for some case reports describing the occurrence of  ventricular fibrillation and 
paroxysmal atrial fibrillation after smoking marijuana.34, 35 Taken together, physicians 
should be reluctant to prescribe medical cannabinoids to (older) patients with a history 
of  severe cardiovascular disease or significant arrhythmia.
Only one study included in our review evaluated the pharmacokinetics of  THC in a 
relatively older subject group.21 This study showed a high inter-individual variability in 
various parameters, consistent with data from young adult subjects, which also showed a 
high variation in Tmax and Cmax.
25, 36-38 One must keep in mind that the pharmacokinetic 
profile of  THC is highly dependent on the route of  administration. As compared to 
inhalation, oral and sublingual administration of  THC is characterized by a slower 
absorption, a more extensive first pass effect and a lower rate of  drug delivery to the 
brain, probably resulting in fewer and delayed adverse effects.31, 37 Remarkably, oral 
administration results in relatively high plasma concentrations of  the metabolite 11-OH-
THC, which in turn contributes to psycho-active symptoms.25 Ageing also affects several 
relevant pharmacokinetic parameters, such as reduced hepatic clearance, because of  an 
decrease in liver mass and hepatic blood flow,5 which might increase the bioavailability 
of  THC. On the other hand, ageing might also lead to a higher volume of  distribution, a 
prolongation in half  life and lower Cmax, due to a relative increase in body fat. Exploratory 
findings from the current systematic review provide too little information to confirm these 
expected changes in pharmacokinetics of  THC in older persons. Direct comparative 
studies in young versus old subjects are therefore most necessary.
Strengths and weaknesses of the review
This study is the first systematic review on medical cannabinoids in older subjects. It 
was developed and executed according the Cochrane Collaboration guidelines,39 using 
a selection procedure based on strict eligibility criteria and resulting in five controlled 
clinical trials. 
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Our search strategy yielded also three open label studies on the efficacy of  
cannabinoids in older persons.40-42 All showed positive effects of  cannabinoids on 
behavioral disturbances in dementia, anorexia in long term care residents and psychotic 
symptoms in Parkinson’s disease, respectively. None reported cannabinoid related adverse 
effects. The absence of  a control product and blind assessments, however, might have led 
to an overestimation of  the efficacy of  the intervention, which was the main reason not 
to include these studies in our analysis. 
Although only prospective and controlled intervention trials were included for 
analysis in this review, four out of  five included trials still had a moderate to high risk of  
bias. This raises the question whether these studies are methodologically deficient and 
could just have been performed better, or whether research on these frail subjects is too 
difficult and complex in practice to meet the high quality methodological criteria. This 
is an important and general paradox in the quest for high quality evidence in frail older 
subjects: the methods needed for high quality evidence are often themselves interventions 
these subjects can no longer stand or comply to. It is therefore highly relevant to carefully 
adapt the study methods (including design, inclusion criteria and outcome measures) to 
the frailty of  the target population.
This review addresses the upcoming interest in the use of  medical cannabinoids 
in the older patient. There is a growing number of  countries permitting the use of  
medicinal cannabinoids, including 18 states in the USA.2, 43 Furthermore, a recent poll 
among readers from New England Journal of  Medicine, showed that a vast majority 
(76%) of  clinicians from a wide variety of  countries worldwide would recommend the use 
of  marijuana in a 68-year old woman with metastatic breast cancer, suffering from pain 
and nausea. Many responders called for more research on this topic to create a stronger 
basis of  evidence.44 As such, this review points at an important problem, namely the 
under-representation of  older subjects in clinical studies and study reports on the medical 
use of  cannabinoids. This under-representation of  elder participants is however not per 
se linked to cannabinoids as a treatment intervention, but is also seen in other medical 
fields, like oncology and cardiovascular medicine.45, 46 Therefore, it is out most important 
to include a significant number of  older subjects in trials on medical cannabinoids, to be 
able to draw firmer conclusions to support clinical decisions. 
The present study was not without shortcomings. First, we aimed to subtract data on 
medical cannabinoids exclusively in older subjects. As a consequence, we were not able to 
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answer the question whether there is an effect of  age on the efficacy and safety of  medical 
cannabinoids. Hence, this would be an important objective for future research in medical 
cannabinoids. Second, it was not possible to provide reliable summary measures (e.g. 
effect sizes) based on the data reported in the original studies. This was caused by three 
major factors; a high heterogeneity among the included studies, the absence of  reported 
means and standard deviations per treatment group, and the generally very small sample 
sizes. Therefore, only qualitative and descriptive summaries could be provided. 
Conclusions and implications
With the growing number of  older patients, there is an urgent need for evidence 
based therapeutic interventions in this group. Many studies have been conducted on the 
efficacy and safety of  medical cannabinoids in a variety of  conditions in adult patients, 
and in a substantial number of  studies, older subjects were included. Nevertheless, 
our review shows that there is a lack of  evidence concerning the use of  cannabinoids 
specifically in older patients, resulting in scarcity of  data to guide treatment decisions. 
Adequately powered trials are needed to assess the efficacy and safety of  cannabinoids 
in older subjects, including a critical evaluation of  the risk-benefit ratio, as the potential 
symptomatic benefits might be attractive for elderly with specific complaints and limited 
lifespan expectancy. It is highly worthwhile to conduct well designed studies on the 
efficacy of  cannabinoids in symptom management in dementia, given the initial positive 
results on weight loss and agitation in this patient population, and the great lack of  other 
effective and safe strategies in this field.
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Supplementary material
Appendix 1 - PubMed search strategy
1. Cannabinoids [MeSH Terms] 
2. Cannabinoids [tiab] 
3. Cannabinoid [tiab] 
4. Cannabinol [tiab] 
5. Cannabidiol [tiab] 
6. Tetrahydrocannabinol [tiab] 
7. THC [tiab] 
8. CBD [tiab] 
9. Marinol [tiab] 
10. Cesamet [tiab] 
11. Sativex [tiab] 
12. Nabilone [tiab] 
13. Dronabinol [tiab] 
14. Delta-9-tetrahydrocannabinol [tiab] 
15. Delta-9-THC [tiab] 
16. Cannabis [tiab] 
17. Marihuana [tiab] 
18. Marijuana [tiab] 
19. Hashish [tiab]
20. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19
21. Aged [MeSH] 
22. Frail [tiab] 
23. Elderly [tiab] 
24. Elder [tiab] 
25. Older [tiab] 
26. Aging [tiab] 
27. Ageing [tiab] 
28. Geriatric* [tiab] 
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
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30. Clinical Query: Therapy/broad = ((clinical[Title/Abstract] AND trial[Title/
Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] 
OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR 
therapeutic use[MeSH Subheading])
31. 20 and 29 and 30
32. Limit 31 to English language
Appendix 2 - EMBASE search strategy
1. (cannabinoids or cannabinoid or cannabinol or cannabidiol or 
tetrahydrocannabinol or THC or CBD or marinol or cesamet or sativex or 
nabilone or dronabinol or delta-9-tetrahydrocannabinol or delta-THC or 
cannabinol or marihuana or marijuana or hashish or cannabis).ti,ab.
2. exp cannabinoid/
3. (frail or elder or older or elderly or aging or geriatric*).ti,ab.
4. aged/
5. 3 or 4
6. 1 or 2
7. 5 and 6
8. exp “clinical trial (topic)”/
9. exp randomization/
10. exp clinical trial/
11. ((clinical and trial) or random*).ti,ab.
12. 8 or 9 or 10 or 11
13. exp drug therapy/
14. 12 or 13
15. 7 and 14
16. limit 15 to English language
Appendix 3 – CINAHL search strategy
1. TI ( cannabinoids OR cannabinoid OR cannabinol OR tetrahydrocannabinol 
OR THC OR CBD OR marinol OR cesamet OR sativex OR nabilone OR 
dronabinol OR delta-9-tetrahydrocannabinol OR delta-THC OR cannabinol 
OR cannabidiol OR marihuana OR marijuana OR hashish OR cannabis ) 
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2. AB ( cannabinoids OR cannabinoid OR cannabinol OR tetrahydrocannabinol 
OR THC OR CBD OR marinol OR cesamet OR sativex OR nabilone OR 
dronabinol OR delta-9-tetrahydrocannabinol OR delta-THC OR cannabinol 
OR cannabidiol OR marihuana OR marijuana OR hashish OR cannabis )
AB (cannabinoids OR cannabinoids OR cannabinol OR tetrahydrocannabinol 
OR THC OR CBD OR marinol OR cesamet OR sativex OR nabilone OR 
dronabinol OR delta-9-tetrahydrocannabinol OR delta-THC OR cannabinol 
OR cannabidiol OR marihuana OR marijuana OR hashish OR cannabis)
3. 01 or 0201 or 02
4. (MH “Cannabis”)(MH “Cannabis”)
5. 03 or 0403 or 04
6. TI ( frail OR elderly OR elder OR older OR aging OR geriatric* )
7. AB ( frail OR elderly OR elder OR older OR aging OR geriatric* ) 
8. 06 or 07
9. (MH “Aged+”)
10. 08 or 09
11. 05 and 10
12. (MH “Drug Therapy+”)
13. (MH “Clinical Trials+”)
14. TI (clinical and trial)
15. TI (random*)
16. 14 or 15
17. AB (clinical and trial)
18. AB (random*)
19. 17 or 18
20. 16 or 19
21. (MH “Random Assignment”)
22. 12 or 13 or 20 or 21
23. 11 and 22
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Appendix 4 - Cochrane Library search strategy
1. Cannabis
2. Cannabinoid*
3. 01 or 02
4. Elderly
5. 03 and 04
The time when kindness falls like rain
It washes me away and Anna begins to change my mind
And every time she sneezes I believe it’s love
and I’m not ready for this sort of thing
She s talking in her sleep
It s keeping me awake
And Anna begins to toss and turn
And every word is nonsense but I understand them all
Oh lord, I’m not ready for this sort of thing
Her kindness bangs a gong
It’s moving me along and Anna begins to fade away
It s chasing me away
She disappears, and I’m not ready for this sort of thing
Counting crows  -  Anna Begins
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Abstract
Objectives: Neuropsychiatric symptoms (NPS) are highly prevalent in dementia, 
while effective pharmacotherapy without important side-effects is lacking. This 
study aims to assess the efficacy and safety of  oral tetrahydrocannabinol (THC) in 
the treatment of  NPS in dementia.
Design: Randomized, double-blind, placebo-controlled, repeated crossover trial, 
consisting of  six treatment blocks of  two weeks each. 
Setting: Two hospital sites in The Netherlands, September 2011 to December 
2013.
Participants: Patients with dementia and clinically relevant NPS.
Intervention: Within each block THC (0.75mg twice daily in block 1-3 and 
1.5mg twice daily in block 4-6) and placebo were administered in random order for 
three consecutive days, followed by four-day washout.
Measurements: Primary outcome was change in Neuropsychiatric Inventory 
(NPI) score. Analyses were performed intention-to-treat. Data from all subjects 
were used without imputation. Sample size required for a power of  80% was 20 
patients, because of  repeated crossover.
Results: Twenty-two patients (15 men, mean age 76.4 [5.3] years) were included, 
of  whom 20 (91%) completed the trial. THC did not reduce NPI compared to 
placebo (block 1-3: 1.8, 97.5%CI -2.1 to 5.8; block 4-6: -2.8, 97.5%CI-7.4 to 1.8). 
THC was well tolerated, as assessed by adverse event monitoring, vital signs and 
mobility. The incidence of  adverse events was similar between treatment groups. 
Four non-related serious adverse events occurred. 
Conclusions: This is the largest randomized controlled trial studying the efficacy 
of  THC for NPS, to date. Oral THC did not reduce NPS in dementia, but was 
well tolerated by these vulnerable patients, supporting future higher dosing studies. 
Keywords: dementia, neuropsychiatric symptoms, tetrahydrocannabinol, rand-
omized controlled trial.
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Introduction
Nearly all patients with dementia experience behavioral and psychological symptoms 
throughout the course of  the disease, including agitation, delusions and aberrant motor 
behavior.1 These neuropsychiatric symptoms (NPS) result in a reduction in quality of  life 
and cognitive functioning, are distressing to caregivers and lead to early institutionalization 
of  patients.2-5 Agitation, on which a recent consensus definition has been developed,6 
is one of  the most prevalent dementia-related NPS.7 Agitated behavior and aggression 
are commonly treated with antipsychotic agents. In Dutch nursing homes, these are the 
most frequently prescribed psychotropic drugs in dementia patients.8 Unfortunately, 
benefits of  their use are mostly limited,9 while adverse effects are harmful, including 
stroke and increased mortality risk.10 Other frequently used psychotropic drugs, such as 
antidepressants, anti-epileptic drugs and benzodiazepines, also have limited effects and 
serious side-effects in frail dementia patients.11 Citalopram, for example, is often used 
in clinical dementia practice to reduce agitation. High doses have indeed been shown 
effective, yet, the practical application is limited by significant cardiac adverse effects, 
resulting in a clinically significant prolongation of  the QTc interval, compared to placebo 
(difference QTc adjusted for baseline value: 18.1ms [95% confidence interval 6.1 to 30.1], 
p=0.01).12 This highlights the need for alternative pharmacological interventions with an 
improved benefit-to-risk ratio. Medical cannabinoids might be such an alternative. Indeed, 
preliminary studies with oral tetrahydrocannabinol (THC) indicated improvement in 
agitated behavior and nocturnal motor activity in patients with Alzheimer’s disease.13, 14 
Nonetheless, THC may also cause relevant side-effects, such as dizziness and sedation,15 
although data on safety in older patients are lacking.16 Therefore, in this randomized 
controlled trial, we aimed to study the efficacy and safety of  relatively low doses oral 
THC on NPS, with a focus on agitation and aggression, in patients with dementia.
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Methods
Study design
This was a multicenter, phase II, repeated crossover, randomized, double-blind, 
placebo-controlled trial, conducted in accordance with the Declaration of  Helsinki, 
Good Clinical Practice, and International conference on Harmonisation guidelines 
and registered at www.clinicaltrials.org (NCT01302340). The study took place at the 
Alzheimer Centre of  the Radboud university medical center (Radboudumc, Nijmegen, 
The Netherlands) and the Vincent van Gogh Institute (Venray, The Netherlands), 
between September 2011 and December 2013. It was approved by the certified ethics 
committee of  Radboudumc. Written informed consent was provided before screening 
by the patient and closest proxy; the first only in case the patient was judged capable to 
consent. Patients were assessed at baseline, approximately two weeks before start of  study 
medication. Actual study duration was 12 weeks, including two treatment periods of  
three blocks each (Figure 1). In treatment period A (block 1-3), low dose THC treatment 
of  0.75mg twice daily was alternated by placebo. The dosage was increased to 1.5mg 
THC twice daily in period B (block 4-6). Each block contained two drug periods: THC 
for three consecutive days, followed by placebo (or vice versa) and separated by a four-
day-washout period. As the pharmacodynamic effects of  oral THC occurred within 1-2 
hours after administration in a previous phase I study,17 a study period of  three days was 
expected to be sufficient to evaluate the acute effects of  THC on behavior. The duration 
of  the washout period of  four days was determined based on the terminal half  lives of  
THC (mean 71.9 min) and its active metabolite 11-OH-THC (mean 196 min) after oral 
administration of  5mg THC in the same study.17 
The current crossover study was followed by an optional open label extension phase 
of  six months to assess long-term tolerability and safety, of  which the methods and results 
are reported in the Appendix and Appendix Table 1. 
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Allocation to THC and placebo was randomized per block. Therefore, this schematic overview represents an example 
of treatment allocations. Period A: 0.75mg THC twice daily vs. placebo twice daily for three consecutive days, 
separated by a four-day washout period. Period B: 1.5mg THC twice daily vs. placebo twice daily for three consecutive 
days, separated by a four-day washout period.
FIGURE 1 
Schematic overview of study design
Changes to study design
Initially, patients were admitted to the hospital during the three intervention days of  
block 1 and 4, for safety evaluation. The burden of  these admissions was however the 
main reason that patients declined participation. After inclusion of  the first 10 patients 
(‘hospital admission group’), the intervention was judged to be safe by the researchers. 
Therefore, the study protocol was amended, omitting the hospital admissions, which 
was approved by the ethical committee. In the revised protocol (‘ambulatory group’), 
admissions were replaced by a five-hour day clinic visit (day 1), follow-up phone call (day 
2) and home visit (day 3), while safety could still be closely monitored.
Patient eligibility
Patients diagnosed with dementia type Alzheimer, vascular or mixed, according to the 
NINCDS-ADRA18 or NINCDS-AIREN19 criteria were eligible for participation if  they 
suffered from clinically relevant neuropsychiatric symptoms (Neuropsychiatric Inventory 
[NPI] score ≥ 10), with at least agitation or aggression. An informal caregiver had to 
be available. Initially, patients with mild to moderate dementia were included (Clinical 
Dementia Rating Scale [CDR] 0.5-2). After inclusion of  10 patients, this criterion 
was broadened to also include patients with severe cognitive disorders (CDR 2-3). 
Exclusion criteria were: major psychiatric disorder, severe or instable concomitant illness 
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necessitating treatment changes, frequent falling due to orthostatic hypotension, and 
a history of  alcohol or drug abuse. Patients using tricyclic antidepressants and opioids 
were excluded. Additionally, as THC is metabolized in the liver through the cytochrome 
P-450 enzymes (CYP): CYP2C9, CYP2C19 and CYP3A4, patients using drugs from 
a predesigned list of  inhibitors of  these enzymes were excluded. Use of  concomitant 
psychotropic medication was allowed. 
Intervention and randomization
Active treatment consisted of  0.75 and 1.5mg THC in tablet form (Namisol®, Echo 
Pharmaceuticals B.V., Weesp, the Netherlands). These dosages were chosen relatively 
low, based on the positive results of  previous preliminary trials using dronabinol,13, 14 in 
combination with the lack of  experience concerning Namisol® in a frail patient group, 
complying to the generally guiding principle in  pharmacological interventions in older 
patients, namely  ‘to start low, and go slow’. Placebo tablets were matched to the active 
treatment for weight, taste, color and size. Patients’ caregivers were asked to administer 
the tablets daily (with the exception of  hospital admissions). Study medication was 
administered at 10 a.m. and 4 p.m., because NPS often occur later on the day, when 
fatigue and external signals increasingly interfere. The order of  administration of  THC 
and placebo was randomized (1:1) per block. Randomization was performed by the 
Radboudumc pharmacy according to a computer-generated randomization list. The 
allocation sequence was strictly concealed from participants, caregivers, investigators and 
all other personnel directly involved in the study. Treatment allocations were not made 
available until study completion and database lock.
Outcomes
Primary outcome measure
The primary outcome was change in NPS, as measured by NPI.20 This questionnaire 
is frequently used to assess neuropsychiatric psychopathology in interventional studies in 
dementia and sensitive to detect clinical improvement in agitated behavior.21 It evaluates 
12 behavioral domains of  which the frequency and severity of  NPS are scored by a 
caregiver. This results in a final score ranging from 0 to 144 (a higher score indicating 
greater impairment). The 4-point frequency scale was slightly modified to make it 
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suitable for weekly assessment. NPI was assessed at baseline and every third treatment 
day, resulting in two NPI scores per block. 
Secondary outcome measures
Weekly secondary efficacy assessments included Cohen-Mansfield Agitation Inventory 
(CMAI), a 29-item observation instrument for assessment of  agitated behavior22 and 
Zarit Burden Interview (ZBI), a 22-item questionnaire to assess caregiver burden.23 
Safety assessments
Adverse events
Adverse events (AEs) were solicited from patients and their caregivers at all study 
visits, using open questions and clinical observations. All reports of  AEs were recorded, 
whether or not they were deemed to be related to study treatment. AEs were coded 
following the classification of  Medical Dictionary for Regulatory Activities (MedDRA). 
An AE was defined as serious adverse event (SAE) if  it was fatal or life-threatening, 
required (prolonged) hospitalization, or resulted in persistent or significant disability or 
incapacity. 
Mobility assessments
Influence of  study medication on balance and gait was assessed using two functional 
mobility tests for frail older adults: Tinetti Performance–Oriented Mobility Assessment 
(Tinetti POMA)24 and Timed Up and Go (TUG).25 More extensive quantitative gait and 
balance analyses were performed using GAITRiteTM and SwayStarTM.26, 27 Only patients 
who were able to walk ten meters and understood simple instructions were included in 
these assessments. 
Other safety assessments
The occurrence and severity of  ‘feeling high’ and effects on internal and external 
perception were quantified by using the Bowdle Visual Analogue Scale (VAS) rating of  
13 symptom scales28 during all visits. Other assessments of  safety included vital signs, 
physical examination and weight, laboratory tests, electrocardiography and Delirium 
Observation Scale.29 See Appendix Table 2 for a detailed overview of  all assessments. 
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Monitoring
Source document review and verification was performed on a regular basis by Clinical 
Research Centre Nijmegen. Monitoring of  safety was performed by an independent 
Data Safety Monitoring Board (DSMB), which met regularly during trial conduction to 
review unblinded data. The DSMB recommended continuation of  the trial without any 
protocol changes after every review.  
Statistical analysis
The study sample size was estimated based on two-sided testing at 0.025 per treatment 
period, a standard deviation of  NPI score of  eight points at baseline,30 a clinically relevant 
difference of  four points31, 32 and a test-retest correlation of  0.65. Sixteen patients with 
complete data would be sufficient to provide a power of  80%, due to multiple crossover. 
As we expected a rather high attrition rate (25%) among the vulnerable patients in this 
study, we aimed to enroll at least 20 subjects.
Analyses were based on the intention-to-treat principle, which means that data were 
analyzed according to initial treatment assignment, independent of  received treatment, 
compliance or attrition. Data of  all subjects was used in the analysis without imputation. 
Analyses were performed according to a pre-specified statistical analysis plan, which 
was finalized before unmasking of  treatment assignment. Differences between THC 
and placebo on NPI scores were analyzed using linear mixed model with participants as 
random factor and block (six levels) and treatment (three levels: placebo, ‘low dose’ THC, 
‘high dose’ THC) as fixed factors. 95% Confidence intervals (CI) were calculated. Analyses 
were repeated for two dosage regimens versus placebo separately (with 97.5%CI) and 
for hospital-admission group and ambulatory group separately. Other efficacy outcome 
measures were analyzed similarly to the primary analysis. Due to a significant effect of  
type of  assessor on CMAI scores (mean difference
caregivers vs. research staff
 +16.5 points, linear 
mixed model analysis with random intercept per subject, type 3 test of  fixed effects, num 
df=1, den df=302, F=188.47, p<0.0001) analysis of  CMAI scores was repeated with 
additional correction for assessor. The number of  AEs was tabulated by system organ 
class. AEs were assigned to THC or placebo when the event started during treatment 
or during the subsequent washout period. Differences in AE rates between THC and 
placebo treatment were compared by non-linear mixed model analysis, assuming Poisson 
distribution of  AEs. Frequency of  SAEs was analyzed using descriptive statistics. The 
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correlation between time after THC intake (0-240 min) and vital signs was analyzed in 
a linear mixed model with ‘subject’ as random factor and heart rate (HR), systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) as variables. For body sway during 
standing tasks, ranges of  angular velocities and angles in anteriorposterior direction were 
calculated. Gait velocity and stride length variability were selected as outcome measures 
for quantitative gait analysis. Variability was expressed in coefficients of  variation (CV) 
as standard deviation/mean x 100%. Effects of  1.5mg THC twice daily versus placebo 
on body sway and gait were analyzed using a dependent t-test or Wilcoxon signed rank 
test, as appropriate. VAS Bowdle scores could not be obtained from persons with severe 
cognitive disorders and were therefore only assessed in a part of  the study population. 
Analysis of  questionnaires was done as reported elsewhere,33 using three clusters: ‘feeling 
high’, ‘internal perception’ and ‘external perception’. Pharmacokinetic data were also 
collected during the crossover study; these will be described and published separately. 
Results
Study participants
In total, 23 patients were assessed for eligibility of  whom 22 fulfilled the entry 
requirements, who were randomized and received study medication (Figure 2). 
Demographic and baseline characteristics are summarized in Table 1 and an overview 
of  co-morbidities is provided in Appendix Table 3. Baseline NPI scores were significantly 
higher in the ambulatory group compared to the hospital admission group (t= -2.56, 
df=20, p=0.019). Twenty patients (91%) completed the 12-week crossover study and two 
patients dropped out because of  non-related AEs. 
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Abbreviations: T, THC; P, Placebo. Period A: 0.75mg THC twice daily vs. placebo twice daily for three consecutive 
days, separated by a four-day washout period. Period B: 1.5mg THC twice daily vs. placebo twice daily for three 
consecutive days, separated by a four-day washout period. a One patient discontinued in the first block of this period. 
b One patient discontinued in the third block of this period.
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TABLE 1
Demographic and baseline characteristics
All 
(n=22)
Hospital admission 
group
(n = 10)
Ambulatory
 group
(n=12)
Men, n (%) 15 (68) 7 (70) 8 (67)
Age, yr, mean (SD) 76.4 (5.3) 77.3 (5.6) 75.6 (5.2)
BMI, kg/m2, mean (SD) 25.7 (3.3) 25.7 (2.7) 25.7 (3.8)
Ethnicity, n (%)
Caucasian
Other
21 (95.5)
1 (4.5)
9 (90)
1 (10)
12 (100)
0 (0)
Educationa, mean (SD) 4.3 (1.5) 4.0 (1.6) 4.6 (1.3)
Type of dementia, n (%)
Alzheimer
Vascular
Mixed
18 (81.8)
1 (4.5)
3 (13.6)
9 (90)
0 (0)
1 (10)
9 (75)
1 (8.3)
2 (16.7)
Relevant co-medication, 
Number of medication (n patients)
All psychotropic medication
Antipsychotic
Antidepressant
Anxiolytic
Anticonvulsants
Antidementia
33 (18)
2 (2)
6 (6)
7 (5)
1 (1)
17 (11)
19 (10)
1 (1)
1 (1)
0 (0)
1 (1)
16 (10)
14 (8)
1 (1)
5 (5)
7 (5)
0 (0)
1 (1)
MMSE scoreb, mean (SD) 16.9 (7.8) 18.5 (6.0) 15.2 (9.2)
NPI scorec, mean (SD) 35.0 (16.5) 26.2 (17.7) 42.3 (11.8)
NPI agitation/aggression scorec, mean (SD) 4.1 (2.4) 3.6 (2.8) 4.6 (2.0)
CMAI scorec, mean (SD) 58.3 (17.4) 54.0 (19.8) 62.0 (15.1)
ZBI scored, mean (SD) 36.0 (15.1) 34.5 (19.0) 37.3 (11.4) 
Abbreviations: BMI, Body Mass Index; MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory; CMAI, 
Cohen-Mansfield Agitation Inventory; ZBI, Zarit Burden Interview. a Education was determined with seven categories 
where 1 indicates less than six years of primary school and 7 indicates a university degree. b Mean MMSE score 
based on 20 patients (2 missings due to severe cognitive disturbances): 10 patients in hospital admission group and 
10 patients in ambulatory group. c Mean score of two baseline assessments separated by at least one week. d Mean 
ZBI score based on 21 patients: 10 patients in hospital admission group and 11 patients in ambulatory group.
Efficacy
Primary outcome
Study results are presented in Table 2. There was no effect of  THC treatment 
compared to placebo on NPI. No differences were found between low dose THC and 
placebo and between high dose THC and placebo. Analysis per group did also not show 
significant differences between the interventions. A substantial increase in NPI scores 
over the 12-week study duration was found (mean increase per week 0.07 points, trend 
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analysis with random intercept per subject, test of  fixed effects, Num df=1, Den df=234, 
F=12.92, p=0.0004). This increase was observed in both THC and placebo treatment 
periods. Furthermore, for the hospital admission group, NPI scores during hospital 
admissions were significantly lower than scores assessed during home visits. In a post 
hoc analysis, we explored our data for clinically relevant effects, defined as a reduction 
of  four points or more. Overall, THC versus placebo, induced a clinically relevant 
decrease in NPI scores in 38.9% of  treatment blocks (period A, 33.3%; period B, 44.3%; 
χ2=3.19, df=1, p=0.074, ORB versus A 1.58, 95%CI 0.96 to 2.61). An increase in NPI scores, 
indicating a clinically relevant worsening of  NPS, was found in 31.5% (period A, 36.4%; 
period B, 26.2%; χ2=2.88, df  =1, p=0.090, ORB versus A 0.62, 95%CI 0.36 to 1.08).  
Secondary outcomes
No significant differences were found between THC and placebo on agitated behavior 
and caregiver burden, as measured with NPI subscale agitation/aggression, CMAI and 
ZBI (Table 2). Furthermore, no differences were found for low dose THC or high dose 
THC versus placebo on these variables. Overall, a substantial increase of  CMAI and ZBI 
scores was observed over the 12-week study period.
Safety
Adverse events
In total, 184 AEs of  mild to moderate severity occurred during the crossover study 
period, similarly distributed over the THC (91 AEs) and placebo (93 AEs) conditions 
(nonlinear mixed model analysis assuming Poisson distribution of  AEs, random intercept 
per subject, t= -0.29, df=21, p=0.77, incidence rate ratio 0.96, 95%CI 0.7 to 1.3) (Table 3). 
There was no increase in occurrence after administration of  high dose THC. Four SAEs 
occurred in three patients, all requiring (prolongation of) hospitalization: a gastroenteritis, 
increase in dementia-related NPS symptoms, an exacerbation of  a previously known 
vestibular disorder, and symptoms of  a malignancy of  unknown origin. None of  these 
SAEs were judged to be related to study medication. Two patients dropped out due to the 
occurrence of  symptoms of  a malignancy (n=1) and due to extensive use of  psychotropic 
rescue medication (n=1).   
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TABLE 3
Adverse events during crossover study
MedDRA system organ class THC 
Period A
No.
THC 
Period B
No.
Placebo 
Period A
No.
Placebo 
Period B
No.
Severe adverse events (≥grade 3) 0 0 0 0
Mild to moderate adverse events 46 45 48 45
Administration site 3 0 2 2
Blood and lymphatic system disorders 0 0 0 1
Cardiac disorders 1 4 5 1
Ear and labyrinth disorders 3 1 1 3
Gastrointestinal disorder 4 3 4 0
General disorders 6 5 3 6
Injury and procedural complications 3 1 2 2
Investigations 0 0 0 2
Metabolism and nutritional disorders 0 1 2 1
Musculoskeletal disorder 3 3 0 2
Nervous system disorders 9 6 13 6
Psychiatric disorders 9 13 10 15
Renal and urinary tract infections 1 1 1 1
Respiratory disorders 2 6 0 1
Skin and subcutaneous tissue disorders 0 0 2 1
Vascular disorders 2 1 3 1
Numbers are numbers of events. Abbreviations: MedDRA, Medical Dictionary for Regulatory Activities; THC, 
tetrahydrocannabinol. Period A: 0.75mg THC twice daily; period B: 1.5mg THC twice daily.
Treatment compliance and concurrent medication use
Overall treatment compliance to study medication was high; 98.5% of  tablets were 
administered (THC, 99.5%; placebo, 97.8%). Psychotropic rescue medication (mostly 
benzodiazepines) was provided similarly over all conditions: in period A eight times (four 
patients) during THC and 13 times (four patients) during placebo, and in period B ten 
times (four patients) during THC and seven times (three patients) during placebo.
Other safety outcomes
High dose THC increased SBD by 2.6 mmHg compared to placebo within four hours 
after first tablet intake, while no effects were found on HR and DBP. Overall, THC did 
not have an effect on mobility assessed with Tinetti and TUG (Table 4). High dose THC 
did not affect balance when patients were standing on two legs with their eyes open. In 
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the eyes closed condition, body sway increased significantly after administration of  THC, 
compared to placebo (Cohen’s d for pitch velocity, 0.59). No effects were found on velocity 
or stride length variability during walking on preferred speed. Average body weight at the 
end of  the study did not differ from screening (dependent t-test 0.05, 95%CI -1.1 to 1.0). 
Feeling high was not reported nor observed in any patient. Analyses of  questionnaires 
showed low VAS scores (median for feeling high, 0.30; external perception, 0.30; internal 
perception 0.24). THC did not have an effect on VAS scores, with the exclusion of  low 
dose THC on internal perception (mean differenceTHC vs placebo 0.025, 95%CI 0.01 to 0.04, 
linear mixed model analysis, random intercept per subject, type 3 test of  fixed effects: 
Num df=1, Den df=274, F=10.45, p=0.0014), which was judged not to be a clinically 
relevant increase.
TABLE 4
Results of mobility assessments 
THC vs. placebo 
(95%CI)
Low dose THC vs. 
placebo
(97.5%CI)
High dose THC vs. 
placebo 
(97.5%CI)
TUGa +0.1 (-0.4 to 0.6)c +0.4 (-0.3 to 1.0)e 0.05 (-0.6 to 0.7)g
Tinetti POMAb -0.1 (-0.4 to 0.3)d +0.1 (-0.4 to 0.5)f -0.2 (-0.6 to 0.2)h
High dose THC 
Median (range)
Placebo
Median (range) p-value 
SwayStarTM  - Standing on two legs eyes open
Pitch angle (deg) 2.13 (0.90 – 6.05) 2.61 (0.77 – 9.84) 0.41i
Pitch velocity (deg/s) 4.91 (1.75 – 15.27) 3.85 (1.43 – 31.45) 0.98*
SwayStarTM  - Standing on two legs eyes closed
Pitch angle (deg) 3.45 (0.82 – 7.84) 2.38 (0.87 – 9.29) 0.01j
Pitch velocity (deg/s) 6.70 (1.56 – 35.54) .67 (1.82 – 40.99) 0.02k
GAITRiteTM  - Walking on preferred speed
Velocity (cm/s) 93.10 (58.2 – 132.3) 91.70 (50.2 – 125.1) 0.06*
Stride length variability (%CV) 4.49 (1.70 – 13.54) 4.42 (1.82 – 92.19) 0.41*
TUG and Tinetti POMA scores were assessed weekly and analyzed as a linear mixed model, similarly to the 
primary efficacy analysis. SwayStarTM and GAITRiteTM assessments were performed twice in period B (1.5mg THC 
and placebo) and were analyzed using a dependent t-test or Wilcoxon signed rank test (the latter indicated by 
*). Abbreviations: TUG, Timed Up and Go; Tinetti POMA, Tinetti Performance-Oriented Mobility Assessment; CV, 
coefficient of variation. a 60 missing values (29 on THC, 31 on placebo). b 74 missing values (34 on THC, 40 on 
placebo). c t=0.42, df=162. d t= -0.32, df=175. e t=1.04, df=75. f t=0.41, df=83. g t=0.13, df=68. h t=0.90, df=72. 
i t=-0.85, df=17.  j t=2.97, df=17. k t=2.50, df=17.
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Conclusions
In the present study, we found no benefit of  THC treatment (0.75mg and 1.5mg, 
twice daily) on NPS in dementia on either of  the outcome measures. Although THC 
failed to improve NPS, intermittent treatment demonstrated safety in older dementia 
patients. Previous studies all showed positive effects of  THC (2.5 to 7.0mg daily) on 
behavioral and nighttime disturbances.13, 14, 34, 35 However, two of  these studies were RCTs 
with a small number of  patients (n=2; n=15),14, 34 one study had a retrospective design35 
and one was an uncontrolled open label study.13 These factors all introduce bias, possibly 
leading to an overestimation of  the treatment effect. To date, data on safety of  medical 
cannabinoids in older patients are scarce,16 while more comprehensive data result from 
research in younger adult patients.15 These latter studies report more AEs following THC 
treatment, compared to placebo (incidence rate ratio [IRR] 2.18), especially within the 
first two treatment weeks (IRR 2.91).15 Most commonly reported AEs are related to the 
central nervous system, such as dizziness and somnolence. As the patient characteristics 
and route of  administration in these studies are diverse and the administered dosages 
significantly higher (5 to 45mg THC daily), no direct comparison can be made with the 
results provided in the current study. Concerning dementia patients, previous studies 
report no AEs after administration of  2.5mg THC daily.13, 34 Nevertheless, administration 
of  higher dosages (5.0 to 7.0mg daily) resulted in the occurrence of  AEs, such as sedation, 
euphoria and delirium.14, 35 The current study is the first to assess safety by using reports 
of  AEs, as well as vital signs and mobility assessments. The lack of  relevant side effects 
suggests that the current dosages are well tolerated when administered for a short 
duration. This suggests that it might be worthwhile to conduct higher dosing studies, 
provided that the dose is gradually increased. 
To our knowledge, this is one of  the largest randomized controlled trial studying the 
efficacy of  THC in dementia patients by using a scientifically sound design. Due to the 
expected acute psycho-active effects of  THC, we chose a repeated measurements design 
with short intervention periods. This design made it possible to conduct a methodologically 
valid trial, warranting the need of  a relatively small number of  subjects, and is therefore 
suitable for research in frail, dementia patients. The attrition rate in the crossover study 
was low (9%), and treatment compliance high (98.5%). Most participating caregivers 
experienced dementia-related NPS as a serious problem, leading to a high internal 
motivation to complete study participation. 
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This study also had limitations. Despite the fact that we have included the number 
of  patients needed based on the power analysis prior to study conduction, there are 
several factors that might have reduced our ability to detect a treatment effect. First, the 
administered dosages were fixed. We chose our dosages relatively low to minimize safety 
risks for these frail participants, based on the dosages used in previous studies in dementia 
patients,13, 14 and the safety results of  the phase I study on healthy young volunteers,17 
expecting dementia patients to be more vulnerable to the psycho-active adverse effects 
of  THC. In retrospect, the dosages administered could have been higher. Second, the 
intervention period was relatively short, based on the expected acute pharmacodynamic 
effects of  oral THC.17 The introduction of  longer treatment periods might increase 
the ability to detect an effect, as NPS can vary. Third, the hospital admissions led to 
significantly lower NPI scores compared to scores assessed during home stays. This 
may be caused by the daily structure that was offered by the nursing staff and minimal 
presence of  the informal caregiver. Fourth, we found a larger standard deviation in 
NPI scores than expected, based on previous studies resulting in a lower power.30 Fifth, 
although the NPI total score at baseline is comparable to other intervention studies on 
dementia-related NPS, the severity of  agitation is lower, represented by lower baseline 
NPI agitation/aggression and CMAI scores.12, 36 Sixth, we observed an increase in NPI, 
CMAI and ZBI scores over time. These outcome measures were assessed by an informal 
caregiver, closely involved in the care for the participant. Therefore, a high burden of  
study participation or a failure to observe an expected treatment effect, are possible 
explanations for this increase. Last, we did not include nursing home patients. This was 
hampered by legislation on drug delivery, despite the fact that these patients probably 
are the main target group for psychoactive interventions in NPS. This study, however, is 
an informative step in the development of  new drug therapies, specifically targeting this 
complex patient group.
To conclude, oral THC up to 1.5mg twice daily did not reduce behavioral 
disturbances in patients with dementia. Yet, assessments of  safety by using reports of  
adverse events, vital signs and mobility showed that the intervention was well tolerated by 
this patient group. As we studied a relatively low dose, these results suggest that it might 
be worthwhile to conduct future higher dose studies in the treatment of  dementia-related 
behavioral disturbances.  
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Supplementary material
Appendix: Open label extension phase
Methods. At the end of  the 12-week study period, patients were asked to participate 
in an optional, open label extension study when study treatment was well tolerated and 
intuitively judged to be profitable based on blinded NPI scores. In this extension study, 
subjects visited the research center at 4 weeks, 3 months and 6 months for assessment 
of  NPI, CMAI, ZBI, mobility, Mini Mental State Examination (MMSE) and safety 
parameters. All patients who participated in the optional open label extension phase were 
included in the safety analysis, as assessment of  long term tolerability and safety was the 
primary objective of  this study phase. Additionally, patients with three completed NPI 
scores during this extension phase were included in the analysis of  long term efficacy. 
Mean differences of  the three time points were compared using repeated measures 
ANOVA.
Results. Twelve out of  22 patients (54.5%) entered the open label extension study 
on the patients’ or caregivers’ request, of  whom five (41.7%) completed this six month 
treatment period. Reasons for premature discontinuation were: lack of  efficacy (n=2), lack 
of  study drug compliance (n=1), illness of  the primary caregiver (n=1), and admission 
to a nursing home (n=3). These latter patients dropped out, as the nursing homes were 
not in the possession of  a permit for handling THC for research purposes, which is 
mandatory in The Netherlands. Median treatment duration was 140 days (range 15 to 
188 days). Two patients received a daily dose THC of  1.5mg, nine patients received 3mg 
and one patient 4.5mg THC. In total, 16 AEs of  mild to moderate severity occurred. The 
most common AEs were ‘agitation’ (n=2), ‘anaemia’ (n=2) and ‘urinary tract infection’ 
(n=2). One severe AE occurred: a hospitalization in a specialized dementia care unit for 
further observation of  cognition and behavior. AEs did not lead to study discontinuation 
in any of  the patients. THC did not affect cognition, mobility or weight. Furthermore, no 
differences were found on the different time points on NPI, CMAI and ZBI (Appendix 
Table 1).
Conclusion. This preliminary open label study phase showed that long term 
treatment with low dose THC was well tolerated by patients with dementia and did not 
affect behavioral disturbances or caregiver burden. These results must be interpreted 
with caution, as the attrition rate in this phase was high (58.3%).
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APPENDIX TABLE 1
Results of the open label extension phase
Week 4
(n=6)
Week 12
(n=6)
Week 24
(n=6)
p-value
Safety assessments
MMSE 18.2 (15.4)a 18.6 (3.6)a 18.4 (6.8)a 0.96
TUG (s) 13.2 (2.7) 15.2 (5.4)b 13.6 (4.0)a 0.38
Tinetti POMA 25.3 (1.9) 24.4 (4.3)a 25.6 (3.2)a 0.44
Weight (kg) 79.0 (10.6) 78.2 (10.9) 76.8 (9.4) 0.14
Efficacy assessments
NPI total 25.3 (11.9) 28.2 (11.1) 23.3 (12.9) 0.70
NPI agitation scale 3.0 (3.3) 3.3 (2.6) 2.2 (3.0) 0.72
CMAI 53.8 (16.1) 53.3 (15.3) 56.6 (22.7)a 0.83
ZBI 38.0 (20.5) 42.5 (17.1) 32.4 (15.1)a 0.51
Values are means (SD) from all patients with three NPI assessments. Abbreviations: MMSE, Mini Mental State 
Examination; TUG, Timed Up and Go; Tinetti POMA, Tinetti Performance-Oriented Mobility Assessment; NPI, 
Neuropsychiatric Inventory; CMAI, Cohen-Mansfield Agitation Inventory; ZBI, Zarit Burden Interview. a Results based 
on five patients. b Results based on four patients.
 
CHAPTER 3
Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial
69
3
AP
PE
N
D
IX
 T
AB
LE
 2
Sc
he
du
le
 o
f a
ss
es
sm
en
ts
 p
er
 g
ro
up
 d
ur
in
g 
tr
ia
l p
er
io
d.
 
Pe
rio
d 
A
Pe
rio
d 
B
Bl
oc
k 
1
Bl
oc
k 
2
Bl
oc
k 
3
Bl
oc
k 
4
Bl
oc
k 
5
Bl
oc
k 
6
W
1
W
2
W
3
W
4
W
5
W
6
W
7
W
8
W
9
W
10
W
11
W
12
D
1
D
2
D
3
D
1
D
2
D
3
D
3
D
3
D
3
D
3
D
1
D
2
D
3
D
1
D
2
D
3
D
3
D
3
D
3
D
3
N
PI
H
os
pi
ta
l 
1
1
1
1
1
1
1
1
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
1
1
1
1
1
1
1
1
CM
AI
H
os
pi
ta
l 
2
2
2a
2
2
2a
1
1
1
1
2
2
2a
2
2
2a
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
ZB
I
H
os
pi
ta
l 
1
1
1
1
1
1
1
1
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
1
1
1
1
1
1
1
1
TU
G
 &
 T
in
et
ti
H
os
pi
ta
l 
2
2
2b
2
2
2b
1
1
1
1
2
2
2b
2
2
2b
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
G
R
 &
 S
w
ay
H
os
pi
ta
l 
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
W
ei
gh
t
H
os
pi
ta
l 
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Am
bu
la
to
ry
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Vi
ta
l s
ig
ns
H
os
pi
ta
l 
16
c
13
13
16
c
13
13
1
1
1
1
16
c
13
13
16
c
13
13
1
1
1
1
Am
bu
la
to
ry
c
9c
1
9c
1
1
1
1
1
9c
1
9c
1
1
1
1
1
B
ow
dl
e
H
os
pi
ta
ld
 
4
4
4
4
4
4
1
1
1
1
4
4
4
4
4
4
1
1
1
1
Am
bu
la
to
ry
e
2
1
2
1
1
1
1
1
2
1
2
1
1
1
1
1
EC
G
H
os
pi
ta
l 
1
1
1
1
1
1
Am
bu
la
to
ry
1
1
2
1
1
D
OS
H
os
pi
ta
l
3
3
3
3
3
3
3
3
3
3
3
3
Am
bu
la
to
ry
Bl
oo
d
H
os
pi
ta
l 
1
Am
bu
la
to
ry
1
B
ol
d 
nu
m
be
rs
 in
di
ca
te
 th
e 
as
se
ss
m
en
ts
 w
hi
ch
 a
re
 u
se
d 
in
 th
e 
an
al
ys
es
. A
bb
re
vi
at
io
ns
: N
PI
, N
eu
ro
ps
yc
hi
at
ric
 In
ve
nt
or
y;
 C
M
AI
, C
oh
en
-M
an
sfi
el
d 
Ag
ita
tio
n 
In
ve
nt
or
y;
 Z
B
I, 
Za
rit
 B
ur
de
n 
In
te
rv
ie
w
; T
U
G
, T
im
ed
 U
p 
an
d 
G
o;
 G
R
, G
AI
TR
ite
TM
; B
ow
dl
e,
 V
is
ua
l A
na
lo
gu
e 
Sc
al
e 
B
ow
dl
e 
fo
r f
ee
lin
g 
hi
gh
; E
CG
, E
le
ct
ro
ca
rd
io
gr
ap
hy
.
a  
Th
e 
fir
st
 a
ss
es
sm
en
t o
f C
M
AI
 w
as
 u
se
d 
in
 th
e 
an
al
ys
is
. b
 T
he
 fi
rs
t a
ss
es
sm
en
ts
 o
f T
U
G
 a
nd
 T
in
et
ti 
w
er
e 
us
ed
 in
 th
e 
an
al
ys
is
. c
 T
he
 fo
llo
w
in
g 
vi
ta
l s
ig
ns
 a
ss
es
sm
en
ts
 o
n 
da
y 
1
 o
f w
ee
k 
1,
 2
, 7
 a
nd
 8
 w
er
e 
us
ed
 in
 th
e 
an
al
ys
is
: p
re
do
se
, 1
5
 m
in
, 3
0
 m
in
, 4
5
 m
in
, 1
, 2
, 3
 a
nd
 4
 h
ou
rs
 p
os
td
os
e.
 D
ur
in
g 
da
y 
3
 o
f w
ee
k 
3
 to
 6
 a
nd
 9
 to
 1
2
, v
ita
l s
ig
ns
 w
er
e 
as
se
ss
ed
 ir
re
sp
ec
tiv
e 
of
 ti
m
e 
to
 ta
bl
et
 a
dm
is
si
on
. d
 B
ow
dl
e 
VA
S 
on
 w
ee
k 
1,
 2
, 7
 a
nd
 8
 (d
ay
 1
 to
 3
): 
1
 a
nd
 3
 h
ou
rs
 p
os
td
os
e.
 D
ur
in
g 
da
y 
3
 o
f w
ee
k 
3
 to
 6
 a
nd
 9
 to
 1
2
, B
ow
dl
e 
VA
S 
w
as
 a
ss
es
se
d 
irr
es
pe
ct
iv
e 
of
 ti
m
e 
to
 ta
bl
et
 a
dm
is
si
on
. e
 B
ow
dl
e 
VA
S 
on
 w
ee
k 
1,
 2
, 7
 a
nd
 8
 
(d
ay
 1
): 
1
 a
nd
 3
 h
ou
rs
 p
os
td
os
e.
 D
ur
in
g 
da
y 
3
 o
f w
ee
k 
1
 to
 1
2
, B
ow
dl
e 
VA
S 
w
as
 a
ss
es
se
d 
irr
es
pe
ct
iv
e 
of
 ti
m
e 
to
 ta
bl
et
 a
dm
is
si
on
.
370
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
APPENDIX TABLE 3
Relevant medical history and co-morbidity
Number of patients (%) with relevant co-morbidity or 
medical history
All 
(n=22)
Hospital 
admission group
(n = 10)
Ambulatory
 group
(n=12)
Cardiovascular disorders
Hypertension
Hypercholesterolemia
Rhythm disorder
Vascular disorder
Ventricular hypertrophia
Heart failure
Cardiac ischemia
Vascular disorder
Other
17 (77.3)
8 (36.4)
4 (18.2)
6 (27.3)
5 (22.7)
4 (18.2)
1 (4.5)
2 (9.1)
5 (22.7)
1 (4.5)
9 (90.0)
4 (40.0)
0 (0.0)
3 (30.0)
2 (20.0)
3 (30.0)
0 (0.0)
1 (10.0)
2 (20.0)
3 (30.0)
8 (66.7)
4 (33.3)
4 (33.3)
3 (25.0)
3 (25.0)
1 (8.3)
1 (8.3)
1 (8.3)
3 (25.0)
1 (8.3)
Genito-urinary disorders
Kidney failure
Urinary difficulty
Infection
Surgery
Other
14 (63.6)
6 (27.3)
3 (13.6)
4 (18.2)
3 (13.6)
6 (27.3)
6 (60.0)
3 (30.0)
1 (10.0)
1 (10.0)
1 (10.0)
3 (30.0)
8 (66.7)
3 (25.0)
2 (16.7)
3 (25.0)
2 (16.7)
3 (25.0)
Gastrointestinal disorders
Constipation
Surgery
Infection
Other
10 (45.5)
2 (9.1)
5 (22.7)
3 (13.6)
3 (13.6)
3 (30.0)
0 (0.0)
1 (10.0)
2 (20.0)
1 (10.0)
7 (58.3)
2 (16.7)
4 (33.3)
1 (8.3)
2 (16.7)
Musculoskeletal disorders
Fracture or lesion
Other
8 (36.4)
6 (27.3)
4 (18.2)
5 (50.0)
5 (50.0)
1 (10.0)
3 (25.0)
1 (8.3)
3 (25.0)
Neurological disorders
Cerebrovascular disease
Mobility disorder
Other
8 (36.4)
4 (18.2)
2 (9.1)
4 (18.2)
4 (40.0)
1 (10.0)
0 (0.0)
3 (30.0)
4 (33.3)
3 (25.0)
2 (16.7)
1 (8.3)
Endocrine disorders
Diabetes mellitus
Other
7 (31.8)
6 (27.3)
1 (4.5)
3 (30.0)
2 (20.0)
1 (10.0)
4 (33.3)
4 (33.3)
0 (0.0)
Ear disorders
Loss of hearing
Other
6 (27.3)
5 (22.7)
1 (4.5)
3 (30.0)
2 (20.0)
1 (10.0)
3 (25.0)
3 (25.0)
0 (0.0)
Respiratory disorders
Pneumonia
Chronic obstructive pulmonary disease
Other
5 (22.7)
1 (4.5)
1 (4.5)
3 (13.6)
2 (20.0)
1 (10.0)
0 (0.0)
1 (10.0)
3 (25.0)
0 (0.0)
1 (8.3)
2 (16.7)
Psychiatric disorders
Depression
Delirium
5 (22.7)
3 (13.6)
2 (9.1)
3 (30.0)
1 (10.0)
1 (10.0)
2 (16.7)
2 (16.7)
1 (8.3)
Dermatological disorders
Skin malignancy
Other
4 (18.2)
4 (18.2)
2 (9.1)
1 (10.0)
1 (10.0)
1 (10.0)
3 (25.0)
3 (25.0)
1 (8.3)
Eye disorders 4 (18.2) 1 (10.0) 3 (25.0)
Malignancies 2 (9.1) 0 (0.0) 2 (16.7)
Values are numbers of patients and percentages. The disorders are categorized by Medical Dictionary for Regulatory 
Activities
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If I ventured in the slipstream
Between the viaducts of your dream
Where mobile steel rims crack
And the ditch in the back roads stop
Could you find me?
Would you kiss my eyes?
To lay me down in silence easy
To be born again, to be born again
Van Morrison  -  Astral Weeks 
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Abstract
Objectives: To study the efficacy and safety of  low dose oral tetrahydrocannabinol 
(THC) in the treatment of  dementia-related neuropsychiatric symptoms (NPS).
Methods: This is a randomized, double-blind, placebo-controlled study. Patients 
with dementia and clinically relevant NPS were randomly assigned to receive THC 
1.5mg or matched placebo (1:1) 3 times daily for 3 weeks. Primary outcome was 
change in Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 and 
21 days. Analyses were based on intention-to-treat. 
Results: Twenty-four patients received THC and 26 received placebo. NPS 
reduced during both treatment conditions. The difference in reduction from 
baseline between THC and placebo was not significant (mean difference NPItotal: 
3.2, 95% confidence intervan [CI] -3.6 to 10.0), nor were changes in scores for 
agitation (Cohen-Mansfield Agitation Inventory: 4.6, 95%CI -3.0 to 12.2), quality 
of  life (Quality of  Life-Alzheimer’s Disease: -0.5, 95%CI -2.6-1.6) and activities 
of  daily living (Barthel Index: 0.6, 95%CI -0.8 to 1.9). The number of  patients 
experiencing mild or moderate adverse events was similar (THC, n=16; Placebo, 
n=14, p=0.36). No effects on vital signs, weight or episodic memory were observed. 
Conclusions: Oral THC of  4.5mg daily showed no benefit in NPS, but was 
well-tolerated, which adds valuable knowledge to the scarce evidence on THC in 
dementia. The benign adverse event profile of  this dosage allows to study whether 
higher doses are efficacious and equally well tolerated. 
Classification of  Evidence: This study provides Class I evidence that for patients 
with dementia-related NPS low dose THC does not significantly reduce NPS at 21 
days, though it is well tolerated. 
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Introduction
Most patients with dementia will experience neuropsychiatric symptoms (NPS) 
over the course of  their disease.1 While nonpharmacologic interventions are preferred, 
data on their efficacy remains limited and the interventions are not easily applicable in 
clinical practice.2 The pharmacological treatment is challenging, as currently available 
medications have important drawbacks concerning the benefit-to-risk ratio.3-6 This 
implicates a serious health care problem, as 62% of  community-dwelling patients and up 
to 80% of  nursing home residents suffer from clinically relevant symptoms.7, 8 Structured 
analgesic treatment has recently been demonstrated to be beneficial for dementia-
related NPS and in particular agitation.9 Delta-9-tetrahydrocannabinol (THC), the 
main constituent of  cannabis, has both psychoactive and analgesic properties,10, 11 
and might therefore serve as an alternative pharmacological treatment. Indeed, some 
preliminary studies suggested improvement in agitation and nocturnal motor activity in 
patients with Alzheimer’s disease (AD).12, 13 The effect of  THC on the endocannabinoid 
system is mediated by 2 cannabinoid receptors; CB1 receptors are expressed in several 
brain regions, especially the basal ganglia, cerebellum, hippocampus, amygdala, and 
hypothalamus, whereas CB2 receptors are primarily found in cells and organs of  the 
immune system. Therefore, THC probably has a wide range of  CB1-mediated receptor 
interactions with the endocannabinoid system affecting emotion, cognition and behavior. 
Moreover, psychotropic effects are also exerted through interaction with other receptors 
and neurotransmitters, such as acetylcholine, dopamine, serotonin, ϒ-aminobutyric 
acid, glutamate, norepinephrine, prostaglandins, and opioid peptides.14 Interestingly, 
several animal studies also suggest a neuroprotective effect of  cannabinoids in the disease 
pathology of  AD itself, which is primarily based on a reduction in the inflammatory 
response by microglia cells, and the increase of  amyloid-β clearance.15, 16 Nonetheless, 
firm evidence of  the efficacy and safety of  THC or other cannabinoids in this vulnerable 
patient group is lacking and even data on older patients in general are scarce.17 The 
current paper reports the largest study carried out so far on evaluating the efficacy and 
safety of  oral THC for behavioral disturbances in patients with dementia. 
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Methods
Standard protocol approvals, registrations, and patient consents
This study was conducted in accordance with the ethical principles of  the Declaration 
of  Helsinki and Good Clinical Practice (GCP), approved by a certified ethics committee 
of  the Radboud university medical center (Radboudumc) and registered at www.
clinicaltrials.org (NCT01608217). Assessments were done by researchers from the 
department of  Geriatric Medicine of  Radboudumc (Nijmegen, the Netherlands) and 
the department of  Elderly of  Vincent van Gogh Institute (psychiatric hospital, Venray, 
the Netherlands), from November 2012  to June 2014. Participants were recruited from 9 
participating institutes throughout the south-east of  The Netherlands, including geriatric 
outpatient clinics (n=2), psychiatric clinics (n=3), nursing homes (n=3, including in total 
6 locations) and a regional network of  integrated care for community-dwelling dementia 
patients. Written informed consent was provided at screening by the patient and closest 
involved proxy; the first only in case the patient was judged capable to consent.
Study design
This was a randomized, double-blind, placebo-controlled, multicenter, phase II trial. 
Potential participants were screened for eligibility within 4 weeks prior to start of  study 
medication, by assessment of  somatic and cognitive status and severity of  behavioral 
disturbances. Assessments were done at the outpatient clinic, nursing home or at home, 
depending on patient preference. Study intervention was initiated after baseline. Efficacy 
assessments were scheduled after 14±2 treatment days (phone call), and 21±2 treatment 
days (visit). For the purpose of  safety assessment and compliance, several phone calls 
were performed by the researchers during the intervention period (day 2, 7, and 14). 
Follow up assessments by telephone were performed two weeks after study completion. 
Participants
Patients diagnosed with AD, vascular or mixed dementia, according to the National 
Institute of  Neurological and Communicative Disorders and Stroke-Alzheimer’s 
Disease and Related Disorders Association18 or National Institute of  Neurological 
Disorders and Stroke-Association Internationale pour la Recherche en l’Enseignement 
en Neurosciences19 criteria were eligible for participation if  they suffered from clinically 
CHAPTER 4
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial
77
4
relevant NPS (minimal Neuropsychiatric Inventory [NPI] score ≥ 10), with symptoms 
reported on agitation, aggression or aberrant motor behavior, existing at least one month 
prior to screening. A caregiver had to be available, who was in touch with the patient at 
least twice a week and supervised patient’s care. Exclusion criteria were current major 
psychiatric disorders, any severe or instable concomitant illness; in particular seizures, 
arrhythmias necessitating treatment other than a β-blocker or digoxin, severe heart 
failure, or any concomitant disease necessitating treatment changes. Other exclusion 
criteria were frequent falling due to orthostatic hypotension, a history or current alcohol 
or drug abuse, and use of  tricyclic antidepressants, fluoxetine or carbamazepine. Use of  
concurrent psychotropic medication was allowed, provided that the dose and frequency 
were kept stable within 2 weeks before and during trial conduction. Analgesic drugs had 
to be stopped prior to baseline assessments, although use of  analgesic and psychotropic 
escape medication was allowed. 
Changes to study protocol
We initially recruited patients suffering from behavioral disturbances as well as 
persistent pain complaints, to secondarily assess the efficacy of  THC on pain in patients 
with dementia. However, the number of  eligible patients with both symptoms was much 
lower than predicted from literature.20 After inclusion of  the first 8 patients, the criterion 
of  pain was omitted. In the amended study, pain assessments were still included, allowing 
secondary evaluation of  the efficacy of  THC in reducing pain-related behavior and pain 
intensity in a subgroup of  patients, of  which the methods and results are described in 
Appendix 1 and Appendix Table 1.
Intervention and randomization
Active treatment consisted of  1.5mg THC in tablet form (Namisol®, Echo 
Pharmaceuticals, Weesp, The Netherlands) 3 times daily for a period of  3 weeks. This 
daily dose was based on preliminary positive results of  previous trials in patients with 
severe AD.12, 13, 21 Control treatment consisted of  matched placebo tablets. Additionally, 
patients received 1000mg acetaminophen 3 times daily in case of  pain complaints, 
or of  suspected pain in noncommunicative patients, based on physical examination 
at screening and information from the caregiver or physician. Study medication was 
administered at 9 a.m., 2 p.m., and 8 p.m. by the primary caregiver or nursing home 
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staff. Study medication was packed and distributed by the pharmacy of  Radboudumc 
according to Good Manufacturing Practice. Randomization (allocation ratio 1:1) was 
performed by an independent statistician using a computer-generated randomization 
program, of  which the algorithm was stratified per centre and minimized22 for NPI score, 
dementia severity, sex and current opioid use. Treatment allocation was strictly concealed 
from participants, caregivers, investigators and all other personnel directly involved in the 
study and was not made available until study completion and database lock.
Outcome measures
Primary outcome measure
The primary outcome was change in NPS, measured with Neuropsychiatric Inventory 
(NPI).23 This questionnaire evaluates 12 behavioral domains, including agitation/
aggression and aberrant motor behavior, which were the behavioral domains of  interest. 
The frequency and severity of  NPS were scored per domain by questioning a caregiver, 
which resulted in a total score ranging from 0 to 144 (a higher score indicating greater 
impairment). NPI was assessed at baseline, day 14 (by telephone interview) and day 21 
by trained researchers.  
Secondary efficacy outcome measures
Secondary outcomes included assessment of  agitated behavior and aggression (Cohen-
Mansfield Agitation Inventory [CMAI]24), activities of  daily living (Barthel Index25) and 
quality of  life (Quality of  Life-Alzheimer’s Disease Scale [QoL-AD]26). These were all 
assessed at baseline and day 21. Overall change was assessed by the primary caregiver, 
using the Caregiver Clinical Global Impression of  Change (CCGIC), a 7-point scale 
ranging from marked improvement to marked worsening from baseline. 
Safety assessments
Adverse events
Adverse events (AEs) were solicited from patients and their caregivers at all visits and 
phone calls up to 2 weeks after study drug discontinuation, using clinical observation, 
open questions and a set of  questions on possible THC-related adverse symptoms, 
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including the most frequently reported AEs in the phase I study with healthy elderly.27 AEs 
were coded following the classification of  Medical Dictionary for Regulatory Activities. 
An AE was defined as serious if  it was fatal or life-threatening, required or prolonged 
hospitalization, or resulted in persistent or significant disability or incapacity. 
Other safety assessments
Other safety assessments consisted of  evaluation of  blood pressure, heart rate and 
weight, assessed at screening, baseline and day 21, and ECG and biochemistry and 
hematology blood samples, assessed at screening and day 21. The Paired Associate 
Learning Wechsler Memory Scale-Revised (PAL WMS-R)28 was used for assessment of  
possible effects of  THC on episodic memory function (baseline and day 21). 
Statistical analysis
The study sample size was estimated, based on a clinically relevant difference of  4 
points on NPI,29, 30 a standard deviation of  12 points,31, 32 and an estimated correlation 
with baseline of  0.6 and interclass correlation coefficient of  0.6. Approximately 130 
patients were required for a power of  80% (2-sided testing at 0.05). We were not able 
to enroll this number of  subjects within the available time period, due to serious delay 
in getting formal approval for THC use at all sites from the Health Care Inspectorate. 
After trial ending, we performed an analysis to calculate the power to yield a statistically 
significant difference in favor of  THC, in case we would have been able to extend the 
study to 130 subjects. This analysis is known as the calculation of  conditional power. The 
analysis used 10,000 simulated extensions of  the outcome data of  the realized sample to 
the planned sample size, based on the real data that were acquired. Efficacy and safety 
analyses were based on the intention-to-treat principle and performed in accordance 
with a prespecified statistical analysis plan, finalized before unmasking of  treatment 
assignment. The primary endpoint, mean difference (including 95% confidence intervals 
[CI])  in NPI total score from baseline to 14 and 21 treatment days, was evaluated in a 
linear mixed model with participants as random factor and treatment, centre, baseline 
NPI, Clinical Dementia Rating score, sex, current opioid use and time as fixed factors. All 
assumptions for regression models were assessed by viewing plots of  the residual values 
to check for linearity and homoscedasticity. Analysis was repeated for all NPI subdomain 
scores. In a post hoc analysis, we determined the efficacy for 2 subgroups; ambulatory 
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patients and inpatients. Other secondary efficacy outcome measures, weight and vital 
signs were assessed similarly to the primary analysis (without data on day 14, as these 
were not collected). Pearson correlation coefficients were calculated for change from 
baseline of  NPI and CCGIC scores on day 14 and day 21. Due to the limited number 
of  participants included in the PAL-WMS-R assessments group, these differences were 
compared using Mann-Whitney U test. For analysis of  AEs, the number of  patients with 
at least 1 unique episode was tabulated per treatment group and group difference on 
incidence (using χ2) and severity of  AEs (using Mann-Whitney U) was analyzed. Statistical 
analyses were done using SAS version 9.2 and SPSS version 20 for Windows. 
Classification of Evidence
This interventional study provides Class I evidence that oral THC of  4.5mg daily 
is not effective in reducing behavioral disturbances in dementia patients (ΔNPItotal: 3.2, 
95%CI -3.6 to 10.0) and is well tolerated (occurrence of  AEs THC vs. placebo; 16 
[66.7%] vs. 14 [523.8%] patients, χ2, p=0.36).
Results
Study participants
In total, 54 patients were assessed for eligibility of  whom 50 were randomized and 
received study medication (THC, n=24; Placebo, n=26) (Figure). Patient characteristics 
are presented in Table 1. Overall, 47 patients (94%) completed the study, while 3 patients 
discontinued participation due to the occurrence of  adverse events (n=2) and withdrawal 
of  informed consent (n=1).
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THC = tetrahydrocannabinol
FIGURE 1 
CONSORT flowchart of recruitment and selection
Recruitment of participants through:
• geriatrie outpatient clinics
• psychiatrie clinics 
• nursing homes 
• regional network for integrated care 
• general practitioners
• advertising in local newspapers and 
informative website for dementia care
Assessed for eligibility 
n = 54 
Randomized 
n = 50
Excluded (n = 4)
• unable to assess safety due to severe 
behavioral disturbances (n = 2) 
• not meeting inclusion criteria (n = 1)
• declined to participate (n = 1)
Allocated to placebo treatment (n = 26)
• received allocated intervention (n = 26)
• did not receive allocated intervention (n = 0)
Lost to follow up (n = 0)
Discontinued intervention (n=2)
• occurrence of an adverse event (n = 1)
• withdrawal of informed consent (n = 1)
Analyzed (n = 26) 
Excluded from analysis (n = 0)
Allocated to THC treatment (n = 24)
• received allocated intervention (n = 24) 
• did not receive allocated intervention (n = 0)
Lost to follow up (n = 0) 
Discontinued intervention (n = 1) 
• due to the occurrence of an adverse event
Analyzed (n = 24) 
Excluded from analysis (n = 0)
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TABLE 1    
Demographics and patient characteristics
All 
(n=50)
THC
(n=24)
Placebo
(n=26)
Men, n (%) 25 (50.0) 11 (45.8) 14 (53.8)
Age, yr, mean (SD) 78.4 (7.4) 79.0 (8.0) 78.0 (7.0)
Domestic situation, n (%)
Community dwelling
Specialized dementia care unit
Nursing home
24 (48.0)
13 (26.0)
13 (26.0)
13 (54.2)
4 (16.7)
7 (29.2)
11 (42.3)
9 (34.6)
6 (23.1)
BMI, kg/m2, mean (SD)a 25.0 (3.5) 25.0 (3.8) 25.0 (3.4)
Ethnicity, n (%)
Caucasian
Other
50 (100.0)
0 (0.0) 
24 (100.0)
0 (0.0)
26 (100.0)
0 (0.0)
Education, mean (SD)b 3.8 (1.6) 3.8 (1.6) 3.8 (1.6)
Type of dementia, n (%)
Alzheimer
Vascular
Mixed
34 (68.0)
7 (14.0)
9 (18.0)
16 (66.7)
3 (12.5)
5 (20.8)
18 (69.2)
4 (15.4)
4 (15.4)
CDR ratio, n (%)
1
2
3
11 (22.0)
19 (38.0)
20 (40.0)
5 (20.8)
9 (37.5)
10 (41.7)
6 (23.1)
10 (38.5)
10 (38.5)
MMSE score, mean (SD)c 4.8 (6.7) 15.9 (6.7) 14.0 (6.8)
Comorbidities, n (%)
Vascular disorders
Nervous system disorders
Gastrointestinal disorders
Musculoskeletal disorders
Renal and urinary disorders
Psychiatric disorders
Other
21 (42.0)
19 (38.0)
18 (36.0)
17 (34.0)
15 (30.0)
14 (28.0)
24 (48.0)
12 (50.0)
11 (45.8) 
7 (29.2)
8 (33.3)
7 (29.2)
7 (29.2)
22 (91.7)
9 (34.6)
8 (30.8)
11 (42.3)
9 (34.6)
8 (30.8)
7 (26.9)
20 (76.9)
Concomitant psychotropic medication, n (%)d
Antipsychotics
Antidepressants
Benzodiazepines
Anticonvulsants
Cholinesterase inhibitors
Memantine
Melatonin
10 (20.0)
20 (40.0)
21 (42.0)
0 (0.0)
8 (16.0)
3 (6.0)
13 (26.0)
7 (29.2)
9 (37.5)
8 (33.3)
0 (0.0)
5 (20.8)
2 (8.3)
5 (20.8)
3 (11.5)
11 (42.3)
13 (50.0)
1 (3.8)
3 (11.5)
1 (3.8)
8 (30.8)
Concomitant analgesic medication, n (%)d
Acetaminophen
NSAIDs
Opioids
15 (30.0)
2 (4.0)
2 (4.0)
5 (20.8)
1 (4.2)
1 (4.2)
10 (38.5)
1 (3.8)
1 (3.8)
Subgroup of patients with pain, n (%)e 23 (46.0) 8 (33.3) 15 (57.7)
Abbreviations: BMI, Body Mass Index; CDR, Clinical Dementia Rating; MMSE, Mini Mental State Examination; NSAID, 
nonsteroidal anti-inflammatory drugs; THC, tetrahydrocannabinol.
a 3 missings on THC, 4 missings on placebo.
b Education was determined with seven categories where 1 indicates less than six years of primary school and 7 
indicates a university degree. 6 missings on THC, 8 missings on placebo.
c 11 missings on THC, 10 missings on placebo.
d Concomitant medication used at time of screening. All analgesic medication was stopped prior to baseline 
assessments. When indicated, patients received acetaminophen for the duration of the intervention period.
e patients reporting pain, who are able to reliably assess pain intensity using VRS, or patients with a PACSLAC-D 
score of 4 points or more at baseline.
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Treatment compliance and concurrent medication use
Median treatment compliance, based on remaining pill count, was 98% (67 to 100%) 
in the THC group and 100% (94 to 100%) in the placebo group. Twenty-nine patients 
received acetaminophen (THC, n=13; Placebo, n=16). Four patients (16.7%) in the 
THC group received escape medication, compared to 2 patients (7.7%, p=0.33) in the 
placebo group, which consisted of  benzodiazepines (oxazepam 5mg, lorazepam 1mg) 
and acetaminophen (500mg).
Efficacy
Study results are presented in Table 2. NPI total score decreased in both treatment 
conditions after 14 (THC, p=0.002; placebo, p=0.002) and 21 days (THC, p=0.003; 
placebo, p=0.001). There was no difference between THC and placebo over 21 treatment 
days (ΔNPItotal: 3.2, 95%CI - 3.6 to 10.0). Additionally, no differences were observed on 
agitation (ΔNPIagitation: - 0.1, 95%CI - 2.0 to 1.9), aberrant motor behavior (ΔNPIaberrant 
motor behavior: 0.3, 95%CI - 1.0 to 1.7), or other NPI subdomains (see Appendix Table 2), 
except for the domain ‘eating disorders’ in favor of  placebo (ΔNPIeating disorders: 1.0, 95%CI 
0.0 to 1.92). Analysis per subgroup showed no benefit of  THC in community-dwelling 
patients (ΔNPItotal: 5.0, 95%CI - 1.8 to 11.7) nor in inpatients (ΔNPItotal: 1.5, 95%CI - 
10.0 to 13.1). There were no significant differences between the intervention groups on 
CMAI, QoL-AD and Barthel Index. CCGIC scores after 3 weeks showed that 8 (36.4%) 
patients in the THC group had minimal to marked improvement from baseline, which 
was not significantly different from 12 patients (50.0%) in the placebo group (χ2, p=0.35). 
A strong correlation was observed between NPI and CCGIC scores (day 14: Pearson’s 
r=0.65, p<0.001; day 21, Pearson’s r=0.73, p<0.01). The conditional power to still detect 
a difference in NPI score of  at least 4 points in favor of  THC treatment, in case we would 
have been able to extend the trial from the actual number of  subjects (n=47, 23 on THC 
and 24 on placebo) to the initially planned number of  subjects (130, 65 per treatment 
arm), was 5%.
484
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
TABLE 2
Overview of study results of the application of THC on neuropsychiatric symptoms 
in dementia
n THC n Placebo
Mean difference
THC vs. placebo
(95% CI)
Primary outcomes
NPI total score
Baseline
Day 14
Day 21
24
19
23
37.4 (13.7)
31.0 (11.3)
27.8 (13.1)
26
23
24
35.6 (13.0)
26.1 (16.9)
23.9 (16.8) +3.2 (-3.6 to 10.0)
NPI agitation/aggression subscale
Baseline
Day 14
Day 21
24
19
23
5.7 (3.8)
4.1 (4.7)
4.5 (4.1)
26
23
24
6.2 (4.3)
5.0 (3.9)
4.4 (4.3) -0.1 (-2.0 to 1.9)
NPI aberrant motor behavior subscale
Baseline
Day 14
Day 21
24
19
23
4.5 (4.6)
4.9 (4.0)
3.6 (3.9)
26
23
24
5.2 (4.1)
4.3 (4.2)
3.7 (4.3) +0.3 (-1.0 to 1.7)
Secondary outcomes
CMAI
Baseline
Day 21
24
23
58.8 (18.5)
56.5 (17.5)
26
24
61.6 (16.4)
53.7 (18.3) +4.6 (-3.0 to 12.2)
Barthel Index
Baseline
Day 21
24
22
13.8 (5.1)
13.3 (5.0)
25
24
13.3 (5.3)
12.0 (5.5) +0.6 (-0.8 to 1.9)
QoL-AD
Baseline
Day 21
24
21
28.3 (4.9)
27.5 (4.6)
24
22
29.6 (5.2)
29.1 (5.0) -0.5 (-2.6 to 1.6)
CCGIC a
Day 14
Day 21
20
22
3.7 (1.0)
3.5 (1.3)
25
24
3.4 (1.2)
3.2 (1.4) +0.2 (-0.5 to 0.9)
Safety assessments
Heart rate, bpm
Baseline
Day 21
23
22
69.8 (11.4)
66.3 (8.6)
24
24
74.5 (12.5)
71.6 (8.0) -3.3 (-7.5 to 0.9)
Systolic Blood Pressure, mmHg
Baseline
Day 21
23
22
138.6 (21.2)
143.7 (16.8)
24
24
143.1 (15.9)
141.3 (20.9) +3.4 (-6.5 to 12.2)
Diastolic Blood Pressure, mmHg
Baseline
Day 21
23
22
77.5 (8.0)
76.9 (7.1)
24
24
82.0 (10.4)
78.2 (9.3) -1.8 (-6.6 to 3.1)
Weight, kg
Baseline
Day 21
22
20
71.0 (14.3)
70.4 (13.8)
22
22
70.9 (13.8)
71.1 (12.9) -0.1 (-0.8 to 0.7)
Abbreviations: CCGIC, Caregiver’s Clinical Global Impression of Change; CI, confidence interval; CMAI, Cohen-
Mansfield Agitation Inventory; NPI, Neuropsychiatric Inventory; QoL-AD, Quality of Life-Alzheimer’s Disease Scale; 
THC, tetrahydrocannabinol.
Group numbers are means and standard deviations (SDs). Estimates of overall mean differences over day 14 and 
21 are based on linear mixed model analysis for repeated measures with correction for (subscale) NPI score at 
baseline, center, Clinical Demantia Rating stage, sex, current opioid use, week and using a random intercept. A 
negative mean difference favors THC for NPI (range 0-144), CMAI (range 29-203) and CCGIC (range 1-7). A positive 
mean difference favors THC for Barthel Index (range 0-20) and QoL-AD (range 13-52).
a 7-point scale; 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, unchanged; 5, 
minimal worsening; 6, moderate worsening; 7, marked worsening.
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Safety 
Adverse events
The occurrence of  AEs was similarly divided along treatment groups (Table 3). In the 
THC group, 16 patients (66.7%) experienced at least 1 AE, compared to 14 (53.8%) in 
the placebo group (χ2, p=0.36). Two patients dropped out due to the occurrence of  AEs; 
one patient developed pneumonia within 2 days after initiation of  THC treatment, and 
one patient experienced persistent nausea on placebo. One serious adverse AE occurred 
during placebo treatment, which was not related to study medication. This patient was 
admitted to a specialized dementia care unit due to high caregiver burden. 
Other safety outcomes
There were no changes between  the groups concerning heart rate, blood pressure 
and weight (Table 2). Episodic memory scores were available for 18 patients with a mild 
dementia severity. PAL WMS-R scores decreased by 1.2 points in the THC group and 
1.4 points in the placebo group, which was not significantly different (p=1.0).
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TABLE 3
Patients experiencing adverse events
MedDRA system organ class 
and preferred term
THC 
n=24
Placebo
n=26
One or more adverse event, n (%) 16 (66.7) 14 (53.8)
Severe adverse events, n (%)  0 (0.0) 0 (0.0)
Nervous system disorders 10 (41.7) 13 (50.0)
Dizziness 4 (16.7) 4 (15.4)
Somnolence 2 (8.3) 4 (15.4)
Aphasia 1 (4.2) 1 (3.8)
Bradykinesia 0 (0.0) 1 (3.8)
Miosis 0 (0.0) 1 (3.8)
Muscle spams 0 (0.0) 1 (3.8)
Sensory loss 0 (0.0) 1 (3.8)
Headache 1 (4.2) 0 (0.0) 
Muscular weakness 1 (4.2) 0 (0.0)
Balance disorder 1 (4.2) 0 (0.0) 
Psychiatric disorders 7 (29.2) 4 (15.4)
Cognitive disorder 3 (12.5) 1 (3.8)
Restlessness 2 (8.3) 1 (3.8)
Agitation 0 (0.0) 1 (3.8)
Euphoric mood 0 (0.0) 1 (3.8)
Apraxia 1 (4.2) 0 (0.0) 
Delirium 1 (4.2) 0 (0.0)
Investigations 1 (4.2) 6 (23.1)
Gamma-glutamyltransferase increased 1 (4.2) 2 (7.7)
Aspartate aminotransferase increased 0 (0.0) 2 (7.7)
Blood alkaline phosphatase increased 0 (0.0) 1 (3.8)
Hepatic enzyme increased 0 (0.0) 1 (3.8)
Gastrointestinal disorders 4 (16.7) 2 (7.7)
Nausea 2 (8.3) 1 (3.8)
Diarrhoea 0 (0.0) 1 (3.8)
Abdominal pain, upper 1 (4.2) 0 (0.0) 
Gastrooesophageal reflux disease 1 (4.2) 0 (0.0) 
General disorders 2 (8.3) 3 (11.5)
Fatigue 2 (8.3) 2 (7.7)
Malaise 0 (0.0) 1 (3.8)
Injury and procedural complications 1 (4.2) 3 (11.5)
Fall 1 (4.2) 3 (11.5) >>
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Respiratory disorders 4 (16.7) 0 (0.0)
Pneumonia 2 (8.3) 0 (0.0) 
Chronic obstructive pulmonary disease 1 (4.2) 0 (0.0) 
Nasopharyngitis 1 (4.2) 0 (0.0) 
Cardiac disorders 1 (4.2) 2 (7.7)
Chest pain 0 (0.0) 1 (3.8)
Syncope 0 (0.0) 1 (3.8)
Presyncope 1 (4.2) 0 (0.0)
Musculoskeletal disorders 3 (12.5) 0 (0.0)
Back pain 1 (4.2) 0 (0.0)
Neck pain 1 (4.2) 0 (0.0)
Pain in extremity 1 (4.2) 0 (0.0)
Eye disorders 0 (0.0) 2 (7.7)
Drye eyes 0 (0.0) 1 (3.8)
Eye heamorrhage 0 (0.0) 1 (3.8)
Renal and urinary disorders 0 (0.0) 2 (7.7)
Renal impairment 0 (0.0) 1 (3.8)
Urge incontinence 0 (0.0) 1 (3.8)
Skin disorders 2 (8.3) 0 (0.0)
Intertrigo 1 (4.2) 0 (0.0)
Skin disorder, NOS 1 (4.2) 0 (0.0)
Metabolism and nutrition disorders 0 (0.0) 1 (3.8)
Decreased appetite 0 (0.0) 1 (3.8)
Blood and lymphatic system disorders 1 (4.2) 0 (0.0)
Anaemia 1 (4.2) 0 (0.0)
Social circumstances 0 (0.0) 1 (3.8)
Family stress 0 (0.0) 1 (3.8)
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities; THC, tetrahydrocannabinol. Values are numbers 
of patients (%).
Discussion
We found no benefit of  4.5mg oral THC daily on behavioral disturbances in patients 
with dementia after 3 weeks of  treatment. Additionally, there were no benefits for THC 
on quality of  life, activities of  daily living or pain-related behavior and pain intensity 
(Appendix), while THC was safe and well-tolerated. The number of  patients experiencing 
AEs was similar in both groups, while known THC-mediated AEs, such as dizziness, 
somnolence and falls were more frequently reported during placebo treatment. None of  
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the participants reported a feeling “high”, nor was behaving ‘high’ observed by caregivers 
or research staff. The current trial is the largest randomized controlled trial (RCT) so far 
studying oral THC in NPS in dementia, with valid and rigorous trial methods. The study 
sample was representative for the overall dementia population, in terms of  age, dementia 
severity and domestic situation. Patients with very severe aggressive behavior could not 
be included, as the study’s safety assessments cannot be adequately conducted in this 
group. Taking into account this limitation associated with this specific patient population, 
we have included a sample that is representative for the majority of  the target population 
suffering from clinically relevant NPS; the level of  behavioral disturbances, assessed by 
NPI, was moderate and comparable to previous intervention trials.33-35 We observed an 
improvement in NPS in both groups over the duration of  the study period, which has 
been reported before.34, 35 The substantial degree of  improvement in the placebo group 
is striking (Table 2), and may be due to many factors including attention and support by 
the study team, expectations of  patients and caregivers concerning THC, and training of  
nursing home personnel (together called the Hawthorne or in-study effect 36). To correct 
for this substantial placebo response within individual patients, it might be worthwhile 
to implement an individually randomized crossover design in future studies. Despite the 
fact that we studied a vulnerable patient population the attrition level was low (6%) and 
adherence high (98 to 100%). This suggests a highly motivated group of  participants and 
caregivers, in combination with the occurrence of  only mild AEs. This study also has 
some limitations. Most importantly, we failed to enroll the planned number of  patients, 
despite comprehensive recruitment efforts throughout various health care settings. 
Rigorous national regulations on medical cannabinoids hindered implementation of  the 
study in the participating clinics. Additionally, fewer than expected patients visiting the 
clinics suffered from clinically relevant NPS as well as pain. Omitting the latter inclusion 
criterion significantly stimulated the recruitment. Despite this underenrollment, the 
conditional power of  5% emphasizes that it was very unlikely that exposure of  more 
participants to the study interventions and assessments would have influenced our 
conclusion. Contrary to the current RCT, previous studies all reported positive effects 
of  oral THC (2.5-7mg daily) in patients with dementia.12, 13, 21, 37 However, important 
methodological factors significantly limit the robustness of  these findings: inclusion 
of  small number of  patients (n=2 and n=15) and uncontrolled or retrospective study 
designs. In a previous randomized trial we studied dosages up to 3mg THC daily, and 
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did not observe a significant reduction in NPS, nor any relevant adverse events, effects 
on vital functions or mobility (unpublished data, 2014). Therefore, we used a dosage of  
4.5mg THC daily in this study. 
Recent developments regarding the extended legalization of  marijuana for medical 
purposes in over 30 US states has stimulated the discussion of  the therapeutic potential 
and safety profile of  cannabinoids for various indications.38, 39 Momentarily, effective and 
safe treatments for NPS in dementia patients are lacking.40 Several pharmacotherapeutic 
options have been explored, such as acetylcholinesterase inhibitors and antidepressants,33, 
34 but they often have a suboptimal benefit-risk profile. For example, while high-dose 
citalopram appears to effectively reduce agitation and overall behavioral disturbances, 
significant cardiac adverse effects limit its usefulness in this vulnerable population.34 Our 
current trial indicates that 4.5mg THC daily can be safely administered to patients with 
dementia. The observation that there was no biological signal of  AEs, suggests that the 
dosage was too low, as a psychoactive drug is rarely effective without showing any side 
effects. Therefore, our results warrant further research using higher dosages of  THC in 
the treatment of  dementia-related NPS. 
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Supplemental material
Appendix: Efficacy of THC in the treatment of pain in dementia 
patients with NPS.
Methods: The efficacy on pain-related behavior and pain intensity was evaluated in 
a subgroup of  patients suffering from NPS as well as pain. This subgroup was defined 
as follows: 1) patients with persistent pain complaints, who could indicate their own pain 
intensity reliably, as judged by a research physician, or 2) patients with score of  four points 
or more at baseline on the Pain Assessment Checklist for Seniors with Limited Ability 
to Communicate, Dutch version (PACSLAC-D). The PACSLAC-D1 is an observational 
assessment scale for assessment of  pain in non-communicative persons and was used 
in this study to assess pain-related behavior at baseline and after 21 days of  treatment. 
Pain intensity was assessed by self-report, using the Verbal Rating Scale (VRS).2 This 
is a six-point scale ranging from ‘no pain’ to ‘worst imaginable pain’. VRS assessments 
were done at every visit by means of  an interview with the participant, and on a daily 
basis using a diary. Efficacy of  THC on pain reduction was evaluated in a linear mixed 
model with participants as random factor and baseline scores as fixed factor. VRS diary 
scores were not analyzed, as these assessments did not appear to be feasible in this patient 
group because of  their cognitive decline, and resulted in too few available and reliable 
scores. Pearson correlation coefficients were calculated for change from baseline for 
PACSLAC-D and VRS interview scores, NPI and PACSLAC-D at day 21, NPI and 
VRS interview at day 21
Results: In total, 23 patients were included in the subgroup ‘pain’. Within this 
group, more patients received placebo than THC (15 vs. 8 patients). PACSLAC-D scores 
were available for 20 patients (THC, n=7; placebo, n=13), while 13 patients completed 
the VRS interview assessments (THC, n=4; placebo, n=9). No treatment differences 
between THC and placebo were observed on PACSLAC-D (-1.1, 95%CI -6.0 to 3.8) 
or VRS (-0.03, 95%CI -0.95 to 0.90) (Appendix Table 1). Overall, there is an indication 
that a reduction in PACSLAC-D score is positively correlated with VRS interview score 
(Pearson’s r 0.35, p=0.06). No correlation was found between PACSLAC-D and NPI 
total score (Pearson’s r 0.21, p=0.21) nor between VRS interview and NPI total score 
(Pearson’s r 0.16, p=0.36).
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Discussion: Low dose of  THC did not result in benefit on pain-related behavior 
and pain intensity, compared to placebo. Our ability to study the analgesic effects of  
THC was limited, due to the small number of  patients included in the pain assessments, 
because of  lower prevalence of  pain related behavioral disturbances than expected  and 
the limitations of  pain assessment in this patient group. These results should therefore 
be interpreted with caution. While self-reporting of  pain is often referred to as ‘gold-
standard’,3 VRS assessments are only suitable for patients with mild dementia severity as 
it requires the capability of  understanding the task and communicating the experienced 
sensation. Therefore, the PACSLAC-D, an observational assessment scale, is developed 
for assessment of  pain in non-communicative persons.1 This scale is more appropriate 
for nursing home patients than for community-dwelling patients, as this first group often 
express pain and discomfort through changes in behavior. Future studies on the efficacy 
of  THC as analgesic treatment, which are still warranted, should focus on a more 
homogeneous patient group, in whom a single pain assessment scale is feasible.
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APPENDIX TABLE 1   
Overview of the results of the application of THC on pain assessments in dementia 
patients
n THC n Placebo
Mean difference
THC vs. placebo
(95% CI)
VRS interview
Baseline
Day 21
5
4
2.6 (1.3)
2.3 (1.0)
11
9
3.1 (1.8)
2.3 (1.0) -0.03 (-1.0 to 0.9) 
PACSLAC-D
Baseline
Day 21
8
7
8.4 (5.2)
7.4 (8.0)
15
13
7.2 (4.1)
6.2 (5.5) -0.4 (-3.8 to 3.0) 
Abbreviations: PACSLAC-D, Pain Assessment Checklist for Seniors with Limited Ability to Communicate-Dutch 
version; VRS, Verbal Rating Scale.
Group values are means and standard deviations. Estimates of mean differences are based on linear mixed model 
analysis for repeated measures with participant as random effects for the subgroup of patients with pain. A negative 
mean difference favors THC for VRS and PACSLAC-D. 
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APPENDIX TABLE 2   
Study results of the application of THC on neuropsychiatric symptoms in dementia  
for all subdomains of Neuropsychiatric Inventory
n THC n Placebo THC vs. placebo
(95% CI)
NPI delusions 
Baseline
Day 14
Day 21
24
19
23
1.8 (3.0)
1.9 (3.6)
2.0 (3.5)
26
23
24
1.8 (3.3)
1.3 (2.6)
1.5 (2.7) +0.7 (-0.5 to 1.9)
NPI hallucinations
Baseline
Day 14
Day 21
24
19
23
0.8 (2.6)
0.3 (1.4)
0.0 (0.2)
26
23
24
0.3 (1.2)
0.3 (1.7)
0.3 (1.2) -0.2 (-0.9 to 0.4)
NPI agitation/aggression 
Baseline
Day 14
Day 21
24
19
23
5.7 (3.8)
4.1 (4.7)
4.5 (4.1)
26
23
24
6.2 (4.3)
5.0 (3.9)
4.4 (4.3) -0.1 (-2.0 to 1.9)
NPI dysphoria
Baseline
Day 14
Day 21
24
19
23
2.9 (4.0)
1.6 (2.4)
2.3 (2.6)
26
23
24
3.4 (3.6)
2.1 (2.7)
1.8 (2.8) 0.0 (-1.0 to 1.1)
NPI anxiety
Baseline
Day 14
Day 21
24
19
23
2.5 (4.0)
2.1 (3.5)
1.5 (2.8)
26
23
24
2.6 (3.7)
1.0 (2.6)
1.3 (2.3) +0.5 (-0.7 to 1.8)
NPI euphoria
Baseline
Day 14
Day 21
24
19
23
(2.5)
0.3 (1.4)
0.5 (1.3)
26
23
24
0.3 (0.9)
0.3 (1.7)
0.0 (0.2) +0.1 (-0.5 to 0.6)
NPI apathy
Baseline
Day 14
Day 21
24
19
23
5.0 (3.7)
5.1 (3.5)
4.1 (3.4)
26
23
24
2.5 (3.1)
2.4 (3.3)
2.3 (3.1) +0.1 (-1.1 to 1.3)
NPI disinhibition
Baseline
Day 14
Day 21
24
19
23
2.5 (3.3)
1.5 (2.6)
2.1 (3.2)
26
23
24
3.1 (3.4)
2.1 (3.0)
2.4 (3.4) -0.1 (-1.6 to 1.4)
NPI irritability
Baseline
Day 14
Day 21
24
19
23
5.3 (4.3)
5.1 (4.0)
4.3 (4.1)
26
23
24
5.7 (4.8)
4.2 (3.8)
3.9 (4.1) +0.7 (-1.1 to 2.4)
NPI aberrant motor behavior
Baseline
Day 14
Day 21
24
19
23
4.5 (4.6)
4.9 (4.0)
3.6 (3.9)
26
23
24
5.2 (4.1)
4.3 (4.2)
3.7 (4.3) +0.3 (-1.0 to 1.7)
NPI nighttime behavior 
disturbances
Baseline
Day 14
Day 21
24
19
23
2.5 (3.6)
1.4 (2.8)
0.8 (2.0)
26
23
24
2.5 (3.1)
2.2 (3.4)
1.8 (2.8) -0.7 (-1.8 to 0.4)
NPI appetite and eating 
abnormalities 
Baseline
Day 14
Day 21
24
19
23
3.1 (4.0)
2.8 (3.8)
2.0 (3.0)
26
23
24
2.1 (3.4)
0.8 (1.9)
0.7 (1.6) +1.0 (0.0 to 1.9)
Abbreviations: NPI, Neuropsychiatric Inventory.
Group values are means and standard deviations. Estimates of overall mean differences are based on linear mixed 
model analysis for repeated measures with participant as random effects. A negative mean difference favors THC 
for NPI subdomains.
There’s a little bird that somebody sends
Down to the earth to live on the wind
Borne on the wind and he sleeps on the wind
This little bird that somebody sends
He’s light and fragile and feathered sky blue
So thin and graceful, the sun shines through
This little bird who lives on the wind
This little bird that somebody sends
He flies so high up in the sky
Out of reach of human eye
And the only time that he touches the ground
Is when that little bird, is when that little bird
Is when that little bird dies
Marianne Faithfull  -  This Little Bird 
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Abstract
There is a great concern about the safety of  THC-based drugs in older 
people ( ≥65 years), as most of  THC-trials did not include such group. In this 
phase 1, randomized, double-blind, double-dummy, placebo-controlled, crossover 
trial, we evaluated the safety and pharmacokinetics of  three oral doses of  Namisol®, 
a novel THC in tablet form, in older subjects. Twelve healthy older subjects (6 
male; mean age 72±5 years) randomly received a single oral dose of 3mg, 5mg, or 
6.5mg of  THC or matching placebo, in a crossover manner, on each intervention 
day. The data of  11 subjects were included in the analysis. The data of  1 subject 
were excluded due to non-compliance to study medication. THC was safe and 
well tolerated. The most frequently reported adverse events (AEs) were drowsiness 
(27%) and dry mouth (11%). Subjects reported more AEs with THC 6.5mg than 
with 3mg (p=0.048), 5mg (p=0.034) and placebo (p=0.013). There was a wide inter-
individual variability in plasma concentrations of THC. Subjects for whom the 
Cmax fell within the sampling period (over 2 h), Cmax was 1.42–4.57 ng/mL and 
Tmax was 67–92 min. The AUC0-2 h (n=11) was 1.67–3.51 ng/mL. Overall, the 
pharmacodynamic effects of  THC were smaller than effects previously reported 
in young adults. In conclusion, THC appeared to be safe and well tolerated by 
healthy older individuals. Data on safety and effectiveness of  THC in frail older 
persons are urgently required, as this population could benefit from the therapeutic 
applications of  THC.
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Introduction
The cannabis plant (Cannabis sativa L.) has been used to treat a range of  symptoms and 
diseases for more than 4000 years.1, 2 Its broad therapeutic applications reflect the various 
pharmacological  and physiological effects of  cannabinoids, the bioactive components 
of  the cannabis plant.3 The plant contains more than 60 cannabinoids, such as delta-9-
tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol, and cannabichromene.3 
While the pharmacological effects of  most cannabinoids are still not known, THC 
appears to be responsible for most of the physical and psychoactive effects of  cannabis.3 
Cannabinoids exert their effects by binding to two cannabinoid receptors, i.e. CB1, which 
is expressed primarily in the central nervous system, and CB2, which is found primarily in 
the immune system and hematopoietic cells.4-6 In recent years, cannabinoid-based drugs 
and non-smoking routes of  drug administration have been investigated in clinical trials. 
To date, there are only two oral cannabis-based medicines (dronabinol and nabilone) 
available by prescription in some countries, and one available as an oromucosal mouth 
spray (nabiximols). Dronabinol (synthetic THC) and nabilone (THC analog), are approved 
by the United States Food and Drug Administration, and in some European countries, 
for appetite stimulation in AIDS-related anorexia and chemotherapy-induced nausea 
and vomiting. Nabiximols (Sativex®), which contains both THC and CBD, is approved 
in the United Kingdom and in some other European countries and Canada, but not in 
the USA, for the management of  pain and spasticity in patients with multiple sclerosis. 
Growing interest in the medical use of  cannabis has recently led to the development 
of  Namisol®. Namisol®  is a novel cannabinoid-based drug formulation that contains 
THC ( ≥ 98%) in tablet form. It was developed using a novel drug delivery technology, 
AlitraTM to improve its absorption and bioavailability.7 The results of the first trial in 
humans investigating the optimal route of administration, safety, pharmacokinetics, and 
pharmacodynamics of  the drug showed that Namisol® (5mg, 6.5mg, and 8mg) might 
have more favorable pharmacokinetics and pharmacodynamics than currently available 
cannabinoid-based drugs.7 This is because Namisol® showed (1) a faster absorption and 
a shorter time to reach the maximal THC concentrations; (2) a smaller variability in 
Tmax (time to maximum plasma concentration) and plasma concentrations; and (3) faster 
pharmacodynamic effects, which are important for achieving a rapid clinical effect.7 
Klumpers et al. also reported that Namisol® was safe and well tolerated by subjects. 
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However, their study involved only young adults (mean age 21.4 years, range 18-27 
years), and so findings cannot directly be extrapolated to older population (65 years and 
older). Older people are in general more likely to experience adverse drug events, due to 
a combination of age-related physiological changes (such as a decrease in lean body mass, 
diminished renal and hepatic clearance) and a high prevalence of  co-morbidities, which 
can lead to polypharmacy and drug-drug interactions.8-10 The aims of  this trial were first, 
to assess the safety and tolerability of three oral doses of  THC (3mg, 5mg, and 6.5mg) in 
healthy older subjects. Second, to evaluate the pharmacokinetics of THC in older people 
and to investigate the relationship between the drug’s pharmacodynamic effects and the 
plasma concentrations of  THC and its active metabolites 11-hydroxy-delta 9-THC (11‐
OH‐THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THC-COOH).
Experimental procedures
Study design and participants
This phase 1, randomized, double-blind, double-dummy, placebo-controlled, 
crossover trial (ClinicalTrials.gov ID NCT01740960) was approved by the local ethics 
committee (Registration number: NL40591.091.12) and carried out at the Radboud 
university medical center, Nijmegen, The Netherlands. The trial was performed according 
to the International Conference on Harmonization guideline for good clinical practice, 
the ethical principles of  the Declaration of  Helsinki, and the related Dutch laws and 
regulations. The subjects were healthy elderly volunteers who were recruited between 
August and November 2012 through personal contacts and word of  mouth. All subjects 
provided written informed consent before they were screened for eligibility. Inclusion 
criteria were age 65 years or older; physically healthy, based on a medical history, physical 
examination, electrocardiography (ECG), results of  hematological and biochemical blood 
tests on screening; and body mass index between 18.0 and 30 kg/m2. Main exclusion 
criteria were high falls risk (based on body sway test); regular cannabis use (defined as 
smoking one or more cannabis cigarettes per week); history of sensitivity/idiosyncrasy 
to cannabis; history of  drug or alcohol abuse; smoking more than ten cigarettes a day; 
history of  severe co-morbidities (e.g. COPD GOLD III or IV; heart failure NYHA III 
or IV) or diabetes mellitus; history of  psychiatric or cognitive disorders; consumption of  
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more than six units of  (methyl)xanthine products per day (e.g. coffee, tea, cola, chocolate); 
use of  drugs that inhibit cytochrome P450 (CYP) 2C9, CYP2C19 and CYP3A4, and was 
not possible to discontinue the use of  the drugs during the study period.
Randomization and masking
Subjects were randomly allocated to receive a single dose of  3mg (two 1.5mg tablets), 
5mg (one tablet), or 6.5mg (one 5mg and one 1.5mg tablet) of  Namisol® or matching 
placebo in a double-blind, double-dummy manner on each intervention day. Subjects 
received three tablets per visit, two of  6 millimeter and one of  9 millimeter (Namisol® 
or matching placebo). This double-dummy technique was used because of  difference of  
the size of  Namisol®  tablets, 1.5mg (6 mm) and 5mg (9 mm). Each subject acted as his/
her own control and therefore received all study medications (single dose per visit) in a 
crossover design on four occasions (visits 1-4). The washout period between the visits was 
2 weeks. Namisol® and placebo tablets were identical in appearance. The randomization 
codes were generated by a computer algorithm for random numbers and could only be 
accessed by the site pharmacist. Study drugs were labeled with a unique identification 
number before delivery to the investigators. Sponsor, investigators, site staff, and subjects 
were masked to assignment.
Interventions
The intervention period (visits 1 to 4) was preceded by a screening visit (visit 0) that 
occurred maximally 2 weeks before randomization, during which subjects’ medical 
history was taken and they underwent a physical examination, ECG, hematological and 
biochemical blood tests, the Mini Mental State Examination (MMSE), the Geriatric 
Depression Scale (GDS-30) test, and body sway test, using the SwayStarTM. Subjects who 
fulfilled the eligibility criteria were randomly allocated to receive the trial medications, 
which were administered orally with 100 mL water. Subjects were asked to abstain from 
smoking (12 h) and consuming alcohol (24 h), grapefruit (48 h) or quinine (24 h) and 
xanthine-containing beverages or foods (12 h) before each intervention. They were asked 
not to drive a car for 24 h after ingestion of  the trial medication or to drink more than 
2 glasses of  alcohol a day or to smoke more than ten cigarettes per day. All subjects 
were instructed to contact the investigator if  they developed fever (38ᵒC or higher) 3 
days before the intervention day and not to start any medication without consulting the 
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investigator. Subjects who used medication that interacts with THC had to discontinue 
the medication temporarily during the study period (approximately 8 weeks).
Safety assessments
The primary endpoint of  the trial was safety of  Namisol®, which was assessed by 
evaluating the incidence and severity of  adverse events (AEs) using a standardized THC 
AEs checklist and spontaneous reporting, vital signs (including systolic and diastolic 
blood pressure, and heart rate), 12-lead ECG, Visual Analog Scales (VAS-subtest feeling 
high), and laboratory safety tests (hematology and chemistry). The Test for Attentional 
Performance (TAP-subtest alertness) and SwayStarTM were used to evaluate the effects 
of  Namisol®  on subjects’ attention and body sway. On each intervention day, safety was 
monitored by research staff for 3.5 h after dosing. Moreover, subjects were telephoned 
24 h after drug (active or placebo) ingestion to determine the occurrence of  AEs after 
discharge. All AEs were recorded with regard to their time of  onset, severity, duration, 
and possible relationship to the study drug. The Medical Dictionary for Regulatory 
Activities was used for coding AEs.
VAS-feeling high: “Feeling high” was assessed with the Bowdle VAS for psychedelic 
effects.11 Subjects were asked to score “feeling high” on a 100-mm horizontal line, with 
“0” indicating not feeling high and “100” indicating feeling extremely high.
TAP-Alertness: A computerized subtest of  the TAP was used to measure alertness 
(reaction time) under two conditions. First, a simple reaction time to a visual  stimulus, 
a cross “X”, appearing on the monitor screen at randomly varying intervals. The 
subject had to respond as quickly as possible by pressing a key when “X” appeared 
on the screen. Second, the visual stimulus as preceded by a cue stimulus presented as 
warning tone. The subject had to respond only when “X” appeared on the screen. TAP 
scores are given in milliseconds.
Body sway: The SwayStarTM (http://www.b2i.info/web/index.htm), a wireless device 
attached to the trunk (L3–L5), was used to measure body sway over 1 min. The subjects 
were asked to stand quietly and relaxed with feet slightly apart on a firm surface, first 
with eyes open for 30 sec and then with eyes closed for 30 sec. The range of  pitch velocity 
scores (anterior–posterior movements) was used for analysis. Scores are given in degrees 
per second.
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Blood sampling and laboratory analysis
Venous blood samples were collected in EDTA-coated tubes (6 mL) before and at 
40, 55, and 120 min after dosing, for the measurement of  plasma concentrations of  
THC, 11‐OH‐THC, and THC-COOH. The tubes were placed on ice and within 60 
min were centrifuged for 10 min (2000g, 4ᵒC). The plasma was pipetted into two 1.5 mL 
cryotubes, which were stored at -80ᵒC until analysis. The plasma concentrations were 
analyzed at the Analytisch Biochemisch Laboratorium b.v. (Assen, The Netherlands), 
using liquid chromatography/mass spectrometry/mass spectrometry. The lower limit 
of  quantification was 0.1 ng/mL for THC and 11‐OH‐THC, and 0.5 ng/mL for 
THC-COOH. The analysis was performed using a validated assay according to good 
laboratory practice standards. The acceptance criteria for an analytical run was based 
on bioanalytical methods validation for human studies,12, 13 which included accuracy, 
precision, selectivity, post-preparative stability, dilution of  samples, freeze/thaw stability, 
refrigerator stability, whole blood stability, and long term stability.
Pharmacodynamic assessments
The VAS-feeling high, TAP-alertness, and body sway were used to evaluate the 
secondary endpoint of  this trial, the relationship between pharmacodynamic effects 
of  Namisol® and the plasma concentrations of  THC and its active metabolites. All 
assessments were carried out directly after blood sampling, pre-dosing and at 40, 55 and 
120 min after dosing.
Statistical analysis
Descriptive statistics were used to describe the study population. The continuous 
data are expressed as means ±standard deviation (±SD), and categorical data are 
expressed as frequencies. This study is descriptive and explorative. The primary 
endpoint was the safety of  THC on incidence and severity of  reported AEs. To 
explore the association between administered dose of Namisol® (3mg, 5mg, and 6.5mg) 
and the occurrences of  AEs, Generalized Estimating Equations (GEE) were used to 
compare the proportion of  subjects experiencing one or more AEs, and random effects 
analyses with non-linear mixed models (NLMIXED) to compare the number of  AEs per 
subject per dose, assuming that AEs had a Poisson distribution. The VAS, TAP, and body 
sway scores were analyzed in relation to the Namisol® doses, using linear mixed models. 
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The effects of  the three Namisol® doses on the plasma concentrations of  THC, 11-OH-
THC, and THC-COOH, which were measured 40, 55, and 120 minutes after dosing, 
were analyzed with linear mixed models to take into account the longitudinal character 
of  the data. Pharmacokinetic parameters including maximum plasma concentration 
(Cmax), time to maximum plasma concentration (Tmax), and area under the curve from t 
=0 to 2 h (AUC) were calculated using Phoenix WinNonlin 6.3 (Certara, L.P./Pharsight 
Ltd). For secondary endpoint of  the study, the TAP and body sway scores were analyzed 
in relation to THC, 11-OH-THC, and THC-COOH plasma concentrations, using 
linear mixed models. In all linear mixed models we used “volunteer” as a random effect. 
P values <0.05 were considered to indicate significance.
No correction was made for multiple testing because of  the explorative character of  
study. All statistical analyses were performed using SASTM software (version 9.2).
Results
Baseline characteristics
Twelve healthy elderly subjects (6 male; mean age 72±5 years, range 65-85 years) 
were randomized. Their demographic characteristics are summarized in Table 1. None 
of the subjects had ever used cannabis and all were in good physical and mental health. 
Only one subject was a cigarette smoker (average 5 cigarettes/day); 11 subjects used 
moderate amounts of  alcohol. Four subjects had no relevant medical history and did 
not use medications. The most common health problems were hypertension (n=3) and 
hypercholesterolemia (n=3). The subjects used an average of  2±2.1 medications, with 
cardiovascular drugs such as lipid-lowering drugs, aspirin, and beta-blockers being the 
most commonly used medications.
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TABLE 1
Demographics and baseline characteristics of subjects randomized in the trial.
Characteristics N=12
Male, n (%) 6 (50)
Female, n (%) 6 (50)
Age, mean (SD); [range] years 72.1 (5); [65-80]
Caucasian race, n (%) 12 (100)
Smokers, n (%) 1 (8)
Cannabis users, n (%) 0 (0)
Alcohol users, n (%) 11 (91.7)
≤ 2 alcoholic beverage/day, n 8
3-4 alcoholic beverage/day, n 3
BMI, mean (SD); kg/m2 26.4 (1.5)
Weight, mean (SD); kg 77.3 (9.8)
Height, mean (SD); centimeter 170.9 (9.2)
SBP, mean (SD); mmHg 134.3 (10.6)
DBP, mean (SD); mmHg 76.7 (6.9)
HR, mean (SD); beats/minute 61.3 (10.4)
MMSE-30, mean (SD) 29.8 (0.6)
GDS-30, mean (SD) 0.17 (0.4)
Number of medications used by subject, mean (SD) 2 (2.1)
Concomitant medications, n (%)a
Lipid lowering 7 (58.3)
Aspirin 4 (33.3)
Beta-blockers 3 (25.0)
ACE-inhibitors 2 (16.7)
Calcium channel blockers 2 (16.7)
Thiazide diuretics 2 (16.7)
Proton pump inhibitors 1 (8.3)
Laxatives 1 (8.3)
Eye drops 1 (8.3)
Comorbidites, n (%)
Hypertension 3 (25.0)
Hypercholesterolemia 3 (25.0)
Cholecystectomy (past) 2 (16.7)
Valve disease 1 (8.3)
Stable angina 1 (8.3)
Myocardial infarction (past) 1 (8.3)
Colon cancer (past) 1 (8.3)
Glaucoma 1 (8.3)
Abbreviations: BMI, body mass index; SPB, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; 
MMSE, Mini Mental State Examination; GDS, Geriatric Depression Scale.
a Number of subjects who used one or more medications.
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Safety and tolerability
The data of  11 subjects (5 men and 6 women) were included in the analysis. The data 
of  one subject were excluded due to non-compliance to study medication. Table 2 lists 
all reported AEs by dose (40 in total). The first AEs were observed 20 min after dosing. 
All AEs were mild and most occurred between 55 and 120 min after dosing and resolved 
spontaneously before the end of  the intervention day (within 3.5 h after dosing). There 
were no serious adverse events (SAEs) during the trial. More subjects reported one or 
more AEs with Namisol® 3mg (5 subjects, p=0.036), 5mg (5 subjects, p=0.036) and 6.5mg 
(7 subjects, p=0.008) than with placebo (1 subject) and overall the subjects reported 
fewer AEs with placebo (total 1 event, p=0.013), Namisol® 3mg (9 AEs, p=0.048) and 
5mg (8 AEs, p=0.034) than with Namisol® 6.5mg (22 AEs). Overall, the most frequently 
reported AEs were drowsiness (27%; including one on placebo), dry mouth (11%), 
coordination disturbance (9%), and headache (9%). There were no clinically relevant 
changes in systolic or diastolic blood pressure (difference of  20 mmHg and 15 mmHg at 
rest, respectively) and heart rate (difference of  20 beats/minute) after the administration 
of  trial medication. The ECG parameters (e.g. QT and RR intervals) were unchanged 
from screening to the end of  trial, and all laboratory test results were within the normal 
range. VAS-Feeling high scores indicated that four subjects (three females and one male) 
“felt high” after THC. Subject A, a 71-year old woman (BMI 28.1 kg/m2) had a VAS 
score of  8 mm 120 min after 3mg Namisol, and 13 and 16 mm 55 and 120 min after 
5mg Namisol®, respectively. Subject B, a 68-year-old man (BMI 26.1 kg/m2), had VAS 
scores of  9 and 7 mm 55 and 120 min after 5mg Namisol, respectively. Subject C, a 
71-year-old woman (BMI 26.5 kg/m2), had a VAS score of  25 mm 120 min after 6.5mg 
Namisol®, and subject D, a 73-year-old women (BMI 23.5 kg/m2), had a VAS score of  
6 mm 120 min after 6.5mg Namisol®. No significant changes were found in subjects’ 
attention performance (TAP-scores p = 0.18) or body sway (eyes open p = 0.18; eyes 
closed, p=0.16) after the administration of  trial medication.
Pharmacokinetic parameters
The mean THC, 11-OH-THC, and THC-COOH concentration-time curves 
are shown in the Figure. Plasma concentrations of THC, 11‐OH‐THC, and THC-
COOH were dose-dependent and significantly increased with increasing the dose 
of  Namisol® (p<0.0001). Table 3 lists the mean pharmacokinetic parameters of  
THC. There was a wide inter-individual variability in plasma concentrations of  
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THC, 11‐OH‐THC and THC- COOH. In one subject the THC concentration 
had not reached a maximum by 120 min after 3mg Namisol®, and in four and 
five subjects after 5mg and 6.5mg Namisol®, respectively. For subjects for whom 
Cmax fell within the sampling interval (120 min), the geometric mean THC Cmax 
was 1.42 ng/mL (range 0.53–3.48) for 3mg (n=10), 3.15 ng/mL (range 1.54–
6.95)  for 5mg (n=7), and 4.57 ng/mL (range 2.11–8.65) for 6.5mg (n=6).
TABLE 2
Overview of all 40 drug-related adverse events reported by subjects or observed by 
investigator during the trial. 
Placebo, Namisol® Totala
n=11 3mg, n=11 5mg, n=11 6.5mg, n=11
1 Drowsiness b 1 (9) 5 (45) 2 (18) 4 (36) 12 (27)
2 Dry mouth 0 (0) 0 (0) 2 (18) 3 (27) 5 (11)
3 Coordination disturbance 0 (0) 1 (9) 1 (9) 2 (18) 4 (9)
4 Headache 0 (0) 1 (9) 1 (9) 2 (18) 4 (9)
5 Concentration problem 0 (0) 0 (0) 1 (9) 2 (18) 3 (7)
6 Blurred vision 0 (0) 0 (0) 0 (0) 2 (18) 2 (5)
7 Relaxation 0 (0) 1 (9) 0 (0) 1 (9) 2 (5)
8 Euphoria 0 (0) 1 (9) 0 (0) 1 (9) 2 (5)
9 Dizziness 0 (0) 0 (0) 1 (9) 1 (9) 2 (5)
10 Nausea 0 (0) 0 (0) 0 (0) 1 (9) 1 (2)
11 Dry eyes 0 (0) 0 (0) 0 (0) 1 (9) 1 (2)
12 Malaise 0 (0) 0 (0) 0 (0) 1 (9) 1 (2)
13 Visual hallucinations 0 (0) 0 (0) 0 (0) 1 (9) 1 (2)
Total number of adverse 
events/dosec
1, p=0.013 9, p=0.048 8, p=0.034 22, p=1 40
Number of subjects with one or 
more adverse events, n (%)d
1(9), p=1 5(45), p=0.036 5(45), p=0.036 7(64), p=0.008 18 (41)
a Total number of reports per adverse event.
b Number (n) and percentages (%) of subjects reported an adverse event.
c p-values based on pair-wise comparisons of Namisol® 6.5mg (reference) with placebo, and with the doses of 3mg 
and 5mg, using NLMIXED analyses. 
d p-values based on pair-wise comparisons of each of Namisol® doses with placebo (reference), using Generalized 
Estimating Equations analyses. 
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TABLE 3
The mean pharmacokinetic parameters of THC after administration of single dose 
Namisol®
Parameters (mean and range) 3 mg (n=11) 5 mg (n=11) 6.5 mg (n=11)
THCa 1.2 (0.13-3.48) 1.9 (0.26-6.95) 2.61 (0.23-8.65)
11-OH-THCa 1.69 (0.47-4.34) 2.34 (0.37-8.37) 3.12 (0.37-8.61)
THC-COOHa 13.9 (1.27-27.0) 19.3 (2.23-48.8) 26.6 (3.51-56.8)
AUC0-2 h (h ng/mL) 1.67 (0.80-4.14) 2.61 (0.97-7.55) 3.51 (1.26-11.45)
3 mg (n=10) 5 mg (n=6) 6.5 mg (n=5)
Cmax (ng/mL)
b 1.42 (0.53-3.48) 3.15 (1.54-6.95) 4.57 (2.11-8.65)
Tmax (h)
b 0.92 (0.67-0.92) 0.92 (0.67-0.92) 0.67 (0.67-0.92)
a Plasma concentrations
b Reported for subjects who reached the Cmax within 2 h
Pharmacokinetic/pharmacoynamic effects
Since only 7 of  174 (4%) “feeling high” measurements had scores higher than “0”, 
it was not possible to calculate the association between the VAS-feeling high and the 
plasma concentrations of  THC, 11‐OH‐THC, and THC-COOH. Body sway with eyes 
open scores were not associated with the plasma concentrations of  THC (p = 0.14), but 
with the concentrations of  its metabolites. An increase of  1 ng/mL in 11‐OH‐THC 
and THC-COOH plasma concentrations was accompanied by a mean increase in 
body sway with eyes open of  0.08 degrees/second (p = 0.006; 95%CI: 0.02 to 0.14) and 
0.0081/s (p = 0.024; 95% CI: 0.001 to 0.014), respectively. Furthermore, increases in 
plasma concentrations were associated with increase in body sway with eyes closed. An 
increase of  1 ng/mL in THC, 11‐OH‐THC, THC-COOH plasma concentrations was 
accompanied by a mean increase in body sway with eyes closed of  0.09 degrees/second 
(p = 0.0002; 95% CI:0.04 to 0.13), 0.121/s (p<0.0001; 95%CI: 0.08 to 0.16), and 0.007 
1/s (p = 0.0087; 95% CI:0.002 to 0.012), respectively. However, there were no significant 
differences in the body sway scores  between  Namisol® and  placebo and  therefore, 
observed changes in body sway scores associated with the plasma concentrations are 
clinically not relevant.  TAP-alertness scores were not associated with the plasma 
concentrations of  THC (p = 0.52), 11‐OH‐THC (p = 0.65), or THC-COOH (p = 0.84).
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FIGURE 
Mean THC, 11-OH-THC, and THC-COOH concentration-time curves.
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Discussion
Safety and tolerability
Owing to the broad therapeutic application of  cannabinoids, older individuals are 
probably the fastest growing population of  users, with an estimated prevalence between 
6.5% and 37% of  medicinal cannabis users aged between 60 and 93 years.14-17 However, 
the growing interest in the medical applications of  cannabinoids should be accompanied 
by discussion of  their safety and efficacy in older patients.17 Several randomized clinical 
trials have demonstrated the safety and efficacy of cannabinoid-based medicines in the 
treatment of  conditions that are common in older individuals.18-21 However, most of  these 
trials either did not include older subjects or, if  they were included, did not analyze data by 
age group, which makes it difficult to draw firm conclusions about the safety and efficacy 
of  cannabinoids in older patients.17 To our knowledge, this is the first phase I trial of  the 
safety and pharmacokinetics of  a cannabis-based medicine that included solely older 
individuals. Single oral doses of  Namisol®  of  3mg, 5mg, and 6.5mg were generally safe 
and well tolerated by the healthy older individuals. The 6.5mg dose was associated with 
more AEs than the lower doses, but there was no significant difference in the incidence of  
AEs between the 3mg and 5mg doses. The most frequently reported AEs were drowsiness 
(27%) and dry mouth (11%). All AEs were mild and resolved spontaneously within 3.5 
h. There were no moderate or SAEs. Four of  the eleven subjects reported “feeling high” 
after the administration of  Namisol®, but only 4% of  VAS scores were higher than “0”. 
The sensation was mild in intensity (VAS scores ranging between 6 mm and 25 mm, out 
of  100 mm) and of short duration. In the previous study of  Namisol® in young adults 
(mean age 21 years), 85% and 100% of  subjects had at least one AE after 5mg and 
6.5mg, respectively, and one subject dropped out because of  drug-related syncope with 
the 5mg dose; all AEs were mild to moderate in severity.7 Our findings, with zero drop-
outs and 45% and 64% of  subjects reporting only mild AEs with the 5mg and 6.5mg 
doses, respectively, suggest that THC is tolerated better by older individuals (mean age 
72 years) than by younger individuals, a finding which we had not anticipated. However, 
the low rate of  unwanted (side) effects in older individuals may be correlated with a lower 
rate of  wanted (therapeutic) effects. Further studies are required to assess the effectiveness 
of  the three doses Namisol® in the treatment of  conditions in older individuals.
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Pharmacokinetic an pharmacodynamic effects
Our findings showed substantial inter-individual variation plasma concentrations 
of  THC, 11‐OH‐THC, and THC-COOH, which is in line with previous studies that 
included individuals of  different ages, but did not report data for older patients separately.7, 
22, 23 In some subjects, THC concentrations did not reach a maximum within the sampling 
period of  120 min after dosing. This is in contrast with previously published data for 
young adults, where maximal concentrations of  THC were reached between 39 and 56 
min after oral Namisol®.7 For subjects for whom Cmax fell within the sampling period, the 
mean Cmax (3.15 ng/mL with the 5mg dose and 4.57 ng/mL with the 6.5mg dose) was 
similar to that reported for young adults (2.92 ng/mL with 5mg and 4.43 ng/mL with 
6.5mg).7 In this study, the sample schedule was based on previously published data for 
young adults,7 but did not cover a full pharmacokinetic curve in older subjects. Therefore, 
and because of  the limited number of  samples collected, the pharmacokinetic data should 
be handled with caution when extrapolating to other studies. Unfortunately, it was not 
possible to compare our data with those of  other pharmacokinetic studies involving older 
subjects, because we did not find any pharmacokinetic studies of  THC that reported data 
separately for older individuals. In our trial, the first pharmacodynamic effects of  THC 
occurred 20 min after dosing and the maximal effects were reported between 55 and 120 
min. These results are quite promising for achieving a rapid clinical effect when compared 
with the action of  dronabinol, which has an onset of action between 30 min and 1 h, and 
maximal effects between 2 and 4 h.24 We found no significant differences in body sway 
scores (eyes open and closed) after the administration of  THC. Body sway with eyes open 
scores were associated with plasma concentrations of  11‐OH‐THC, and THC-COOH, 
but not THC. This is in line with previous studies that showed a larger effect after 11‐
OH‐THC administration than after THC administration.25-27 Comparison of  the effects 
of  THC and placebo showed that although higher plasma concentrations of  THC and 
its metabolites were associated with higher body sway with eyes closed scores in our older 
subjects, this effect was not clinically relevant and would not increase the risk of  falls. 
Interestingly, the pharmacodynamic effects of  THC were smaller than we had expected 
for older people, based on the effects seen in young adults.7 A possible explanation for 
this could be the age-related physiological changes such as delayed gastric emptying 
time, decreased gastrointestinal motility and absorption surface which could affect the 
absorption and bioavailability of  THC. Furthermore, cannabinoid receptors (CB1 and 
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CB2) are G-protein-coupled receptors.
28 Impairments in intracellular function and levels 
of  G-proteins have been observed with aging,29 which may alter the pharmacodynamics 
in older adults. Further comparison studies are required to compare the pharmacokinetic 
and pharmacodynamic effects of  THC in younger and older adults.
Strengths and limitations of the study
The primary strengths of  our study were, first, its design; a randomized, double-blind, 
placebo-controlled trial. Second, it is the first RCT of  the safety and pharmacokinetics of  
cannabis-based medicine that exclusively included older subjects, so that our findings add 
to the sparse literature on the safety and pharmacokinetics of  THC in older people. A 
potential limitation of  our study is that we could not perform a complete pharmacokinetic 
analysis of  THC in older individuals because the study was primarily designed to assess 
the safety and tolerability of  THC and therefore, only four blood samples were collected 
(over 120 min). We are currently investigating the efficacy of  THC in the treatment of  
pain and behavioral disturbances in patients with dementia. In one of  these studies, we will 
be collecting a sufficient number of blood samples to allow a complete pharmacokinetic 
analysis of  THC and its metabolites in older subjects. In conclusion, Namisol®, a novel 
THC in tablet form, appeared to be safe and well tolerated by healthy older individuals. 
Data on safety and effectiveness of  cannabinoid-based medicines in frail older persons 
with multiple co-morbidities are urgently required, as this population could benefit from 
the therapeutic applications of  cannabinoids.
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You’ll know heartache
Still more crying
When you’re thinking of your mother’s only son
Take to your bed
You say there’s peace in sleep
But you’ll dream of love instead
Joan Armatrading  -  Down To Zero 
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Abstract
Rationale: data on safety, pharmacodynamics, and pharmacokinetics of  
tetrahydrocannabinol (THC) are lacking in dementia patients.
Methods: in this randomized, double-blind, placebo-controlled, crossover trial, 
we evaluated the safety, pharmacodynamics, and pharmacokinetics of  THC in ten 
patients with dementia (mean age 77.3±5.6). For 12 weeks, participants randomly 
received oral THC (weeks 1-6, 0.75mg; weeks 7-12, 1.5mg) or placebo twice daily 
for three days, separated by a 4-day washout period.
Results: only six of  the 98 reported adverse events were related to THC. Visual 
analog scale (VAS) feeling high, VAS external perception, body sway-eyes-open, and 
diastolic blood pressure were not significantly different with THC. After the 
0.75mg dose, VAS internal perception (0.025 units; 95 % Confidence Interval 
[CI] 0.010 to 0.040) and heart rate (2 beats/min; 95 % CI 0.4 to 3.8) increased 
significantly. Body sway-eyes-closed increased only after 1.5mg (0.59°/s; 95 % CI 0.13 
to 1.06). Systolic blood pressure changed significantly after both doses of  THC 
(0.75mg, -7 mmHg, 95%CI -11.4 to 3.0; 1.5mg, 5 mmHg, 95%CI 1.0 to 9.2). 
The median Tmax  was 1-2 h, with THC pharmacokinetics increasing linearly with 
increasing dose, with wide inter-individual variability (CV% up to 140 %). The 
mean Cmax (ng/mL) after the first dose (0-6 h) was 0.41 (0.18-0.90) for the 0.75mg 
dose and 1.01 (0.53-1.92) for the 1.5mg dose. After the second dose (6-24 h), the  Cmax 
was 0.50 (0.27-0.92) and 0.98 (0.46-2.06), respectively. 
Conclusions: THC was rapidly absorbed and had dose-linear pharmacokinetics with 
considerable inter-individual variation. Pharmacodynamic effects, including adverse 
events, were minor. Further studies are warranted to evaluate the pharmacodynamics 
and efficacy of  higher THC doses in older persons with dementia.
Keywords: tetrahydrocannabinol (THC); safety; pharmacodynamics; pharma-
cokinetics.
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Introduction
In recent years, there has been increased interest in the medical applications of  delta-
9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid of  the cannabis 
plant (Cannabis sativa L.). A number of  studies have demonstrated its effectiveness in 
the management of  clinical conditions that are very common in older people, such 
as neuropsychiatric symptoms (e.g., agitation and aggression) in dementia, pain (e.g., 
neuropathic and spasticity in multiple sclerosis), and anorexia.1-4 These therapeutic 
effects of  THC are mediated primarily by two cannabinoid receptors: CB1 and CB2.
5-
7 CB1 receptors are mainly expressed in the basal ganglia, cerebellum, hippocampus, 
hypothalamus, and dorsal horn,8 and CB2 receptors are primarily found on immune cells 
and tumor cells.9 THC also interacts with other receptors and neurotransmitters in the 
brain, such as acetylcholine, dopamine, serotonin, gamma-aminobutyric acid, glutamate, 
norepinephrine, prostaglandins, and opioid peptides.10 These broad and complex 
interactions underlie the potential pharmacological effects of  THC as multi-target 
drug candidate for the management of  behavior, mood, pain, and anorexia in patients 
with dementia. Oral, fixed-dose THC-based drugs have recently been developed. For 
example, dronabinol (Marinol®) and nabilone (Cesamet®) have been approved in North 
America and some European countries for appetite stimulation in AIDS-related anorexia, 
chemotherapy-induced nausea and vomiting, and pain. Namisol® is the most recently 
developed THC-based formulation in tablet form but has not yet gained marketing 
approval.11 Unfortunately, preapproval clinical trials of  oral THC excluded old persons 
from participation or did not include sufficient numbers, and most recent studies that 
included older participants did not perform separate analyses for the older subgroup.12-14 
Studies of  the potential effectiveness of  THC in older individuals should include 
assessment of  its safety, and especially in individuals with dementia, many of  whom 
are frail and vulnerable.12 To date, only four small studies have investigated the safety 
and efficacy of  THC as treatment for the neuropsychiatric symptoms of  dementia.15-18 
All studies found THC to be effective and safe in older people with dementia, but as 
the studies were either not randomized or included a limited number of  patients, it is 
not possible to draw firm conclusions about the safe and effective use of  THC in these 
individuals. Furthermore, none of  the studies investigated the pharmacokinetics of  THC 
in this population. We found only one study in the literature that evaluated plasma THC 
6122
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
concentrations (peak levels only) in older individuals (age 51-78 years), but these individuals 
were not demented.19 Drug pharmacokinetics and pharmacodynamics in older people 
may be altered by age-related physiological changes, multiple co-morbidities, or use of  
other medications. Aging is accompanied by an increase in adipose tissue, a decrease in 
lean body mass, and a decrease in total body water,20 changes which increase the volume 
of  distribution of  lipophilic drugs such as THC. Moreover, a decrease in hepatic blood 
flow and the slower metabolism of  older individuals can slow the elimination of lipophilic 
drugs, thereby potentially increasing exposure and side effects.21 In addition, dementia-
related changes in brain volume, number of  neurons, and alteration in neurotransmitter 
sensitivity make older patients with dementia more sensitive to drugs that act on the 
central nervous system.20 Taken together, we hypothesize that the administration of  
THC to older people with dementia may lead to a higher THC concentrations, which 
subsequently lead to an increase in pharmacodynamic effects, including adverse effects, 
compared with previously published data for young adults11 or healthy older individuals 
without dementia.22 Understanding the pharmacodynamics and pharmacokinetics of  
THC in older, frail, dementia patients will help clinicians to minimize side effects and 
maximize benefit. Therefore, the aim of  the present study was to evaluate the safety, 
pharmacodynamics, and pharmacokinetics of  multiple oral doses of  THC in older 
persons with dementia.
Methods
Study design and participants
This study was part of  a multicenter, phase II, repeated crossover, randomized, 
double-blind, placebo-controlled, multiple-dose escalation trial of  the effectiveness of  
THC in the treatment of  the neuropsychiatric symptoms of  dementia (http://www.
clinicaltrials.gov, NCT01302340). The study was carried out at the Radboud university 
medical center, Nijmegen, the Netherlands. Results concerning the effectiveness of  THC 
in the management of the neuropsychiatric symptoms of  dementia will be reported 
separately. Figure 1 provides an overview of  the study design. The study consisted of  two 
treatment periods, A and B. Each period consisted of  three treatment blocks, resulting 
in a total of six blocks (period A, blocks 1 to 3; period B, blocks 4 to 6). Each block 
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lasted two weeks, giving a total study duration of 12 weeks. In each block, participants 
received oral Namisol®, a novel THC in tablet form,11 and matching placebo (ratio 1:1) 
in a double-blind crossover manner for three days, separated by a 4-day washout period. 
In period A, patients received 0.75mg THC twice daily, and in period B, the dose was 
increased to 1.5mg twice daily. Namisol® and placebo were identical in appearance 
and taste, and both were taken under non-fasting conditions with water at 10 a.m. and 
4 p.m. Study participants stayed overnight at the study site on the three intervention 
days (THC and placebo) of  blocks 1 and 4 for safety reasons and to facilitate blood 
sampling, resulting in a total of  four 3-day admissions. The randomization codes were 
generated by an independent pharmacist, using a computer algorithm for random 
numbers. Sponsor, investigators, study staff, and participants were masked to assignment. 
Participants had been diagnosed with dementia type Alzheimer, vascular dementia, or 
mixed Alzheimer/vascular dementia, according to the National Institute of  Neurological 
and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders 
Association (NINCDS- ADRA)23 or Association Internationale pour la Recherché 
et l’Enseignement en Neurosciences (NINCDS-AIREN)24 criteria. All patients had 
had clinically relevant neuropsychiatric symptoms, including at least agitation and/or 
aggression, in the past 30 days (Neuropsychiatric Inventory score ≥10),25 and had an 
informal caregiver who looked after the participant at least once a week. Main exclusion 
criteria were major psychiatric disorders (e.g., major depression or suicidal ideation, 
psychosis, mania, or current delirium), current history of  severe co-morbidities, frequent 
falling due to orthostatic hypotension, history of  current alcohol or drug abuse, and 
use of tricyclic antidepressants, opioids, or drugs from a predesigned list of  cytochrome 
(CYP) 2C9, CYP2C19, and CYP3A4 inhibitors. Written informed consent was obtained 
from participants (if  they were able to consent and to sign) and their legal representatives. 
The study was approved by the local ethics committee and was performed according to 
the International Regulation on Harmonization guideline for good clinical practice, the 
ethical principles of  the Declaration of  Helsinki, and relevant Dutch laws and regulations.
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FIGURE 1
Overview of the treatment period; THC and placebo were administered at random (this is 
an example of random allocation of treatment)
Safety and tolerability assessments
The safety and tolerability of  THC were assessed subjectively and objectively, by 
evaluating the incidence and severity of  adverse events (AEs), carrying out physical 
examinations, laboratory tests (hematology and clinical chemistry), and a 12-lead 
electrocardiogram, and assessing vital signs. The psychedelic effects were assessed with 
visual analogue scales (VAS), and body sway (postural stability) was measured using 
the SwayStar™ (see details below). During the study period, AEs reported by patients 
and caregivers or observed clinically were recorded with regard to their time of  onset, 
severity, duration, and causal relationship to study drugs. The causality was assessed by a 
research physician, blinded to treatment allocation, using a five-point scale: (1) unrelated, 
AE was clearly not related to the intervention; (2) unlikely, AE was doubtfully related 
to the intervention; (3) possible, AE may be related to the intervention; (4) probable, 
AE was likely related to the intervention; and (5) definite, AE was clearly related to the 
intervention. A serious adverse event (SAE) was defined as any event that was fatal or 
life-threatening, that required (prolonged) hospitalization, or that resulted in persistent or 
significant disability or incapacity. All AEs were coded using the Medical Dictionary for 
Regulatory Activities.
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Pharmacodynamic effects
The scores for psychedelic effects, body sway, and vital signs were used to evaluate the 
pharmacodynamic effects of  THC. 
1. Psychedelic effects: The Bowdle VAS for psychedelic effects was used to evaluate 
feeling high, internal perception (inner feelings that do not correspond with 
reality, including mistrustful feelings), and external perception (misperception 
of  an external stimulus or change in awareness of  surroundings).26, 27 Subjects 
were asked to score their perceptions on a 100-mm horizontal line, with “0” 
indicating no effect and “100”  indicating extreme effect. The VAS was assessed 
1 and 3 h after dosing on day 1 of  weeks 1, 2, 7, and 8, in patients who were 
able to understand the instructions and perform the task. A recent study showed 
that individuals with dementia can use the VAS in a similar way to those without 
dementia.28
2. Body sway: Body sway was assessed within 2 h of  dosing on the second day of  
admission of  weeks 1, 2, 7, and 8. Body sway was measured (30 s eyes open and 
30 s eyes closed) with the SwayStar™, a wireless device attached to the trunk 
(http://www.b2i.info/web/index.htm).
3. Vital signs: Systolic and diastolic blood pressure and heart rate were measured on 
day 1 of  weeks 1, 2, 7, and 8, before and at 15, 30, 45 min, and 1, 2, 3, and 4 h 
after the first dose.
Blood sampling and laboratory analysis
Venous blood samples were collected during hospital admission before and at 11, 30, 
45 min, and 1, 1.5, 2, 3, 4, and 6 h after the first dose, and before and at 11, 30, 45 min, 
and 1, 1.5, 2, 3, 4, 6, and 18 h after the second dose (in total covering a 24-h period). 
Plasma was separated by centrifugation (2000×g, 4°C, 10 min) and stored at -80°C until 
analysis. After unblinding, blood samples collected in the THC treatment period were 
analyzed at the Analytisch Biochemisch Laboratorium b.v. (Assen, the Netherlands), 
using liquid chromatography with tandem-mass spectrometer detection. The lower limit 
of  quantification was 0.1 ng/mL for THC and its active metabolite 11-OH-THC. The 
analysis was performed using a validated assay according to good laboratory practice 
standards.29
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Pharmacokinetic analysis
Noncompartmental analysis was performed using Phoenix WinNonlin software 
version 6.3 (Certara, L.P./Pharsight Ltd) to determine the pharmacokinetics of  THC 
and 11-OH-THC. The following pharmacokinetic parameters were calculated for the 
24-h period: terminal half-life (t
1/2
), area under the curve (AUC) from 0 to 24 h (AUC0-24 
h), and apparent clearance (CL/F, being the dose/AUC0-24 h). The following parameters 
were calculated for the two curves (curve 1, 0 to 6 h after the first THC dose; curve 2, 6 
to 24 h after the second dose) separately: the maximum plasma concentration (Cmax), the 
time to reach Cmax(Tmax), AUC from 0 to 6 h (AUC0-6 h), and AUC from 6 to 24 h (AUC6-24 
h), using the linear-up log-down trapezoidal rule. Concentration-time graphs were plotted 
for the two doses. Geometric means plus 95 % confidence intervals (CI) were calculated 
for each pharmacokinetic parameter for each dose. The coefficients of  variation (CV%) 
of  the geometric means were calculated to describe the inter-individual variability in 
pharmacokinetic parameters. The geometric mean ratio (GMR) plus 90% CI of  
AUC0-24 h, CL/F, and t1/2 of  the 1.5mg dose versus the 0.75mg dose were also calculated. 
Statistical analysis
This study is descriptive and explorative, and therefore, no sample size calculation 
was performed. Descriptive statistics were used to describe the study population. 
Continuous data are expressed as means ±standard deviation (±SD), and categorical 
data are expressed as frequencies and percentages. The compliance to study medication 
was calculated for the whole study sample. Differences in AE rates between THC and 
placebo were compared by Wilcoxon signed ranks test. The VAS scores were clustered 
and log-transformed, and the scores are expressed as units, as described previously.11, 27 
The 90% range of  pitch velocity (anterio-posterior movements) scores of  the SwayStar™ 
was used to analyze body sway. Scores are given in degrees per second. The VAS, body 
sway, and vital signs scores were analyzed in relation to the THC dose, using linear mixed 
models with participants as a random effect. Statistical analyses were performed using 
SAS™ software, version 9.2 (SAS Institute, Inc., Cary, NC, USA).
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Results
Participants
The data of  ten patients with dementia were analyzed. Their demographic 
characteristics are summarized in Table 1. The mean age of  participants was 77.3±5.6 
years; their mean body mass index was 25.7± 2.7 kg/m2; seven participants were men; 
and nine participants had Alzheimer’s disease.
Overall, treatment compliance to study medication was high, and almost 98% (THC 
99%; placebo 97.5%) of  the trial drugs were taken.
Safety and tolerability assessments
All participants completed the study as scheduled. In general, THC was safe and well 
tolerated by these older individuals with dementia. In total, 98 AEs were reported during 
the study period. More  AEs were reported with placebo (55 AEs) than with THC (43 
AEs) (period A, 0.75mg THC 21 AEs and placebo 30 AEs, p=0.290; period B, 1.5mg 
THC 22 AEs and placebo 25 AEs, p=0.435). Thirteen (13%) of  the reported AEs were 
considered to be possibly (n=12) or probably (n=1) related to study drugs (THC and 
placebo). Of  these, only six AEs (6% of  total AEs) were considered to be (possibly) related 
to THC, two with 0.75mg (dizziness and fatigue in one patient each), and four with 
1.5mg (agitation in three patients and fatigue in one patient). All were mild and transitory 
in nature. There were no THC-related SAEs. THC treatment was not associated with 
changes in the patients’ physical state, laboratory test results (hematology and clinical 
chemistry), or ECG parameters (e.g., QT and RR intervals).
Pharmacodynamic results
THC did not cause significant changes in scores for VAS feeling high, VAS external 
perception, body sway with eyes open, and diastolic blood pressure (Table 2). The 0.75mg 
dose, but not the 1.5mg dose, was associated with a statistically significant increase in 
VAS internal perception scores (0.025 units, 95% CI 0.010 to 0.040). The 1.5mg dose, 
but not the 0.75mg dose, significantly increased body sway with eyes closed (0.59°/s, 95% 
CI 0.13 to 1.06). The 0.75mg dose significantly decreased systolic blood pressure (-7.2 
mmHg, 95 % CI -11.4 to 3.0), whereas the 1.5-mg dose significantly increased systolic 
blood pressure (5.1 mmHg, 95% CI 1.0 to 9.2). Heart rate increased significantly after 
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the administration of  the 0.75mg dose only (2 beats/min, 95% CI 0.4 to 3.8). None of  
the changes in the pharmacodynamic parameters was associated with an AE.
TABLE 1
Baseline demographic characteristics
Characteristics n=10
Male, n (%) 7 (70)
Age, mean (SD) (years) 77.3 (5.6)
BMI, mean (SD) (kg/m2) 25.7 (2.7)
Ethnicity, n
Caucasian
Other
9
1
Type of dementia, n
Alzheimer
Vascular
Mixed
9
0
1
MMSE score, mean (SD) 18.5 (6.0)
Smokers, n 0
Comorbidities, n
Cardiac rhythm disorder
Hypertension
Ventricular hypertrophy
Diabetes
Electrolyte disturbances
Kidney function disorder
Vitamins deficiency
Hypercholesterolemia
Liver function disorder
Orthostatic hypotension
5
5
3
2
2
2
2
1
1
1
Medications, n
Antidementia drugsa
Memantine
Rivastigmine
Galantamine
Antihypertensivesa
Anticoagulants
Blood glucose lowering drugs
Antidepressants
Antiepileptics
Antipsychotics
Proton pump inhibitor
Other
16
9
5
2
11
4
3
1
1
1
1
12
Abbreviations: BMI, body mass index; MMSE, Mini Mental State Examination
a Some participants used a combination of drugs within the same medication group.
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TABLE 2
Pharmacodynamic effects of THC doses
Parameters a THC 0.75 mg versus placebo (n=10) THC 1.5 mg versus placebo (n=10)
VAS feeling high (U) b -0.010 (95% CI -0.037 to 0.017); 
p=0.47
0.002 (95%CI -0.024 to 0.028), 
p=0.90
VAS external perception (U) b 0.012 (95%CI -0.005 to 0.029); 
p=0.16
-0.014 (95%CI -0.031 to 0.003), 
p=0.11
VAS internal perception (U) b 0.025 (95%CI 0.010 to 0.040), 
p=0.001c
-0.002 (95%CI -0.014 to 0.010), 
p=0.75
Body sway, eyes open (ᵒ/s) 0.37 (95%CI -1.31 to 2.10), 
p=0.63
0.26 (95%CI -0.91 to 1.44), 
p=0.67
Body sway, eyes closed (ᵒs) 0.61 (95%CI -0.63 to 1.85), 
p=0.30
0.59 (95%CI 0.13 to 1.06), 
p<0.05c
Systolic blood pressure (mmHg) -7.2 (95%CI -11.4 to -3.0), 
p<0.001c
5.1 (95%CI 1.0 to 9.2), 
p<0.05c
Diastolic blood pressure (mmHg) 0.2 (95%CI -2.0 to 2.3), 
p=0.86
-0.1 (95%CI -2.2 to 2.0), 
p=0.92
Heart rate (beats/min) 2.1 (95%CI 0.4 to 3.8), 
p<0.05c
-0.4 (95%CI -2.0 to 1.3), 
p=0.66
a All parameters are presented as mean (95% confidence intervals; p value)
b Log-tranformed visual analog scale (VAS) (scores in mm+2). Scores are given in units (U)
c Statistically significant p values (α=0.05)
Pharmacokinetic results
Pharmacokinetic parameters are summarized in Table 3 and 4. The data of  one 
person were excluded because no blood samples were taken after the first THC dose of  
0.75mg, and only a limited amount of  blood was taken after the second dose. Although 
one subject was non-Caucasian, his pharmacokinetic data were within the range of  the 
others. The median Tmax was between1 and2h and was not dose-dependent. For the 
0.75mg dose, the median Tmax was reached 1.5 h (range 0.75-3.08) after the first dose 
and 2 h (range 0.5-2.07) after the second dose; for the 1.5-mg dose, the median Tmax was 
reached 1 h (range 0.5-2.2) after the first dose and 2 h (range 0.5-3.02) after the second 
dose (Table 3). Plasma concentrations of  THC and 11-OH-THC increased linearly 
with increasing dose, but there was considerable inter-individual variation in plasma 
concentrations and hence in pharmacokinetic parameters (Figure 2). For THC, Cmax 
and AUC CV% ranged from 90 to 140%, and for 11-OH-THC from 38% to 62%. The 
elimination phase of  THC was faster than that of  11-OH-THC. The geometric mean 
ratio of  the THC AUC0-24 h versus the 11-OH-THC AUC0-24 h was 1.7 (95% CI 1.1 to 
2.9) and 1.9 (95% CI 1.0 to 3.6) for the 0.75mg and 1.5mg doses, respectively. Individual 
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THC and 11-OH-THC AUCs are presented in Figure 3. Two participants had a 
high THC exposure after the 0.75mg dose. Their AUC0-24 h was 8.0 and 8.4 ng h/mL 
compared with a value ranging between 0.9 and 2.7 ng h/mL in the other participants. 
Three participants had a high exposure after the 1.5mg dose. Their AUC0-24 h was 13, 19, 
and 20 ng h/mL compared with a value ranging between 1.2 and 4.1 ng h/mL in the 
other participants. One participant had a greater increase in THC AUC after the 1.5mg 
dose than the other participants; the AUC GMR for this subject was 7 compared with 
1.7-2.5 (range) for the other participants. The same was seen for 11-OH-THC, but less 
pronounced (Figure 3).
FIGURE 2
The mean concentration time profiles of THC and 11-OH-THC for both the 0.75 and 1.5mg 
doses over 24 h
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FIGURE 3
Individual pharmacokinetic parameter graphs
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TABLE 4
Geometric mean ratios of THC and 11-OH-THC
Parameters THC 11-OH-THC
AUC0-24 h (ng h/mL) 2.40 (1.83 to 3.16) 2.25 (1.82 to 2.77)
CL/F (L/h) 0.83 (0.63 to 1.10) 0.89 (0.72 to 1.10)
t1/2 (h) 1.00 (0.72 to 1.39) 0.88 (0.58 to 1.34)
Geometric mean ratio 1.5 versus 0.75mg over one dosing interval (90% confidence interval)
Discussion
Safety and tolerability
Older people with dementia and physical co-morbidity could greatly benefit from the 
therapeutic application of  cannabinoids. Recent studies have demonstrated that low doses 
of  THC are effective in protecting the brain from neuroinflammation-induced cognitive 
damage.30-32 Although THC-based drugs have recently been approved for clinical use, 
there are only few data on their safety in older individuals with dementia. Our data 
demonstrate that THC doses of  0.75 and 1.5mg twice daily are safe and well tolerated 
by older individuals with dementia. Only six of  the 98 reported AEs were related to THC 
treatment. All AEs were mild and resolved spontaneously without any intervention. Our 
findings are in line with previously published studies showing that THC doses up to 5mg/
day are safe to use in older individuals with dementia.15-17 It is important to note that the 
safety data presented in this study are based upon short-term use of  THC in older subject 
with dementia. Further studies are warranted to evaluate the long-term use of  THC in 
this population.
Pharmacodynamics
Overall, THC had fewer pharmacodynamic effects, including AEs, than we had 
expected for frail older individuals with dementia, based on the effects reported by 
Klumpers et al.11 in young adults (mean age 21 years). We found no statistically significant 
changes in participants’ feeling high, external perception, body sway with the eyes open, 
and diastolic blood pressure after THC. The changes in internal perception, body sway 
with eyes closed, systolic blood pressure, and heart rate after THC were not considered 
clinically relevant, as they were small and were not associated with AEs. The current 
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findings are consistent with our previous findings from a phase 1 study of  Namisol® in 
healthy older individuals without dementia (n=11, mean age 72 years).22
Pharmacokinetics
On the basis of  the AUC and Cmax values, THC has linear pharmacokinetics 
in elderly individuals with dementia, showing a doubling of  the AUC and Cmax with 
doubling dose from 0.75 to 1.5mg. However, there was considerable inter-individual 
variation in plasma concentrations of  THC and 11-OH-THC, which is in line with our 
data from a phase I study involving healthy older individuals,22 and with the results of  
studies involving individuals of  different ages.11, 19, 33 The median Tmax  was reached 1-2 h 
after THC dosing, as has been previously reported for healthy older individuals without 
dementia.22 In contrast, Klumpers et al.11 reported a shorter Tmax between 39 and 56 
min in young adults after Namisol® administration. The AUC0-6 h for older persons with 
dementia was two times higher than would be expected on the basis of  data for young 
adults administered Namisol® (individual concentrations were retrieved and AUC0-6 h 
was calculated).11 A possible explanation for the discrepancies in Tmax and AUC0-6h is 
that, in the current study, THC was taken in nonfasting state, whereas Klumpers et al. 
administered THC to fasting young adults. Stott et al., in their investigation of  the effect 
of  food on the absorption and bioavailability of  cannabinoids, found that the Tmax for 
THC was reached about 2-2.5 h later in the fed state than in the fasting state: the mean 
AUC and Cmax for 11-OH-THC were onefold and threefold higher, respectively, in the 
fed state than in the fasting state.34 Age-related factors, such as delayed gastric emptying 
time, decreased splanchnic blood flow, decreased gastrointestinal motility, and decreased 
absorption surface, could also affect the absorption and bioavailability of  THC in older 
individuals. It was not possible to compare our data with data from other pharmacokinetic 
studies involving older individuals with dementia because we did not find any relevant 
studies that reported data separately for this group. The relatively high THC exposure in 
two participants seems to have been due to a diminished metabolism of  THC to 11-OH-
THC, as in both participants the 11-OH-THC/THC ratio of  the AUC0-24 h was less 
than 1 for both doses, whereas it was almost two in the other participants. However, the 
sum of  11-OH-THC plus THC AUC0-24 h was higher in these two participants than in 
the other participants, but this higher THC exposure was not associated with AEs.
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Strengths and limitations
The main strengths of  the current study were, first, its design.  In this randomized, 
double-blind, placebo-controlled, repeated crossover study, study staff and participants 
were masked to assignment and participants served as their own control. This design 
strengthened the validity of  the safety and pharmacodynamic data. Second, our study 
is the first to evaluate the pharmacokinetics and pharmacodynamics of  THC in older 
individuals with dementia, a frail subgroup of  older persons.
Therefore, this study can be added to the limited literature available on this subject. 
The most notable limitation is that we probably used a very low THC dose-escalation 
regimen, 0.75 to 1.5mg, as only six of  the 98 reported AEs were related to THC treatment 
and the pharmacodynamic effects were in general smaller than we had expected for this 
subgroup of  older persons. A future dose-escalation study is required to determine the 
maximum tolerable dosage. This will help to maximize effectiveness while keeping side 
effects acceptable.
Conclusion
Our findings suggest that low THC doses are safe and well tolerated by frail 
older persons with dementia. Oral THC was rapidly absorbed, showing dose-linear 
pharmacokinetics with maximum plasma concentrations being reached between 1 and 
2 h after dosing, although there was considerable inter-individual variability. Overall, 
THC showed smaller pharmacodynamic effects in frail older individuals than expected 
on the basis of  data for young healthy adults. These reassuring data warrant further 
pharmacodynamic and efficacy studies with higher THC doses in older patients with 
dementia.
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Through the window of my eyes, I can see the rainy day
Sitting in the chair of my cool room, looking for a way to be the one who I am
It’s useless to cry for the things I once have known, 
thinking it will come back and reach my home
Cuby and the Blizzards  -  Window Of My Eyes
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Abstract
Background: Oral tetrahydrocannabinol (THC) is currently studied for its 
possible efficacy in the treatment of  dementia-related neuropsychiatric symptoms 
(NPS), but might lead to increased risk of  falling. In this trial we evaluated the 
effects of  THC on gait and balance in dementia patients.
Design: A randomized, double-blind, placebo-controlled, crossover study.
Setting: Two hospital sites in the Netherlands, September 2011 to December 
2013.
Participants: Eighteen community-dwelling patients with dementia and NPS (15 
male; mean age 77 years).
Intervention: Participants received 1.5mg oral THC twice daily and placebo, in 
random order, for three days, separated by 4-days washout.
Measurements: Balance and gait were assessed using SwayStarTM and 
GAITRiteTM  within two hours after administration of  THC or placebo in two 
consecutive intervention periods, under the following conditions: standing with 
eyes open (EO), standing with eyes closed (EC), preferred speed walking with and 
without performing a cognitive dual task. Adverse events (AEs) were carefully 
assessed.
Results: THC significantly increased sway during standing EC [roll angle 
0.32(0.6)deg, p=0.05; pitch angle 1.04(1.5)deg, p=0.009; pitch velocity 1.96(3.3)
deg/s, p=0.02], but not during standing EO. During preferred speed walking, 
THC increased stride length [4.3(5.4)cm, p=0.005] and related trunk sway in both 
directions [pitch angle 1.18(1.6)deg, p=0.005]. No effects were observed during 
dual task walking. No differences in the number and type of  AEs were found and 
no falls occurred after administration of  THC.
Conclusion: This preliminary study showed that 1.5mg oral THC has a benign 
adverse event profile regarding mobility and was well tolerated by community-
dwelling dementia patients. Potential future studies on higher THC doses should 
further evaluate the effects on mobility in this vulnerable population.
Key words: mobility; fall risk; tetrahydrocannabinol; dementia; safety.
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Introduction
Older patients, especially those with dementia, are susceptible to adverse drug effects, 
due to age-related physiological changes, cognitive disturbances, frequent co-morbidities 
and concurrent medication use.1 When new drug interventions are proposed for this 
specific group, comprehensive safety evaluation is highly important in order to assess 
the benefit-to-harm ratio. This is particularly true for the introduction of  psychotropic 
interventions, as these can lead to deterioration in cognitive and physical functioning, 
including an increased risk of  falling. Medical cannabinoids are currently explored as 
a potential pharmacological treatment of  dementia-related neuropsychiatric symptoms 
(NPS)2 and preliminary studies suggest that low dose oral tetrahydrocannabinol (THC) 
reduces agitation and nighttime disturbances in patients with severe Alzheimer’s disease.3-6 
Moreover, THC and other cannabinoids are more frequently administered to frail, 
older patients because of  further liberalization of  medicinal cannabis prescription for 
other conditions (e.g. pain and cancer related anorexia).7 THC is the main psychoactive 
constituent of  the Cannabis Sativa L plant, and binds to cannabinoid receptors localized 
throughout the central nervous system,8, 9 including areas involved in movement control 
such as the basal ganglia and cerebellum.10 Furthermore, THC might lead to an increased 
risk of  falling by inducing adverse effects such as dizziness, sedation and changes in blood 
pressure, including orthostatic hypotension.11-13 It is particularly important to assess 
effects on mobility in persons with dementia, as cognitive impairment is an independent 
risk factor for falling.14 In the present article, we report on the first exploratory safety 
evaluation of  THC with respect to balance and gait in patients with dementia, as part 
of  a randomized controlled trial (RCT) studying low dose oral THC in the treatment of  
dementia-related NPS. 
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Methods
Study design
This study was part of  a phase II, repeated crossover, double-blind RCT of  12 weeks 
on the efficacy and safety of  two different doses (0.75 and 1.5mg twice daily) of  oral THC 
in the treatment of  dementia related NPS (registered at clinicaltrials.gov NCT01302340; 
accepted for publication by American Journal of  Geriatric Psychiatry). Approval was provided 
by the certified ethics committee of  Radboud university medical center (Radboudumc), 
The Netherlands. The study assessments took place between September 2011 and 
December 2013, at the Radboudumc Alzheimer Centre (Nijmegen, The Netherlands) 
and the Vincent van Gogh Institute for Psychiatry (Venray, The Netherlands). Written 
informed consent was provided at screening by the closest proxy and patient; the latter 
only in case the patient was judged capable to consent. We evaluated gait and balance 
effects of  the highest dose of  1.5mg, as these were expected to be most pronounced. The 
mobility assessments were conducted during two one-week treatment periods, including 
1.5mg THC or placebo for three consecutive days, separated by a four-day-washout 
period. 
Study medication and randomization
Participants received a tablet containing 1.5mg THC (Namisol®, Echo Pharmaceuticals 
B.V., Weesp, the Netherlands) or matched placebo twice daily at 10 a.m. and 4 p.m. 
Randomization of  the order of  administration of  study medication (THC or placebo 
first) was conducted by the pharmacy of  Radboudumc, using a computer generated 
randomization list. The allocation sequence was strictly concealed from participants, 
caregivers and investigators and was not made available until study completion and 
database lock.
Study population
Eligibility criteria for the main RCT included diagnosis of  possible or probably dementia 
type Alzheimer, vascular or mixed according to the NINCDS-ADRA15 or NINCDS-
AIREN16 criteria, and clinically relevant and stable NPS (minimal Neuropsychiatric 
Inventory score ≥ 10). Exclusion criteria were current major psychiatric disorder, any 
severe or instable concomitant illness, frequent falling due to orthostatic hypotension, a 
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history of  current alcohol or drug abuse and use of  tricyclic antidepressants or opioids. 
Additionally, patients using drugs from a predesigned list of  inhibitors of  the cytochrome 
P450 enzymes (CYP): CYP2C9, CYP2C19 and CYP3A4 were excluded, as THC is 
metabolized in the liver through these enzymes. Patients were included in the current 
study on mobility when they were able to walk at least ten meters and understood simple 
instructions. 
Mobility assessments
Quantitative balance and gait assessments were done at baseline, to familiarize 
the patients with the procedure and equipment, and twice during the crossover study: 
once after administration of  1.5mg THC and once after placebo. The assessments 
were carried out on the first or second treatment day within two hours after study drug 
administration as maximum blood concentrations were expected to occur within this 
time frame, according to pharmacokinetic measurements carried out in young, healthy 
volunteers (Tmax of  5mg oral THC: 56.0min).
17 
Static and dynamic balance
Objective, quantitative assessments of  balance during standing (static) and gait 
(dynamic) were done using the SwayStarTM system (BESTec-etp Freiburg GmbH, 
Freiburg, Germany). This accelerometer consists of  a wireless device attached to the 
trunk at the level of  the lumbar spine. The device contains two transducers to register 
angular velocities and displacements of  the trunk in a highly sensitive manner; one in the 
anterioposterior (pitch) direction and one in the mediolateral (roll) direction. It has shown 
to be a valid method for the prediction of  falls.18-20 For analysis, the following variables 
were selected: pitch angle, pitch velocity, roll angle and roll velocity. Peak-to-peak ranges 
for all variables were used, as extreme values might be the result of  exposure to THC. 
Gait
Quantitative gait assessments were done using the GAITRiteTM system (CIR Systems 
Inc, Sparta, United States); a 6.1-meter long electronic walkway containing multiple 
pressure sensors, connected to a computer. The GAITRiteTM system has been shown 
to be a feasible and reliable instrument to obtain various temporal (timing) and spatial 
(distance) gait variables in older persons and patients with dementia.21-26 The following 
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gait variables were selected for analysis as these have been shown to be best associated 
with an increased risk of  falling in elderly or dementia patients: velocity, stride length, 
double support time, and variability in stride length and double support time.25, 27-29 
Furthermore, base of  support was selected as a measure of  gait width as this is expected 
to increase after administration of  THC.30 
Mobility tasks
Each assessment consisted of  two stance tasks and two gait tasks. During stance 
tasks, static balance was assessed while patients were standing on a normal surface with 
their feet at comfortable distance, for the duration of  30 seconds with eyes open (EO), 
followed by 30 seconds with eyes closed (EC). During walking tasks, gait and dynamic 
balance were measured simultaneously. Patients walked at their own preferred speed; 
twice without a dual task and twice while performing an arithmetic, cognitive dual task, 
adjusted to cognitive capacity (mild dementia: continuously naming the months of  the 
year backwards starting from December; moderate to severe dementia: continuously 
counting backwards from 20). In order to achieve steady-state walking, patients started 
walking two meters before the walkway and were instructed to keep walking until two 
meters behind the walkway. Use of  a walking aid was allowed during the measurements 
when necessary, provided that it was used during both assessments. Walking aid prints 
were manually erased from the raw GAITRiteTM data files to derive gait variables. 
Assessment of adverse events
Adverse events (AEs) were solicited from patients and their caregivers at all study visits 
of  the main RCT, using open questions and clinical observations. All reported AEs were 
recorded and coded following the classification of  Medical Dictionary for Regulatory 
Activities, whether or not they were deemed to be related to study treatment. 
Data analysis
For this study, no sample size calculation was done, as these mobility assessments were 
part of  safety assessments of  a phase II trial on the efficacy of  THC on dementia-related 
NPS (n=22). Baseline characteristics were summarized as means and standard deviations 
and as frequencies and percentages for categorical data. Gait tasks were performed twice 
and results were averaged per task for data analysis. Variability of  stride length and double 
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support time was expressed as coefficient of  variation (CoV): standard deviation/mean 
x 100%. Outlier evaluation by scatter plots resulted in several unrealistic extreme values 
in the GAITRiteTM data, caused by technical errors or errors in the footfall registration 
process. These outliers were replaced by the means and standard deviations of  individual 
footfalls of  the same subject during the same task that were registered correctly. Values 
per intervention periods were expressed as means and standard deviations. Differences 
between THC and placebo were compared using paired t-tests. Treatment differences 
were also expressed as relative differences (with 95% confidence intervals [CI]), except 
for the CoVs of  stride length and double support time. No correction for multiple 
comparisons was performed in this exploratory study on safety, as this correction reduces 
false positive results (Type II error), but may also lead to false-negative results (Type I 
error). Occurrence of  AEs was compared between THC and placebo by non-linear mixed 
model analysis, assuming Poisson distribution. Additionally, AEs which were expected 
to influence mobility (fall incidents, dizziness, somnolence and balance disorders) were 
separately reported. 
Results
Patient characteristics
Of  the 22 patients included in the RCT, four patients were excluded for mobility 
assessments due to inability to understand instructions (n=2), or due to missing data 
because measurements could not be performed due to logistical reasons (n=2) (Figure). 
Hence, 18 patients were included in the mobility assessments. Baseline characteristics 
of  these patients are presented in Table 1. For static balance tasks, complete data were 
available for all patients, whereas dynamic balance assessments were missing in one 
patient and gait assessments in another, due to technical failure of  the devices. 
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FIGURE 
CONSORT Flow Diagram
TABLE 1
Baseline characteristics
All 
(n=18)
Men, n (%) 15 (83) 
Age (yr), mean (SD) 77.0 (6)
Ethnicity, n (%)
Caucasian
Asian
17 (94)
1 (6)
Type of dementia, n (%)
Alzheimer
Vascular
Mixed
15 (83)
1 (6)
2 (11)
MMSE score, mean (SD)a 19.1 (6.0)
Use of cholinesterase inhibitors, n (%) 11 (61)
Use of psychotropic medication, n (%) 5 (28)
Baseline gait velocity (cm/s), mean (SD)b 91.8 (20.4)
Abbreviations: MMSE, Mini Mental State Examination.
a Mean MMSE score (range 0 to 30) based on 17 patients.
b Mean gait velocity based on 14 patients.
Excluded, n=4
• Inability to understand instructions (n=2)
• Logistical reasons (n=2)
Assessed for eligibilty
N=22
Randomized
N=18
Allocated to THC first, followed by placebo, n=9
Allocated to placebo first, followed by THC, n=9
Discontinued intervention, n=0
Included in static balance analysis (n=18)
Included in dynamic balance analysis (n=17), 
Reasons for exclusion: technical issues 
Included in gait analysis (n=17),
Reasons for exclusion (n=1): technical issues
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Static balance 
Results on static balance during standing EO and EC are presented in Table 2. No 
differences on body sway were found between the interventions, when patients were 
standing with their eyes open. In the eyes closed condition, roll angle, pitch angle and 
pitch velocity were significantly higher after administration of  THC, compared to 
placebo [0.32 (SD 0.6) degrees (deg), p=0.05; 1.04 (1.5) deg, p=0.009; and 1.96 (3.3) 
degrees per second (deg/s), p=0.02, respectively]. THC resulted in an increase of  39.1 to 
49.2% in angular displacement and angular velocity.
Dynamic balance
Pitch angular displacement increased significantly after THC administration during 
preferred speed walking [1.18 (1.6) deg, p=0.005]. Additionally, the relative differences of  
all sway variables were significantly higher in the THC group compared to placebo (12.0 
to 19.4%). No effects (absolute nor relative) of  THC on dynamic balance were observed 
during walking while performing a cognitive dual task.
Gait
THC resulted in a significantly increase in stride length during walking at preferred 
speed [4.3 (5.4) cm, p=0.005] and a trend for increase in gait velocity (3.84 [7.8], p=0.06) 
(Table 3). Gait velocity during dual task walking after administration of  placebo was 
significantly lower than gait velocity in preferred walking speed mode (77.0 cm/s vs. 89.6 
cm/s, respectively; p=0.001). No effects of  THC on gait were observed during walking 
while performing a cognitive dual task. 
Adverse events
During the 12-week crossover RCT 91 AEs occurred in the THC group (0.75mg THC 
and 1.5mg THC twice daily), compared to 93 events in the placebo group (incidence rate 
ratio 0.96, 95%CI 0.7 to 1.3, p=0.77) (n=22 subjects, independent of  participation in the 
mobility assessments). For these 22 subjects, mobility-related AEs were similarly prevalent 
in THC group, compared to placebo; 10 versus 9 events of  dizziness, 2 versus 2 events of  
somnolence and 1 versus 0 events of  balance disorders, respectively. More falls occurred 
during placebo than during THC treatment (4 versus 2 incidents) and all falls in the THC 
group occurred after administration of  the lower dose (0.75mg THC twice daily). 
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Discussion
The current study is the first to examine the effects of  oral THC on mobility in 
patients with dementia. Our findings showed an increased body sway after administration 
of  1.5mg THC when patients were standing with eyes closed, but not while standing with 
eyes open. Furthermore, THC resulted in a higher stride length, a trend towards increase 
in gait velocity and consequent increase in dynamic sway during preferred speed walking. 
No effects of  THC were observed during dual task walking.
Effects on static balance
We compared our results on static balance with the results of  a previous RCT studying 
oral THC in healthy older volunteers (n=11, mean age 71.1 [1.4] years).31 In this latter 
study, body sway during standing with eyes open and eyes closed was not affected after 
single administration of  3 to 6.5mg THC, compared to placebo. In comparison to these 
healthy volunteers, the current patient group with dementia shows an impaired static 
sway in the placebo condition (data of  comparison not shown), which is in line with 
previous literature.32 
This impaired sway, a priori, suggests that caution is required when administering 
higher dosages of  oral THC to these vulnerable patients, as THC-related effects on sway 
are expected to occur in a dose-dependent manner.17, 33 Additionally, our data showed 
that dementia patients were able to compensate for the effects of  THC on static balance, 
which could not be maintained in the absence of  visual feedback (eyes closed condition). 
This effect was expected, as the amount of  sensory information is important to maintain 
balance, especially for older persons.34 Nonetheless, these data suggest that dosages 
should be carefully and gradually increased in future studies. 
Effects on dynamic balance and gait
THC resulted in a higher stride length, a trend towards increase in gait velocity and 
increase in dynamic sway during preferred speed walking. These effects might be due 
to THC-mediated cognitive disinhibition or increased alertness.35 On the contrary, dual 
task walking resulted in a decreased gait velocity, which was observed in the THC group 
as well as the placebo group. This effect is probably a purposeful adaptation to reduce 
the risks of  falls when performing a more complex task.36 The changes in gait velocity 
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observed here are probably not clinically meaningful, as only an absolute change in 
velocity of  10 cm/s or more is previously determined to be clinically meaningful in older 
adults,37-39 while a relative decrease of  45% or an increase of  60% are judged relevant 
in frail, older inpatients.40 Unfortunately, estimates of  meaningful change in stride length 
and postural sway are lacking.41, 42 
Adverse events
In this study, no difference in the occurrence of  AEs was observed between 1.5mg 
THC twice daily compared to placebo. The AEs were collected during the entire study 
duration of  12 weeks, and concerned all subjects in the main RCT, including the more 
vulnerable subjects which were excluded from the mobility assessments. Furthermore, 
mobility-related AEs (e.g. dizziness, somnolence and balance disorders) did not differ 
between the interventions. The effects observed in the quantitative balance and gait 
assessments were subtle and did not result in the occurrence of  AEs. As such, these results 
suggest that low dose THC administered for short duration was well tolerated by these 
older dementia patients. 
Methodological considerations
This study is the first to investigate the effects of  THC on mobility in patients with 
dementia using quantitative measures of  mobility. This is especially relevant as currently 
used drugs for NPS, such as antidepressants, benzodiazepines and antipsychotics, increase 
the risk of  falling and are associated with impairments in postural control, especially in 
older persons,43 limiting the feasibility of  these interventions. Although most studies focus 
on the effects on postural balance,17, 31, 33 effects on gait seem even more important, as 
most falls occur during walking while performing normal daily activities.44 Therefore, 
the assessments performed in this study are more closely related to physical activities 
in daily life. Inevitable, this study also has some limitations. We assessed the effects of  
THC on mobility as part of  an efficacy trial with a predefined design. The analyses 
therefore had an exploratory and descriptive character and should be interpreted as 
such. The data  did not allow for subgroup analyses on dementia severity or concurrent 
psychotropic medication use. Furthermore, our study sample consisted of  relatively fit 
dementia patients, based on their age [mean 77 (SD 6) years], cognitive status [MMSE 
19.1 (6.0) points] and baseline gait velocity [91 (20.4) cm/s]. To compare, the average gait 
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velocity of  healthy persons of  similar age [80.5 (3.7) years] is slightly higher: 106 (19.3) 
cm/s.45 We excluded patients with important co-morbidity such as those with severe 
cardiac failure and increased fall risk due to orthostatic hypotension. In comparison to 
our sample, nursing home residents with moderate to severe dementia show significantly 
lower mean gait velocity [63 (25) cm/s], stride length [76 (26) cm] and a higher mean 
stride length variability [9.3 (5) %].25 Therefore, our data cannot simply be generalized 
to patients with more severe cognitive disturbances or those with more co-morbidity. It 
should be emphasized that these latter patient groups are more vulnerable and probably 
more suspected for THC-mediated AEs on mobility. 
Clinical implications and future research
These first results suggest that low dose oral THC is well tolerated by community-
dwelling dementia patients concerning mobility and risk of  falling. This dose did not 
show benefit in the treatment of  dementia-related NPS compared to placebo. The data 
presented here support the conduction of  future higher dosing studies, provided that 
the dose is gradually increased. Additionally, these future studies should also address the 
effects of  THC on mobility in more severely demented patients and patients with more 
co-morbidities that might affect balance and gait. 
Conclusion
This preliminary study showed that 1.5mg oral THC has a benign adverse event 
profile regarding balance and gait and was well tolerated by community-dwelling 
dementia patients. Future studies are needed to evaluate the effect of  higher THC doses 
on balance and gait in this vulnerable population.
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I saw a soldier man
He locked his eyes like they were red
Oh but it’s hard they can’t resist
You may risk it all
You’d risk it all for the memory
But it’s living under your skin
Love’s the key to the things that we see
And don’t mind chasing
Leave the light on in the yard for me
War on drugs - Lost In The Dream
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SUMMARY
The studies described in this thesis have been conducted focused on three subjects:
1. To evaluate the status of  current literature on medical cannabinoids in older 
patients.
2. To evaluate the efficacy of  oral tetrahydrocannabinol (THC) in the treatment of  
dementia-related neuropsychiatric symptoms (NPS).
3. To evaluate the safety or oral THC in older persons and patients with dementia.
Medical cannabinoids in older patients
In chapter 2, we reviewed the published reports on intervention studies with 
medical cannabinoids in order to summarize evidence on the indications, efficacy 
and safety in older participants. We developed a systematic literature search, selecting 
controlled intervention trials including solely participants aged 65 years and older or 
reporting separate data on an older subgroup. Five studies could be included that met 
our inclusion criteria, while 105 papers reported the inclusion of  older participants, 
but did not provide data on this subgroup. Due to the high clinical and methodological 
diversity of  the included studies, meta-analysis was not feasible. The studies showed no 
efficacy of  medical cannabinoids on dyskinesia, breathlessness or chemotherapy induced 
nausea and vomiting, while two small, preliminary studies showed that oral THC might 
be useful in the treatment of  anorexia and behavioral disturbances in dementia patients. 
Adverse events were more common during cannabinoid treatment compared to control 
treatments and most commonly included sedation-like effects. Two studies reported 
cardiac arrhythmia and seizure, although a relationship with the study medication could 
not reliably be assessed. 
This chapter shows that there is a lack of  evidence concerning the use of  
cannabinoids specifically in older patients, resulting in scarcity of  data to guide 
treatment decisions. Methodologically sound trials are therefore needed, as the 
potential symptomatic benefits of  cannabinoids might be attractive for older patients 
with specific complaints and limited lifespan expectancy. 
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Efficacy of THC on reducing behavioral disturbances in dementia
In chapter 3 and 4 the efficacy of  oral THC was examined in two randomized, 
controlled trials. In the first trial (THC crossover study, described in chapter 3) 22 
patients (15 men, mean age 76.4 [5.3] years) with dementia and clinically relevant NPS 
were randomly assigned to receive oral THC and placebo during six treatment blocks 
of  two weeks each. In this repeated crossover study, dosages of  0.75mg and 1.5mg THC 
twice daily were compared to placebo. THC did not reduce Neuropsychiatric Inventory 
(NPI) scores, compared to placebo (low dose THC vs. placebo, 1.8, 97.5%CI -2.1 to 5.8; 
high dose THC vs. placebo, -2.8, 97.5%CI-7.4 to 1.8). Additionally, we found no effect 
on agitated behavior (NPI agitation subscale, -0.3, 95%CI -0.9 to 0.2; Cohen-Mansfield 
Agitation Inventory, -1.5, 95%CI -4.0 to 1.0) and caregiver burden (Zarit Burden 
Inventory, 0.3, 95%CI -0.9 to 1.5). THC was well tolerated; the incidence of  adverse 
events was equal between treatment groups. Four serious adverse events occurred, of  
which none were related to study medication.
In the addendum of  chapter 3 we described the results of  an open label extension 
phase, which followed the crossover trial. Twelve patients (55%) participated in this 
optional study, although only five (42%) completed the six month treatment period. 
Study discontinuation was not related to the occurrence of  adverse events. Results 
indicated that long term treatment with low dose THC was well tolerated and did not 
affect cognition, mobility or weight. Additionally, no effects on behavioral disturbances 
or caregiver burden were observed. These results must be interpreted with caution, as the 
attrition rate in this phase was high (58.3%).
Chapter 4 describes a multicenter RCT aiming to evaluate the efficacy of  4.5mg 
THC daily in the treatment of  behavioral disturbances and pain in patients with mild to 
severe dementia (THC parallel design study). Fifty patients with dementia and clinically 
significant NPS with at least agitation, aggression or aberrant motor behavior were 
included and randomly assigned to 1.5mg THC (n=24) or placebo tablets (n=26) three 
times daily for a period of  three weeks. Effectiveness on NPS (using NPI) was evaluated 
after 14 and 21 days of  treatment.THC did not significantly reduce NPI scores (THC 
versus placebo, + 3.2, 95%CI -3.6 to10.0), compared to placebo. Additionally no effects 
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on agitated behavior, daily functioning or quality of  life were observed. In the subgroup 
of  patients also suffering from pain (n=23), no treatment differences were seen concerning 
pain-related behavior (using Pain Assessment Checklist for Seniors with Limited Ability 
to Communicate, -0.4, 95%CI -3.8 to 3.0) and pain intensity (using Verbal Rating Scale, 
-0.03, 95%CI -1.0 to 0.9) (Appendix chapter 4). The number of  patients experiencing 
one or more adverse events was equally divided among treatment groups and there were 
no study medication related serious adverse events. 
We did not find benefit of  doses up to 4.5mg oral THC daily on behavioral 
disturbances in dementia, compared to placebo. Nor were any differences observed 
concerning the secondary efficacy outcome measures, such as agitation, caregiver 
burden or quality of  life in both studies. 
Nonetheless, THC was well tolerated by these vulnerable patients. The observation 
that there was no biological signal of  adverse events suggests that the dosages were 
too low, as a psychoactive drug is rarely effective without showing any side effects. 
Therefore, the results warrant future research using higher dosages of  THC in the 
treatment of  dementia-related NPS.
In depth safety evaluation of THC in older persons and patients with 
dementia
There is a great concern about the safety of  medical cannabinoids in older persons, 
due to the lack of  evidence on this specific group, while cannabinoid-related adverse 
effects, such as sedation, dizziness and psychoactive effects might be especially harmful 
in older patients. Data from young subjects cannot simply be extrapolated to an older, 
more vulnerable population. Therefore, we conducted a phase I, double-blind RCT with 
a crossover design to evaluate the safety and pharmacokinetics of  single oral doses of  3, 
5, 6.5mg THC and placebo in 12 healthy, older subjects (mean age 72±5 years), of  which 
the results are reported in chapter 5. Data of  11 subjects were included in the analysis. 
THC appeared safe and well tolerated. No severe adverse events occurred. Adverse 
events were more common after 6.5mg THC compared to 3mg (p=0.048), 5mg (p=0.034) 
and placebo (p=0.013). Drowsiness (27%) and dry mouth (11%) were most frequently 
reported. Attention and body sway were not affected. Overall, the pharmacodynamic 
effects of  THC were smaller than those reported in young adults. Plasma concentrations 
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of  THC and its metabolites 11-OH-THC and COOH-THC increased dose-dependent, 
although a substantial inter-individual variation was observed.
While conducting the THC crossover study, described in chapter 3, we also collected 
several blood samples for pharmacokinetic analysis from 10 participating patients with 
dementia. The results are described in chapter 6. Based on the AUC and maximum 
concentration (Cmax) values, THC has linear pharmacokinetics in older individuals with 
dementia, showing a doubling of  AUC and Cmax after administration of  1.5mg oral THC 
compared to 0.75mg. The Cmax of  THC after first administration of  0.75mg was 0.41 
(0.18-0.90) ng/mL and for 1.5mg 1.01 (0.53-1.92) ng/mL. Median time to reach this 
maximum concentration (Tmax) was 1 to 2 hours, which is longer than the reported Tmax 
of  oral THC in young healthy volunteers. In line with the results from the phase I study 
with healthy, older subjects, described in chapter 5, a wide inter-individual variability 
in pharmacokinetics of  THC and its active metabolite 11-OH-THC was observed 
(Coefficient of  variation up to 140%). 
In chapter 7 we assessed the effects of  oral THC on mobility in 18 patients with 
dementia, as part of  the safety protocol of  the THC crossover study (chapter 3). 
Qualitative assessments of  balance and gait were conducted within two hours after 
administration of  1.5mg oral THC and placebo, using SwayStarTM for assessment of  
postural and dynamic balance and GAITRiteTM for assessment of  gait during preferred 
speed walking with and without performing a cognitive dual task. THC significantly 
increased sway during standing with eyes closed [roll angle 0.32(0.6)deg, p=0.05; pitch 
angle 1.04(1.5)deg, p=0.009; pitch velocity 1.96(3.3)deg/s, p=0.02], but not during 
standing with eyes open. During preferred speed walking, THC increased stride length 
[4.3(5.4)cm, p=0.005] and related trunk sway in both directions [pitch angle 1.18(1.6)
deg, p=0.005]. Mobility was not affected during dual task walking. No differences in the 
number and type of  adverse events were found and no falls occurred after administration 
of  THC.
Based on these studies, dosages up to 4.5mg THC daily appear to be well tolerated 
by older, dementia patients, concerning the occurrence of  adverse events, vital signs 
and effects on mobility. Additionally, dosages up to 6.5mg THC are well tolerated by 
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healthy, older volunteers and static body sway was not affected. Nonetheless, our data 
also suggest that caution is needed with increasing dose, as the occurrence of  adverse 
events and effects on mobility are expected to occur in a dose-dependent manner. 
Additionally, our data show linear pharmacokinetics of  THC, although a high inter-
individual variation exists. As such, future higher dosing studies can be performed, 
provided that the dose is gradually increased and safety is closely monitored.
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Samenvatting
Probleemgedrag, zoals agressie, onrust en slaapstoornissen, komt veel voor bij 
patiënten met een dementie en vormt een grote belasting voor zowel de patiënt als zijn 
of  haar mantelzorgers. Helaas is de behandeling van probleemgedrag vaak erg moeilijk; 
de huidige beschikbare medicatie geeft veel en soms ernstige bijwerkingen, zoals stijfheid, 
en een verhoogd risico op vallen en beroerte. Daarom is het belangrijk om op zoek te 
gaan naar nieuwe behandelmogelijkheden. Een van die opties zou medicinale cannabis 
kunnen zijn; eerdere, kleine onderzoeken hebben aangetoond dat een lage dosering 
tetrahydrocannabinol (THC), de werkzame stof  uit de cannabisplant, prikkelbaarheid 
en onrust bij patiënten met een ernstige Alzheimer dementie verminderde. Er is een 
steeds toenemende interesse voor het gebruik van medicinale cannabis, waaronder THC, 
bijvoorbeeld in de behandeling van chronische pijn, spierspasmen en misselijkheid. 
Probleemgedrag, en met name agitatie en bewegingsonrust, kunnen worden 
veroorzaakt door niet goed behandelde pijn. Omdat THC zowel een effect heeft op 
gedrag als pijnstillend werkt, zou dit mogelijk een goede behandeling kunnen zijn voor 
probleemgedrag bij dementie. 
In dit proefschrift worden meerdere onderzoeken beschreven, waarbij wij hebben 
geprobeerd een antwoord te krijgen op de volgende vragen:
1. Wat is er tot nu toe bekend in de wetenschappelijke literatuur over het gebruik 
van medicinale cannabis bij oudere patiënten? 
2. Is een lage dosering THC in tabletvorm werkzaam in de behandeling van 
probleemgedrag bij patiënten met dementie? 
3. Is een lage dosering THC in tabletvorm veilig te gebruiken bij ouderen en bij 
patiënten met dementie? Wat is het effect ervan op de aandacht, het geheugen 
en balans en lopen? 
In hoofdstuk 2 hebben wij de huidige wetenschappelijke literatuur op een 
gestructureerde manier onder de loep genomen en gezocht naar informatie over het 
gebruik van medicinale cannabis bij ouderen. Voor welke ziekten is het gebruik van 
medicinale cannabis bij ouderen onderzocht? Is er informatie over de werkzaamheid 
en veiligheid, specifiek bij deze ouderen patiënten? Uit onze zoekstrategie kwamen 
slechts vijf  artikelen naar voren die de werkzaamheid van medicinale cannabis hebben 
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onderzocht bij proefpersonen die allen ouder waren dan 65 jaar, terwijl er 105 artikelen 
waren die oudere proefpersonen lieten deelnemen aan hun onderzoek, maar deze groep 
niet nader hebben onderzocht. De vijf  onderzoeken bij oudere patiënten, onderzochten 
de werkzaamheid van medicinale cannabis voor verschillende aandoeningen: 
bewegingsstoornissen, kortademigheid, misselijkheid en braken na chemotherapie en 
probleemgedrag bij dementie. Alleen de onderzoeken bij patiënten met dementie konden 
aantonen dat medicinale cannabis een gunstige invloed had. Bijwerkingen kwamen 
echter wel vaker voor bij proefpersonen die werden behandeld met medicinale cannabis, 
ten opzichte van proefpersonen die placebo kregen (medicatie zonder werkzame stof). De 
meest voorkomende bijwerking was sufheid. 
Op basis van ons gestructureerde onderzoek van de beschikbare literatuur blijkt 
dat er nog onvoldoende bekend is over de werkzaamheid en veiligheid van medicinale 
cannabis bij ouderen. Ook de studies naar probleemgedrag bij dementie waren te 
klein om een betrouwbaar antwoord hierop te kunnen geven. Daarvoor zijn grotere 
en beter opgezette studies nodig.
Werkzaamheid van THC op probleemgedrag bij dementie
In hoofdstuk 3 en 4 beschrijven we twee onderzoeken die we hebben uitgevoerd 
naar de werkzaamheid van THC in tabletvorm op probleemgedrag bij dementie. Aan 
het eerste onderzoek, beschreven in hoofdstuk 3, namen 22 patiënten met dementie 
en probleemgedrag deel. Zij waren gemiddeld 76 jaar oud. Zij kregen gedurende 12 
weken een behandeling met THC in tabletvorm gedurende drie dagen, afgewisseld met 
placebotabletten, eveneens gedurende 3 dagen. Na elke behandelperiode kregen zij 4 
dagen geen onderzoeksmedicatie. In de eerste helft van het onderzoek kregen zij 0.75mg 
THC tweemaal per dag. Dit werd verhoogd naar 1.5mg THC tweemaal per dag in 
de tweede helft van het onderzoek. Patiënten wisten niet wanneer zij THC kregen of  
placebo; de behandeling was ‘geblindeerd’. Ook de onderzoekers waren hiervan niet op 
de hoogte, zodat het onderzoek zo objectief  mogelijk kon worden uitgevoerd. De ernst van 
het probleemgedrag werd gemeten middels een vragenlijst die werd doorgenomen met 
de mantelzorger: de Neuropsychiatric Inventory (NPI). Er werd geen verschil gevonden 
in scores op de NPI na behandeling met THC in vergelijking met placebo. Daarnaast 
had THC eveneens geen effect op geagiteerd gedrag of  ervaren mantelzorgbelasting. 
Eventuele bijwerkingen werden in deze studie zorgvuldig bijgehouden. THC werd 
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goed verdragen door deze kwetsbare patiënten; THC gaf  evenveel bijwerkingen dan de 
placebo tabletten. 
Wanneer het onderzoek werd afgerond konden patiënten kiezen voor een eventuele 
vervolgstudie. Hieraan hebben 12 patiënten deelgenomen. In deze vervolgstudie kregen 
alle deelnemers een behandeling met THC, gedurende zes maanden. Slechts vijf  van 
de twaalf  deelnemers hebben deze behandeling in zijn geheel afgerond. De overige 
zeven zijn tussentijds gestopt, omdat de behandeling onvoldoende effectief  was. De 
resultaten van dit vervolgonderzoek laten zien dat een langdurige behandeling met een 
lage dosering THC waarschijnlijk geen effect heeft op probleemgedrag, maar ook niet op 
het geheugen, het lopen of  het lichaamsgewicht. Deze resultaten geven slechts een eerste 
indruk, omdat een groot deel van de proefpersonen het onderzoek niet heeft afgerond. 
In het tweede onderzoek, dat wordt beschreven in hoofdstuk 4, wordt een hogere 
dosering THC onderzocht. In deze studie hebben wij gekeken naar de werkzaamheid van 
de behandeling op zowel probleemgedrag als pijn bij patiënten met een dementie. Vijftig 
patiënten hebben deelgenomen, waaronder zowel thuiswonende patiënten, als patiënten 
die in een verpleeghuis verblijven. Allen hadden zij last van probleemgedrag, met onder 
andere geagiteerd of  agressief  gedrag of  bewegingsonrust. De deelnemers werden, 
middels loting, verdeeld over twee behandelgroepen. De eerste groep werd behandeld 
met 4.5mg THC per dag gedurende drie weken, de andere groep kreeg placebo-tabletten. 
Het onderzoek werd dubbelblind uitgevoerd; zowel de deelnemer als onderzoeker wisten 
niet welke behandeling een patiënt kreeg. De ernst van het probleemgedrag werd, evenals 
bij het eerste onderzoek, gemeten middels de NPI. Daarnaast werd ook de werkzaamheid 
op eventuele pijn onderzocht. Dit werd gedaan middels een vragenlijst (voor patiënten 
die de ernst van hun pijnklachten zelf  konden aangeven) of  middels observatie van 
pijngedrag door de onderzoeker of  verpleegkundige (middels de PACSLAC-D). Na 
drie weken behandeling werd er een verbetering gezien op probleemgedrag in beide 
behandelgroepen. Daarbij werd er geen verschil gezien tussen behandeling met THC 
in vergelijking met placebo. Ook werd er geen verschil gezien tussen de behandelingen 
op pijn, functioneren in dagelijkse activiteiten of  kwaliteit van leven. Ook het aantal 
bijwerkingen was gelijk verdeeld over de groepen. Dus ook in dit onderzoek werd de 
onderzoeksmedicatie goed verdragen. 
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Uit deze bovenstaande onderzoeken blijkt dat lage doseringen THC in tabletvorm 
(tot 4.5mg per dag) niet effectief  zijn in de behandeling van probleemgedrag bij patiënten 
met dementie. Tevens konden wij geen effect aantonen op de andere uitkomstmaten, 
zoals geagiteerd gedrag, mantelzorgbelasting of  kwaliteit van leven. Desalniettemin 
werd de behandeling wel goed verdragen door deze kwetsbare patiëntengroep. Het 
kan zijn dat de onderzochte dosering te laag was en daarom is  het belangrijk om 
vervolgstudies te doen om de werkzaamheid van hogere doseringen te onderzoeken. 
De veiligheid van THC bij ouderen en patiënten met dementie
Veel artsen zijn terughoudend met het voorschrijven van medicinale cannabis aan 
oudere patiënten. Dit komt enerzijds doordat er weinig bekend is van de werking bij 
ouderen (zoals blijkt uit ons literatuuronderzoek, beschreven in hoofdstuk 2), terwijl 
cannabis belangrijke bijwerkingen kan geven, zoals sufheid, duizeligheid en een ‘high-
gevoel’, die vooral bij oudere patiënten tot gevaarlijke situaties kunnen leiden (bijvoorbeeld 
tot valincidenten). Gegevens over de veiligheid die reeds zijn verzameld bij jongeren 
kunnen niet zomaar worden toegepast bij een oudere en meer kwetsbare patiëntengroep, 
omdat veranderde lichaamssamenstelling, gebruik van meerdere medicijnen en een 
kwetsbaarder brein bij ouderen allen invloed hebben op de werking van een medicijn. Om 
de veiligheid van medicinale cannabis beter te onderzoeken hebben wij een onderzoek 
uitgevoerd naar de veiligheid van 3, 5 en 6.5mg THC in tabletvorm bij 12 gezonde 
65-plussers (gemiddeld 73 jaar). De resultaten van dit onderzoek worden beschreven 
in hoofdstuk 5 van dit proefschrift. De proefpersonen konden de studiemedicatie 
goed verdragen. Wel traden er na toedienen van 6.5mg THC meer bijwerkingen op 
vergeleken met 3 en 5mg THC en vergeleken met een placebo-tablet. Sufheid en een 
droge mond waren de meest voorkomende bijwerkingen. THC zorgde niet voor een 
verminderde concentratie of  verminderde balans. Ten opzichte van een vergelijkbaar 
onderzoek waaraan jongeren deelnamen, lijkt THC zelfs minder negatieve effecten te 
hebben bij deze oudere, gezonde proefpersonen. Daarnaast hebben we bloedonderzoek 
gedaan om de concentraties van de werkzame stof  in het bloed te bepalen. Hierbij zagen 
we dat de concentratie in het bloed toeneemt, wanneer een hogere dosering THC wordt 
toegediend. Wel viel op dat er grote verschillen bestonden in bloedconcentraties tussen 
de proefpersonen. 
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Tijdens het onderzoek dat wordt beschreven in hoofdstuk 3, zijn er verschillende 
bloedmonsters afgenomen bij 10 deelnemende patiënten met dementie, om de 
concentratie van werkzame stoffen van THC in het bloed te bepalen. De resultaten van 
dit deelonderzoek worden beschreven in hoofdstuk 6. Uit dit onderzoek blijkt dat bij 
oudere patiënten met dementie de bloedconcentraties van de werkzame stof  verdubbelen, 
wanneer de dosering in de tablet wordt verdubbeld. Ongeveer 1 tot 2 uur na inname van 
de medicatie is de concentratie THC in het bloed maximaal. Dit duurt langer dan bij 
jonge, gezonde proefpersonen. Evenals bij oudere, gezonde proefpersonen zien we ook 
bij patiënten met dementie grote verschillen tussen personen in de bloedconcentraties na 
inname van dezelfde dosering THC. 
THC kan leiden tot sufheid, duizeligheid en balansproblemen, en zou daardoor 
in theorie een verhoogd valrisico kunnen geven. Juist bij ouderen met dementie is het 
belangrijk om hier onderzoek naar te doen. Daarom hebben we bij 18 patiënten met 
dementie, die deelnamen aan de eerste patiëntenstudie (beschreven in hoofdstuk 
3) uitgebreid en gedetailleerd onderzoek gedaan naar de balans en het lopen. Dit 
deelonderzoek wordt beschreven in hoofdstuk 7. Het effect van THC op het lopen 
werd gedetailleerd gemeten middels een ruim 6 meter lange mat met elektroden 
(GAITRiteTM), die voetstappen registreerd en daarmee de loopsnelheid, paslengte en 
wisselingen in het looppatroon kan berekenen. De balans werd objectief  en nauwkeurig 
gemeten middels een bewegingssensor op de rug van de patiënt (SwayStarTM). Hiermee 
werd de balans tijdens staan en de balans tijdens het lopen gemeten. Vergeleken met 
toediening van placebo, leidde 1.5mg THC in tabletvorm tot een toename van de balans 
wanneer patiënten stil stonden met hun ogen gesloten. De balans werd niet verstoord als 
patiënten hun ogen open mochten houden. Daarnaast zagen we dat THC ertoe leidde 
dat patiënten wat sneller gingen lopen, waarbij ook de rompbewegingen iets toenamen. 
THC had geen effect op het lopen, wanneer patiënten tijdens het lopen een dubbeltaak 
kregen. Er waren geen verschillen in het aantal of  het type bijwerkingen tussen THC en 
placebo. Daarnaast zijn er geen valincidenten voorgekomen na toediening van 1.5mg 
THC. 
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Op basis van deze onderzoeken kunnen we concluderen dat doseringen tot en met 
4.5mg THC per dag goed worden verdragen door ouderen patiënten met dementie. 
Daarnaast worden doseringen tot 6.5mg THC goed verdragen door gezonde 
proefpersonen van 65 jaar en ouder. Desalniettemin is het wel noodzakelijk om 
voorzichtig te zijn bij het toedienen van hogere doseringen, omdat we verwachten 
dat de bijwerkingen en de negatieve effecten op het lopen en de balans dan zullen 
toenemen. Op basis van het bloedonderzoek zien we dat er grote verschillen 
bestaan in bloedconcentraties tussen proefpersonen. Dit is per persoon niet goed te 
voorspellen. Toekomstige studies kunnen wat ons betreft worden uitgevoerd, maar 
de dosering van de medicatie zal langzaam moeten worden verhoogd en de veiligheid 
van proefpersonen moet daarbij goed in de gaten worden gehouden. 
I’m telling you now, the greatest thing you ever can do now,
Is trade a smile with someone who’s blue now, it’s very easy just.. .
Met a man on the roadside crying, without a friend, there’s no denying,
You’re incomplete, they’ll be no finding looking for what you knew
So anytime somebody needs you, don’t let them down, although it grieves you,
Some day you’ll need someone like they do, looking for what you knew
Led Zeppelin  -  Friends
CHAPTER 9
General discussion
174
9
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
Introduction
The treatment of  neuropsychiatric symptoms (NPS) in dementia poses a significant 
challenge to healthcare professionals, as these symptoms are highly prevalent and 
can have a great impact on both patient and caregiver’s lives. NPS can result from a 
complex interaction between biological, psychosocial and environmental factors, such 
as progressive brain pathology, feelings of  abandonment, intercurrent diseases, pain, 
and confusing surroundings. Professionals should therefore always attempt to identify 
these triggers, in order to start a targeted intervention. When there is no underlying 
cause identified, non-pharmacological and comfort measures are to be preferred in the 
treatment of  NPS, while psychopharmacological interventions should be complemented 
to this, to realize a so called integrated dementia care.1 
Over the past years, a broad variety of  (psycho)pharmacological treatment options 
have been explored. Yet, effective and safe treatment options are still lacking. Up to 
date, those limited drugs available that are effective in reducing NPS also cause relevant 
side effects in this vulnerable population. Thus, there is an urgent need for alternative 
pharmacological treatment options, which might be medical cannabinoids. The first 
preliminary studies on the efficacy of  oral cannabinoids in the treatment of  dementia-
related NPS have been conducted circa 20 years ago, but despite positive findings hardly 
any follow-up studies were performed.2 Only recently, the interest in cannabinoids for 
various medical applications has been growing, partly due to legalization of  its use in over 
30 US states.3 Cannabinoids, including THC, are most frequently used for the treatment 
of  pain, nausea and anorexia. In patients with dementia, suffering from NPS and agitation 
in particular, a structured analgesic treatment has recently been demonstrated to be 
beneficial.4 Therefore, THC might serve as an alternative pharmacological treatment for 
dementia-related NPS, due to its psychoactive as well as its analgesic properties. 
The overall aim of  this thesis was to study the efficacy and safety of  low dose oral 
tetrahydrocannabinol (THC) in the treatment of  behavioral symptoms and pain in 
patients with dementia. Therefore, in this final chapter, the results of  the individual 
studies will be placed in a broader perspective and recommendations for future research 
will be provided. 
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Main findings
This thesis describes the efficacy and safety of  oral THC, the main psycho-active 
component of  the cannabis plant, in the treatment of  dementia-related NPS. Below, the 
main findings are summarized:
• Although trials studying medical cannabinoids include older subjects, there is a 
lack of  evidence of  its use specifically in older patients (chapter 2). 
• No benefits of  oral THC in daily doses up to 4.5mg  were observed in the 
treatment of  behavioral disturbances in dementia patients, compared to placebo 
(chapter 3 and 4).
• The effect of  oral THC on pain intensity and pain behavior remains unclear, 
as the group of  patients suffering from persistent pain was small and pain 
assessments did not appear to be feasible in our study (chapter 4).
• Daily dosages up to 4.5mg THC can be safely used for a duration up to three 
weeks in this frail and cognitively impaired patient group (chapter 3, 4 and 7). 
• 1.5mg oral THC twice daily increases body sway in dementia patients when 
standing with eyes close, but does not negatively affect balance or gait while 
performing several mobility tasks with eyes open (chapter 7).
• Dosages up to 6.5mg oral THC are safe and well tolerated in healthy, older 
volunteers (chapter 5).
• In older patients with dementia, low dose oral THC shows rapid absorption, 
dose-linear pharmacokinetics, although with considerable inter-individual 
variation (chapter 6).
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Efficacy versus safety of oral THC in dementia
Efficacy
Our results show that oral THC up to 4.5mg daily does not have a beneficial effect 
on behavioral disturbances in dementia patients, compared to placebo (chapter 3 and 
4). This finding is in contrast with previous literature on medical cannabinoids in the 
treatment of  dementia-related NPS (see also Chapter 2, Section Efficacy). All previous 
studies reported a positive effect of  oral THC in patients with severe dementia. There 
are several factors that might have caused this discrepancy in findings. First, the previous 
studies have important methodological drawbacks, possibly leading to an overestimation 
of  the treatment effect; two randomized controlled trials (RCTs) analyzed only a small 
number of  patients (n=2; n=12),5, 6 while the other studies had a retrospective or 
uncontrolled design.7, 8 And second, there are also factors that can be appointed in our 
studies that might have diminished the likelihood of  finding a treatment effect. For the 
first study (THC crossover study, chapter 3) we chose  relatively short treatment 
periods in a repeated crossover design, in order to conduct a methodologically valid trial, 
including only a relatively small number of  patients. The length of  the treatment episodes 
and washout were based on the pharmacological profile of  one single oral dose of  5mg 
Namisol® (purified THC)9; a half  life (T½) of  71.9 ± 17.3 minutes for THC and 196 ± 
65.1 minutes for its active metabolite 11-OH-THC. Furthermore, this study showed that 
the pharmacodynamic peak effects were reached approximately 1 to 2 hours after dosing.9 
Therefore, a treatment period of  three days and washout period of  four days was judged 
to be sufficient for both the plasma concentration and the pharmacodynamic effect level. 
We acknowledge that these short treatment periods might have led to a reduced change 
of  finding a treatment effect, as neuropsychiatric symptoms might not be continuously 
present. Furthermore, it is imaginable that there were carry-over effects, which may have 
been influenced by non-pharmacological factors. We observed a significant increase in 
behavioral disturbances and caregiver burden over the course of  the study, which might 
have been caused by caregivers’ attributions, regarding a high experienced burden of  
participation or a failure to observe an expected treatment effect. 
On the contrary, we observed a remarkable improvement in NPS in the intervention 
group of  our second patient study, (mean decrease NPI: -9.6 points), while patients 
receiving placebo treatment improved even more (mean decrease NPI: -11.5 points) (THC 
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parallel design study, chapter 4). This placebo-effect is striking, but similar substantial 
improvements in dementia trials have been reported before10, 11 and may be due to the so 
called ‘Hawthorne effect’, in which factors including attention and support by the study 
team, improved standard care, rater’s expectations about scoring, as well as patients’ 
and caregivers’ expectations concerning the potential treatment effects - specifically 
with regard to cannabinoids -, together might contribute to a temporarily change in 
behavior.12 Another known factor that might have diminished the likelihood of  detecting 
a treatment effect is the heterogeneity of  the studied populations. Previous studies on the 
efficacy of  THC in NPS all included severely demented patients. In contrast, we included 
a more heterogeneous patient group, ranging from community-dwelling to nursing home 
patients, which has possibly led to a high variability in symptoms, disease progression and 
outcomes. This was also represented by the larger standard deviation in the baseline NPI 
total score, which was larger than we had expected based on the literature (16.5 vs. 8.1)13 
(chapter 3). Previous positive findings in other studies might suggest that more severely 
demented (in)patients benefit more from THC than less affected patients do, although 
adequate evidence lacks to confirm this.
Despite these possible shortcomings that might have confounded the estimates of  the 
treatment effects, our studies were the largest, prospective trials evaluating the efficacy of  
oral THC in dementia patients, using randomized, placebo-controlled designs with valid 
and rigorous methods, including adherence to masking and blinded outcome assessment, 
and thereby setting a standard for possible future studies on this subject.
Safety
In this thesis we report on a broad range of  safety aspects regarding oral THC in older 
and cognitively impaired subjects, including the occurrence of  adverse events and effects 
on vital signs, cognition and mobility (chapter 3 to 7). The consistent findings over these 
studies lend credibility that dosages up to 4.5mg THC daily can be safely administered 
for a short duration to dementia patients, as we observed no THC-mediated adverse 
events in our trials (chapter 3 and 4), while effects on mobility were small with a limited 
clinical relevance (chapter 7). It must be stated though, that the results of  these latter 
mobility assessments are preliminary and should be researched more extensively. 
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In retrospect, we could have administered higher doses. The results of  our phase 
I study indicate that single dosages up to 6.5mg oral THC are well tolerated by older 
persons (chapter 5). This study also showed that THC-related adverse events occur in a 
dose-dependent manner, as significantly more patients reported the occurrence of  at least 
one adverse event after administration of  3, 5 and 6.5mg oral THC, compared to placebo. 
Additionally, 6.5mg THC resulted in more adverse events than did 3 or 5mg, including 
drowsiness, dry mouth and coordination disturbances. This is a relevant finding, as these 
types of  adverse events can induce significant health problems, especially in frail, older 
patients with cognitive disturbances. As such, future studies on THC in the treatment of  
dementia-related NPS should evaluate higher dosages (with respect to effectiveness), yet, 
caution is needed when administering dosages of  3mg and more related to possible side-
effects and doses should therefore be gradually increased. 
Why should future studies be conducted?
We did not find a benefit of  low dose oral THC on dementia-related NPS in our 
studies (chapter 3 and 4). The fact that we observed clinically relevant improvement, as 
well as clinical relevant worsening or no meaningful change in behavioral disturbances in 
a similar number of  patients (chapter 3) suggests that 1) changes in NPS were random 
and not a consequence of  the intervention, and 2) for individual patients NPS can change 
over time, independent of  an intervention. As such, severity and frequency of  NPS is 
a challenging outcome measure when evaluating the efficacy of  an (pharmacological) 
intervention in a research setting. The evaluation of  our assessment measures will be 
described below.
Nonetheless, we assume that the dosages used in our trials were too low, as no biological 
signal of  adverse events was observed, while rarely a psychopharmacological intervention 
is effective without showing any side effects. In light of  the preliminary evidence on 
medical cannabinoids in dementia, negative findings on efficacy in combination with 
absence of  adverse reactions, makes it worthwhile to first examine the efficacy of  higher 
doses, before conclusions can be drawn on ineffectiveness of  the compound for this 
specific indication. 
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Selecting the appropriate dose
When studying a new pharmacological intervention, selection of  the optimal dose 
is challenging, especially when it concerns the administration to a vulnerable and 
heterogeneous patient group. After performing a review of  the literature (chapter 2), 
we concluded that previous scientific results on medical cannabinoids in older patients, 
including those with dementia, are extremely scarce. Other trials on medical cannabinoids 
for various indications, such as pain, multiple sclerosis and anorexia, used strikingly high 
doses (up to 60mg oral THC daily) with a large between-study variation.14-16 Preliminary 
trials on NPS in dementia patients showed positive effects of  2.5 to 5.0mg synthetic THC 
daily.5, 7, 8 We contacted the corresponding authors and asked for their motivation on the 
selected dose in their studies, and received the following answers:
Researcher #1: “We have chosen the low dosage of  2.5mg because of  the literature on the use of  
oral dronabinol in dementia and pain. We were aware that particularly in pain or Tourette’s syndrome 
dosages up to 20mg daily were administered. However, as we were piloting the trial and were concerned 
about potential side effects and negative publicity, we chose to stick to the lowest reported dosage. We didn’t 
want any headlines about serious side effects in elderly put on cannabis...”
Researcher #2: “We selected the dose for our study because it was the recommended dose for 
treatment of  anorexia in patients with AIDS. I agree that it may be possible to use higher doses because 
we did not find any serious side effects except for one case of  seizure”
Both researchers had to base their choice on very limited evidence and selected a 
relatively low dose to prevent serious side effects. Several factors, such as age-related 
pharmacokinetic changes, frequent concomitant illnesses, concurrent medication use, 
and difficulties in outcome assessments with regard to reliability and burden, probably 
all contribute to an increased risk of  adverse effects and need to be considered when 
designing a trial to determine the optimum dose in older patients. 
In line with Researcher #1, we also chose a conservative approach in our dose 
selection. The Investigational Medical Product (IMP) used in our studies, which is 
Namisol®, was never administered to this patient group before. Only data from a Phase 
I trial on healthy, young volunteers (mean age 21.4 years) were available at that time.9 As 
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Namisol® is not registered for clinical application, the knowledge of  its effects regarding 
different patient characteristics is limited. Namisol® contains purified, natural THC, 
opposite to the products that were used in previous studies with dementia patients, 
which were all synthetic (dronabinol). To get the best possible reasoning for the dose, 
we compared the mean maximal concentration of  THC and 11-OH-THC of  5mg oral 
Namisol® in young adults to pharmacokinetic data on 20mg oral Marinol® (dronabinol) 
(5), assuming linearity of  the parameters. Based on these data 2.5mg Marinol® equals 
1.25mg Namisol®. Taken into account the lack of  high quality studies, the vulnerability 
of  this patient group, the controversy concerning the intervention (which also exists in 
The Netherlands), and the inexperience concerning Namisol®, we selected relatively 
low doses to investigate a dose-dependent increase of  effects or adverse events (studying 
1.5, 3.0 and 4.5mg THC daily). In this strategy, we complied to the generally accepted 
principle in all guidelines for pharmacological interventions in frail older patients which 
recommends “to start low, and go slow” in increasing dosages, in line with the general 
medical principle “to first do not harm” and the more critical pharmacodynamics in 
older patients. 
To conclude, the chosen doses used in our studies might have been higher in retrospect, 
but the tolerability of  a higher dose would not have been based on available evidence. 
In order to obtain additional data on this IMP and its tolerability in older patients, we 
also conducted a pharmacokinetic sub-study (chapter 6) and performed structured 
safety assessments, including short-term effects on vital signs, adverse event monitoring 
and effects on balance and gait (chapter 3, 4 and 7). As a result, we now provide this 
evidence, with which our study contributes valuable and solid information to the scarce 
literature on this subject.
Challenges to clinical research in dementia
Older patients, including those with dementia, represent a rapidly growing patient 
population, necessitating targeted interventions. This imposes significant challenges 
to the scientific evaluations of  new interventions in this specific group. We faced some 
methodological and practical difficulties while conducting our studies and will address 
some of  the lessons learned.
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Recruitment
With 22 and 50 participants in our patient studies these should be considered 
small. Nonetheless, they are the largest prospective trials on THC in dementia to date. 
Recruitment issues played an important role in the conduct of  both our studies, which 
is not uncommon in dementia studies. These issues resulted in a prolonged recruitment 
period in our THC crossover study and failure to enroll the planned number of  patients 
in the THC parallel design study (chapter 3 and 4). 
Despite comprehensive recruitment efforts, there were several factors that negatively 
influenced the recruitment rate, which were associated to the complexity of  the studied 
population and intervention. Potential participants were recruited through physicians 
from collaborating memory clinics, nursing homes and general practices. Although 
many physicians and informal caregivers recognized the importance of  conducting an 
intervention study for behavioral disturbances, they still seemed reserved. Our trials were 
time consuming, included several hospital admissions (crossover study only) and frequent 
assessments, introducing a significant burden for the patient as well as the caregiver and 
probably leading to selection bias (especially in the crossover study), resulting in the 
inclusion of  relatively healthy and less severe impaired patients. 
Several efforts were made to lower the burden of  participation and to minimize the 
attrition by optimizing the benefit-to-burden ratio. First, home visits and telephone calls 
were performed, avoiding travel problems and reducing the burden to participate. Second, 
despite an overall positive attitude towards THC, the restricted short-term availability 
of  study medication was one of  the major reasons for patients and caregivers not to 
participate. Therefore, we included an optional open label extension phase, following 
the THC crossover trial in case of  positive preliminary effects (so called ‘compassionate 
use’). Unfortunately, it was not possible to incorporate ‘compassionate use’ in our THC 
parallel design trial, as an open label extension phase because of  lack of  ethical and 
license approval. Third,  many patients and informal caregivers appreciated the social 
interaction with the research staff. To provide continuity of  care as much as possible, 
one researcher conducted all study visits for one patient. These actions probably have 
contributed to the very low attrition rates of  our trials (under 9%).  
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Choice of outcome measures
Assessment of behavioral disturbances and agitation
The primary outcome measure in our efficacy studies was the Neuropsychiatric Inventory 
(NPI),17 which is a frequently used tool for the assessment of  NPS in clinical research. 
The NPI evaluates 12 behavioral domains, of  which the frequency and severity is scored 
by the caregiver. The NPI total scores is the sum of  all domain scores. By using this 
scale, our results can be easily compared to other intervention trials. Furthermore the 
scores are solely based on the caregiver’s input and the NPI is therefore suitable for 
assessment in an ambulatory setting, and does not warrant extensive observation periods 
by the researchers. Nonetheless, the NPI also has its methodological shortcomings. First, 
assessment by the caregiver makes the measurements subject to several confounding 
factors, such as their expectations, burden and continuation of  care, etc. Second, the total 
NPI score may not reflect a change in behavior, despite a reduction in individual domain 
scores. For this reason, we conducted additional analyses on the  NPI subdomains of  our 
interest (including agitation, aggression and aberrant motor behavior), but we did not 
find any group differences in these specific symptoms (chapter 4). 
Furthermore, we evaluated several available alternative outcome measures. The 
Pittsburgh Agitation Scale (PAS) assesses the severity of  aberrant vocalization, motor 
agitation, aggression and resisting care by direct observation of  the patient and is 
especially useful in assessment of  NPS in patients with severe dementia.18 It has been 
suggested that the PAS may also allow assessment of  pain in non-communicative patients 
with dementia.19 Unfortunately, this assessment method is not developed for assessment 
of  NPS in community-dwelling patients with mild to moderate dementia.
The Neurobehavioral Rating Scale (NBRS), which was initially developed for assessment 
of  NPS in patients with traumatic brain injury, has been used in several relevant trials 
studying dementia-related NPS.10, 20 It is a 28-item observer-rated instrument of  which 
the reliability has also been assessed in the use in dementia patients.21 Unfortunately, both 
the PAS and NBRS are not available in Dutch. Additionally, the NPI proved to have the 
highest sensitivity in detecting improvement in agitated behavior in dementia, compared 
to the Empirical Behavioral Rating Scale (E-BEHAVE-AD) and NBRS,22 and is therefore to 
be preferred. 
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When assessing agitated behavior in particular, the Cohen-Mansfield Agitation Inventory 
(CMAI) can also be a valuable option and was implemented in our trials as a secondary 
outcome measure. The CMAI is an internationally validated instrument, and mostly 
used in nursing homes.23 Additionally, a large validation study supports construct validity 
of  the CMAI Dutch version across different settings and severity of  dementia.24 
In conclusion, up to date, the NPI and CMAI are to be preferred when studying the 
efficacy of  an intervention on behavioral disturbances and in agitation in particular, as 
they are both frequently used in clinical trials, are well validated, sensitive to change and 
both available in Dutch. Other outcome measures, such as quality of  life, activities of  
daily living or caregiver burden should, in our opinion be used as contributing, secondary 
assessments, though not as a primary outcome measures when studying dementia-related 
NPS. 
Pain assessments
No benefit of  THC was found in the treatment of  pain in patients with dementia 
(chapter 4). However, the number of  available pain assessments in our study was low, 
resulting in preliminary data which must be interpreted with caution. Assessment of  pain 
in dementia is challenging, especially in patients with severe cognitive disturbances, due 
to loss of  judgment, abstract thinking and language skills. As our study sample size was 
expected to be heterogeneous, by including patients with dementia ranging from mild 
to very severe and by conducting assessments in various settings, we selected two pain 
assessments measures: 1) assessment by self-report and 2) an observational instrument. 
Self-reporting of  pain is often referred to as ‘gold-standard’,25 but requires the capability 
of  understanding the task and communicate the experienced sensation. Studies have 
demonstrated that mildly to moderately demented patients are capable in using self-
report scales to assess pain intensity.26 Although the Verbal Rating Scale (VRS) is one 
of  the most commonly used assessment methods, only 13 (57%) of  patients in our pain 
subgroup included in our study, were able to use the VRS. 
The Pain Assessment Checklist for Seniors with Limited Ability to Communicate 
– Dutch version (PACSLAC-D) was assessed as an observational instrument for pain-
related behavior. Although this instrument is commonly used in nursing homes, it has 
some limitations regarding the use in this study. First, the PACSLAC-D was not feasible 
for assessment of  pain in community-dwelling patients with mild dementia, who were 
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able to adequately report their complaints and did not express pain through exaggerated 
behavior. And second, no single item on the PACSLAC-D is an exclusive marker for pain 
and can overlap with behavioral symptoms due to dementia itself. Future studies on the 
efficacy of  an analgesic treatment in dementia, which THC might still be, should focus 
on a more homogeneous patient group, in whom one outcome assessment regarding pain 
is feasible.
Missing data
In the THC parallel design study, a relatively high rate of  missing data was observed, 
leading to limitations in the analysis of  some outcome measures, such as for episodic 
memory, quantitative mobility assessments, pain-related behavior and pain intensity 
(chapter 3 and 7). Missing data can bias results and limit the statistical power to detect 
significant effects. Factors contributing to missing data in our studies are: 1) specific 
assessments, such as episodic memory testing and self-reporting of  pain intensity, 
were only feasible for patients with a mild dementia severity and resulted in missings 
in the more severely demented subjects, 2) there were missing values due to patients’ 
unwillingness to cooperate or severe behavioral disturbances, and 3) data collection was 
sometimes prioritized for assessment of  main outcome measures to reduce participants 
burden when patients were at risk to be lost to follow-up (resulting in missing secondary 
outcomes). These factors are highly related to the participants characteristics, as all were 
suffering from cognitive disturbances, co-morbidities and behavioral disturbances, and 
thereby were a challenge for traditional research methods, which are not developed for, 
and not very well fitting this vulnerable and functionally impaired group of  individuals.
In the current studies, missing data were therefore often nonrandom, as more severe 
demented participants were not able to complete the abovementioned assessments due to 
severe cognitive impairments, behavioral disturbances or fatigue. 
To prevent high numbers of  missing data, we selected proxy-directed questionnaires 
and observational assessments (NPI, CMAI, ZBI, Barthel Index, QoL-AD, PACSLAC-D) 
as primary and secondary efficacy outcome measures. Furthermore, burdensome 
assessments such as extensive physical examination, blood sampling, cognitive and 
mobility assessments were kept to a minimum. Nonetheless, a certain amount of  missing 
data could not be prevented and were most common in patients with severe dementia or 
severe behavioral disturbances. 
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Patient and caregiver participation
Participating in a trial may easily overburden dementia patients and their caregivers. 
Involvement of  patients or their representatives in the design of  a new study will probably 
provide valuable information on the benefit-to-burden ratio and can result in studies that 
are more suited to the needs, possibilities and wishes of  those participating, probably 
stimulating recruitment and retention rates. The THC crossover study was judged to be 
burdensome, due to its multiple hospital admissions, blood sampling and weekly visits 
(which was also reflected in the increasing NPI scores over the study period). Therefore, 
we implemented ‘patient participation’ in the design phase of  the THC parallel design 
study, resulting in a simple study design, with a limited number of  outcome assessments, 
limited number of  outcome assessments, often assessed by a caregiver
Future directions
Future directions in the clinical practice
Behavioral disturbances in dementia can be various and highly prevalent, affecting 
both community-dwelling and institutionalized patients. Momentarily, psychotropic 
drugs, such as antipsychotics, benzodiazepines and antidepressants are not registered for 
the treatment of  behavioral disturbances in dementia, although these interventions are 
mentioned in the Dutch guidelines and can be prescribed ‘off-label’.1 
Atypical antipsychotics are probably the most extensively studied and used 
psychotropic drugs in the treatment of  dementia-related NPS. The best evidence is for the 
atypical antipsychotics risperidone and aripiprazole, specifically regarding the treatment 
of  agitated and aggressive behavior.27-29 Nonetheless, treatment duration of  the studies 
is often short, the effects tend to be limited and many studies had potentially important 
methodological limitations. Studies on the long-term effects are lacking.28 The adverse 
effects of  antipsychotics in this frail patient group are well known among physicians and 
include sedation, mobility disorders, falls and fall-related injuries. Less common, but more 
severe adverse effects are an increased risk of  cerebrovascular events and death (OR for 
mortality: 1.54).30 The evidence for other treatment options is limited, although some 
positive findings have been reported on carbamazepine and memantine.29 Furthermore, 
there is a growing interest in the use of  antidepressants for this indication. A recent 
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trial studying the efficacy of  high dose citalopram in patients with Alzheimer’s disease, 
reported a significant reduction in agitation and overall behavioral disturbances.10 This 
latter finding was reflected by a group difference of  six points on the NPI after nine weeks 
of  treatment. Unfortunately, relevant adverse effects on falls and cardiac conduction raise 
concerns on the safety of  this treatment and limits its use in this vulnerable patient group. 
Based on the results of  this thesis, we cannot yet recommend the use of  oral THC 
in the treatment of  dementia-related NPS. The benign adverse-event profile observed in 
our studies warrants further research on the possible efficacy of  higher doses.  
Future directions in research
Despite centuries of  experience on the medical application of  cannabinoids, evidence 
on its efficacy and safety in older patients is lacking (chapter 2). Future studies should 
evaluate the benefit to risk ratio of  higher dosages. In this section, we provide some 
directions on the most appropriate design, setting and dose that can be incorporated.  
Study design
The studies described in this thesis underline that it is possible to conduct a 
methodological valid trial, even when studying a vulnerable patient group. To minimize 
bias, future studies should at least be randomized and placebo-controlled, with blinded 
outcome assessment. Based on our experience after the THC parallel design study, we 
suggest to keep future studies as simple as possible, regarding both the design and type 
and number of  assessments and include patient and proxy participation in the phase 
of  design development. In this way, patients’ and caregivers’ burden can best kept to 
a minimum, which reduces the change of  drop-outs and missing data. To correct for a 
possible substantial placebo response, which was observed in our parallel design study, it is 
probably worthwhile to implement an individual crossover design including two treatment 
periods, in which a participant serves as his or her own control. This will probably also 
reduce the reluctance of  patients and their caregivers to participate, as every participant 
will receive active treatment. To optimize the chance of  finding a treatment effect, the 
treatment periods should be extended to approximately six weeks in a future phase II 
trial. Phase III studies should evaluate the intervention for a longer period, which should 
be at least three months, to monitor treatment beyond the timeframe of  the Hawthorne 
effect.
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Participants
An important limiting factor in the THC parallel design study (chapter 4) was the 
large variation in NPI scores between participants and relatively low mean agitation 
subscore at baseline. The NPI total score of  our population was 35.0 points, which 
is comparable to or higher than the scores reported in other intervention trials on 
behavioral disturbances in dementia.10, 11 As stated before, the NPI is a sum of  various 
and heterogeneous symptoms, and does not necessarily imply that agitated behavior is 
present at a clinically relevant level. The overall baseline severity of  agitated behavior of  
our population, which is represented by the NPI agitation/aggression score of  4.1 and 
CMAI score of  58.3, was lower than reported in other intervention trials (Porsteinsson 
et al., NPI agitation/aggression score 7.9; Fox et al., CMAI score 68.0; Howard et al., 
CMAI score 62.5, NPI agitation/aggression score not provided).10, 31, 32 Therefore, we 
suggest that future studies include patients with clinically relevant agitation, represented 
by a NPI agitation/aggression subscore of  4 points or more. 
The wide range of  cannabinoid-mediated receptor actions and interaction with 
various neurotransmitters, such as acetylcholine, dopamine, serotonin and opioid 
peptides,33 in combination with the first positive clinical study effects on oral THC on 
behavioral disturbances suggests that patients suffering from more severe dementia will 
probably benefit most from treatment with THC. 2-4 Unfortunately, subgroup analysis 
in our parallel study showed no benefit of  THC in community-dwelling patients 
(NPITHC versus placebo 5.0, 95%CI -1.8 to 11.7) or inpatients (NPITHC versus placebo 1.5, 95%CI -10.0 
to 13.1), representing patients with mild and moderate to severe dementia, respectively. 
Our results therefore cannot confirm this statement (chapter 4). The baseline scores by 
patient subgroup for dementia severity (rated by Clinical Dementia Rating, CDR) are 
provided in the Table, in order to select the most appropriate patient group for future 
studies, with regard to baseline severity scores of  behavioral disturbances and between 
subject variation. 
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TABLE
Assessment scores by dementia severity (data from the TCH parallel design study  
on the efficacy of THC in NPS in dementia)
CDR 1a 
(n=11)
CDR 2 b
 (n=19)
CDR 3 c
(n=20)
NPI total score 32.7 (12.2) 34.6 (12.1) 40.3 (14.4)
NPI agitation/aggression subscore 5.2 (4.5) 5.3 (4.1) 6.9 (3.7)
CMAI total score 56.1 (15.5) 59.6 (16.1) 63.2 (19.5)
Values are means and standard deviations. 
Abbreviations: CDR, Clinical Dementia Rating; NPI, Neuropsychiatric Inventory; CMAI, Cohen-Mansfield Agitation 
Inventory. a CDR 1, mild dementia. b CDR 2, moderate dementia. c CDR 3, severe dementia.
In line with the treatment intensity, the severity of  NPS and agitation is highest 
in patients with severe dementia (CDR 3). For NPI agitation/aggression subscore the 
variability of  scores in this subgroup was also the smallest. This makes this subgroup 
favorable for a future intervention trial. To be able to recruit sufficient participants a 
future multicentre trial is preferred, including nursing homes and specialized psychiatric 
dementia care units. Nonetheless, rigorous national regulations on medical cannabinoids 
limited a rapid and easy implementation of  the study in the participating clinics of  our 
study. Therefore, future studies should take into account these time consuming regulatory 
requirements prior to study conduct. 
Dose
Future studies should evaluate higher doses, as 4.5mg oral THC daily appeared to 
be safe and without clear biological effects when administered for a short duration. Our 
phase I study showed that single doses up to 6.5mg oral THC were well tolerated by 
healthy elderly volunteers, and that adverse events occurred in a dose dependent manner 
(chapter 5). Future studies should increase the dose gradually. Nonetheless, based on 
our findings, we suggest that doses up to 5mg THC twice daily can be safely studied in 
dementia patients. Considering the large variety in symptoms, concurrent morbidities 
and treatment response of  dementia patients, in combination with the substantial 
inter-individual variation in pharmacokinetics of  oral THC (chapter 6), it might be 
worthwhile to implement an individually tailored dose titration from a low initial dose. 
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Conclusion
The work included in this thesis describes the largest randomized controlled trials on 
the efficacy and safety of  oral THC in the treatment of  dementia-related neuropsychiatric 
symptoms and thereby adds to the scarce literature on this subject to date. The results 
show no benefit of  doses up to 4.5mg oral THC daily in NPS in dementia patients, 
although comprehensive safety results, including occurrence of  adverse events, effects on 
vital signs, gait and balance and pharmacokinetics suggest that the intervention is well 
tolerated by this frail population and offers an evidence base for future research on this 
topic. The emerging international consideration for cannabinoids in the treatment of  
various conditions, in combination with these preliminary results offer chances to future 
research concerning its applicability in neuropsychiatric symptoms, and offers hope for 
patients with dementia and their caregivers, who are in urgent need for better treatments. 
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Dankwoord
In de afgelopen vijf  jaar ben ik getraind in het maken van korte en bondige 
formuleringen, maar aangezien het dankwoord, het meest gelezen hoofdstuk van dit 
proefschrift, geen word limit kent, wil ik deze kans niet onbenut laten om uit te pakken. 
Allereerst wil ik mijn proefpersonen én hun mantelzorgers danken. Zonder 
hen is klinisch onderzoek niet mogelijk. Ik ben ontzettend onder de indruk van de 
betrokkenheid, enthousiasme en hun doorzettingsvermogen. Ik realiseer me goed dat 
ik veel van hen heb gevraagd; onder andere opnames in het ziekenhuis, wekelijkse 
huisbezoeken en héél erg veel bloedafnames en vragenlijsten. Het is een voorrecht te 
mogen ervaren dat de deur altijd open stond en zij bereid waren zowel de leuke als 
moeilijke gebeurtenissen met me te delen.
Dit proefschrift is het resultaat van de jarenlange inspanning van een heel team. 
Helaas blijft dat vaak onzichtbaar op de publicaties. Daarom wil ik iedereen bedanken 
met wie ik in de jaren heb mogen samenwerken om de studies en dit proefschrift tot een 
succes te maken, allereerst het promotie team:
Beste Marcel, deze promotie begint en eindigt bij jou; je hebt me de kans gegeven 
deze onderzoeken op te zetten en uit te voeren, en me tot en met de afronding fantastisch 
begeleid. Ik bewonder je creatieve geest, razendsnelle correcties en positieve blik (in 
tegenstelling tot die van mij, is jouw glas altijd half  vol!). Heel erg bedankt!
Beste Marjolein, wat heb je ontzettend veel tijd in dit project gestoken! Ik ben je 
eerste promovendus, maar ik had me geen betere co-promotor kunnen wensen. Niet 
alleen heb ik ontzettend veel geleerd van je management skills, je kritische blik en je 
vermogen om zelfs de kleinste foutjes uit mijn artikelen te halen, maar ik heb ook erg 
genoten van je gezelligheid. 
Beste Robbert-Jan, in dit team begonnen als co-promotor, maar inmiddels ben ook 
jij gepromoveerd (zij het met een iets grotere prestatie dan die van mij). Jouw frisse blik 
en onderzoekservaring vanuit de psychiatrie is van grote meerwaarde geweest voor het 
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project. Ik waardeer je rust en je oprechte interesse voor alles wat met wetenschap te 
maken heeft. 
Beste Kees, je bent wat later betrokken geraakt bij mijn promotie. Natuurlijk kende ik 
je al als docent vanuit de opleiding geneeskunde en ik vind het een eer om met je samen 
te mogen werken. Dank voor je kritische bijdrage aan dit proefschrift. Ik kijk ernaar uit 
om nog veel meer van je te leren tijdens mijn stage interne geneeskunde. 
Leden van de manuscriptcommissie: prof. dr. Koopmans, prof. dr. van Marum 
en prof. dr. Vernooij, hartelijk dank voor het beoordelen van dit manuscript op zijn 
wetenschappelijke inhoud.
Dear dr. Paul Rosenberg, thank you so much for your important contribution to 
this thesis. It was an honor to meet you at the AAIC Conference in Washington D.C. I 
wish you all the best in conducting more research on this fascinating and important topic. 
Beste Amir, dank voor je bijdrage aan de studies, je positieve instelling en het feit dat 
je op elk moment van de dag bereid was voor overleg. Succes met de laatste loodjes van 
je eigen proefschrift!
Lieke, Michiel, Caspar, Vera, Janny, Esther en Peter, allen heel erg bedankt! 
Ongelofelijk hoeveel werk jullie hebben verricht binnen dit project! Daarnaast de lieve 
onderzoeksverpleegkundigen van de afdeling Geriatrie: Willemien, Lucia, Johan†, 
Nanda, Loes, Willy. Jullie hebben met veel enthousiasme, precisie en geduld zo’n 
120 opnamedagen tot een groot succes gemaakt. Ik wil Ton Feuth bedanken voor het 
verrichten van de statistische analyses en het iets begrijpelijker maken van wat voor mij 
complete abracadabra was. Eveneens had ik in het begin niet veel kaas gegeten van Good 
Clinical Practice, SOPs, delegation logs en drug accountability. Dankzij het Clinical Research 
Centre Nijmegen heb ik deze onderzoeken kunnen uitvoeren volgens de hoogste 
kwalitatieve standaarden, wat zelfs een audit van de Inspectie voor de Gezondheidzorg 
heeft overleefd. Mijn speciale dank gaat uit naar Hettie Maters, mijn monitor, maar 
vooral ook steun en toeverlaat. Je bent een fantastisch mens! Medewerkers van de apotheek, 
wat hebben jullie een werk gehad aan de Namisolstudies. Het is bewonderenswaardig hoe 
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jullie je door de administratie, het verpakken, herverpakken, nogmaals herverpakken en 
de inspectiebezoeken heen hebben gevochten. Saskia van de Velde, Marieke Welzen 
en Nienke Lankheet, bedankt voor de fijne samenwerking. Daarnaast wil ik Angela 
Colbers danken voor het heldere licht dat ze heeft geworpen op de farmacokinetische 
data en analyses. Leden van het Consortium (o.a. Harry, Marjan, Tim, Venesa, 
Joyce, Dagmar, Emanuel, Luuk, Dyonne); met vallen en opstaan en vechten tegen 
de achterblijvende rekruteringscijfers hebben we, volgens mij, een prachtig project 
neergezet. Ik vond het een eer om hier deel van te mogen uitmaken. 
Alle arts-assistenten en klinisch geriaters, en met name Marianne en Jurgen, die 
me ook tijdens mijn onderzoeksperiode vaak uit de brand hebben geholpen; dank voor 
jullie interesse, ondersteuning en vooral relaxte overgang terug naar de klinische praktijk.
William, jouw charmes, grijze haren en vlotte babbel hebben menig vrouwelijk 
patiënt het hoofd op hol gebracht. Niet alleen heb je hart voor je patiënten, je hebt 
ook een wonderbaarlijk talent voor rekruteren van proefpersonen. Jouw bijdrage is 
onbetaalbaar geweest.
Dankzij alle onderzoekers van de afdeling Geriatrie heb ik een fantastische tijd gehad! 
Een superleuke groep, waarmee menig koffiepauze, pubquiz en nacht van de professoren 
volledig uit de hand kon lopen! In het bijzonder wil ik mijn kamergenootjes Gerrita, 
Sharon, Daan, Saskia, Marit, Lonneke, Lotte, Linda, Kim en Sondra bedanken 
voor de ontzettend leuke tijd die ik met ze heb gehad en voor het geduld dat ze af  en toe 
voor mij moesten opbrengen.
Lieve Aisha, mijn maatje van het eerste uur. Ondanks dat we ongeveer opgesloten 
zaten in ons ‘hokje’ op de afdeling, heb ik me geen moment verveeld dankzij jou! Ik 
bewonder je openheid, oprechtheid en natuurlijk je onderzoekstalent. Wat ben je 
ongelofelijk slim. Menig maal heb je me uit de brand geholpen toen ik als ware alpha 
weer ruzie had met SPSS. Ik zie je minder vaak dan ik zou willen, maar ik wens je al het 
geluk in je onderzoekscarrière en natuurlijk met je prachtige gezinnetje.
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Lieve Annelien, je begon als onderzoeksassistent, maar transformeerde je als snel 
tot onderzoeker, projectmanager, rekruterings-kampioen, ‘personal assistant’ (sorry) en 
bovenal mijn vriendin. Het leukste gedeelte van dit promotietraject was de tijd dat jij 
onderdeel van het team uitmaakte. Je voelt me haarfijn aan en bent niet zo snel onder de 
indruk van mijn gezeur en uitspattingen. Natuurlijk is sushi-candy niet voldoende om je 
hiervoor te bedanken. Je bent geweldig! ZTWK!
Ook mijn vrienden en familie wil ik bedanken: voor het aanhoren van mijn frustraties 
en mijn gebedel om onnodig schouderklopjes (ik ken mezelf), maar vooral voor het aller-
noodzakelijkste waarmee je een promotietraject heelhuids door komt: afleiding! 
Natuurlijk de gezelligste mensen van Nijmegen Atletiek: Leonie, Evelien, Debby, 
Jeanine en Freek N en in het bijzonder mijn marathon buddies Freek, Jan en Yves; ik 
zou met plezier zelfs de Dijkenloop marathon lopen, als het maar met jullie is!
Lieve Lotti, Maud, Eefje en Myrte, mijn vriendinnen vanaf  de kleuterschool. Het 
is mooi dat we ieder onze eigen kant op zijn gegaan en we toch altijd weer bij elkaar 
terugkomen. Fijn dat jullie ook bij deze belangrijke gebeurtenis in mijn leven aanwezig 
willen zijn. 
Lieve Lonneke, Saskia, Lindy en Ronne, dank jullie wel voor ruim tien jaar 
vriendschap. Wat hebben we in die jaren veel meegemaakt. Van mooie (studenten)feestjes 
tot koophuizen en baby’s. Fijn dat jullie altijd in de buurt zijn. Lonnie, wat vind ik het 
een eer dat je mijn paranimf  wilt zijn. 
Mijn lieve broers, Len en Ron, dank voor jullie onvermoeide pogingen mij met beide 
benen op de grond te laten staan. Af  en toe had en heb ik jullie nuchtere commentaar 
nodig. Met jullie voelt het altijd fijn om thuis te komen. 
Lieve Albert, mijn maatje. Jij weet me altijd op te vrolijken met je enthousiaste en 
grappige verhalen. Als jij ergens bent straalt de kamer van de energie. Ik bewonder jouw 
levenslust, doorzettingsvermogen en discipline. Dankjewel dat je me al die jaren hebt 
ondersteund, geadviseerd en gestuurd als dat nodig was. Je bent lief.  
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Lieve Pap en Mam, al die jaren hebben jullie me ondersteund en mijn frustraties, 
geklaag en enthousiasme aangehoord. Heel erg bedankt voor jullie interesse in alles wat 
ik doe. Papa, terwijl Mama al mijn verhalen aanhoort en mij van advies voorziet, steun 
jij me door het feit dat je er altijd bent als ik je nodig heb en door mij te wijzen op 
fantastische muziek en concerten. Deze muzikale opvoeding is een rode draad in mijn 
leven. De lyrics in dit proefschrift heb ik voor jullie uitgekozen. Ik hou van jullie.
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